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Abstract 
Organometallic ruthenium(II) complexes [(TI 6_arene)RuCI(X)(Y)l (X, Y are 
monodentate or chelating ligands) are cytotoxic to cancer cells, and complexes of the 
type of ft71 6-arene)RuCl(en)] (en = ethylenediamine) are especially effective 
inhibitors of the growth of cisplatin-resistant cell lines. Introduction of the tricyclic 
anthracene ligands THA (1,4,9,10-tetrahydroanthracene) and DHA (9,10-
dihydroanthracene) into Ru(II) complexes are shown to enhance their anticancer 
activities. Two novel dinuclear his Ru(arene) complexes (arene = biphenyl, THA) 
were also prepared by use of the bifunctional ligand of N, N'-bis-(2-aminoethyl)-1,6-
diaminohexane and have been investigated for their cytotoxicity. They exhibit a 
distinct profile of antitumour activity, compared with their corresponding 
mononuclear complexes, which is likely to be associated with interstrand cross-
linking of DNA. The distribution of the populations of the diastereomers in the 
dinuclear complex [((9 6-biphenyl)RuCl)2(H2N(CH2)2NH(CH2)5NH(CH2)2NH2- 
N,N;N",N")] 2  was determined in solution using NMR methods and compared with 
the mononuclear complex [(1 6-biphenyl)RuCl(H2N(CH2)2NH(CH2CH 3))]t 
The structures of monofunctional adducts of {(rl 6-arene)Ru(II)(en)} 2 (arene 
= biphenyl, THA and DHA) with guanine derivatives have been studied in the solid 
state by X-ray crystallography, and in solution using 2D 1 H, 1 H NOESY and 1 H, 15N 
FISQC NMR methods. These guanine adducts show interesting features, including 
Ru(II) binding to guanine N7, stereospecific hydrogen-bonding of en NH with G 06, 
and strong arene-nucleobase stacking. These studies suggest a potential DNA-
binding mode involving simultaneous intercalation and coordination. The diamine 
NH group and hydrophobic arene group as well as the Cl leaving group may 
therefore all play important roles in anticancer activity. 
Thermodynamic and kinetics studies were made of the binding of 1(71 6_ 
 (arene = THA, DHA, biphenyl, p-cymene, or benzene; X = Cl' or 
H20) to nucleotides and nucleosides (G, I, A, C, T) using 1 H, 31P and 15N ( 15N-en) 
NTvIR spectroscopy, together with pH titrations. ((Tl  binds only to 
N7 of G, to N? and Ni of I, and to N3 of T. Binding to N3 of C was very weak, and 
there was almost no binding to A. The reactivity of the various binding sites of 
nucleobases towards Ru at neutral pH decreased in the order G(N7) > I(N7) > I(NI) 
> T(N3) > C(N3) > A(M), A(N1). Such site-selectivity appears to be controlled by 
the en NH2 groups, which H-bond to exocyclic oxygens but are non-bonding and 
repulsive towards exocyclic amino groups of nucleobases. Additionally, significant 
amounts of the 5-phosphate-bound species (40-60%) were present at equilibrium in 
reactions with the nucleotides 5-TMP, 5'-CMP and 5-AMP. In contrast, no binding 
to the phosphodiester groups of 3',5'-cyclic-GMP (cGMP) or cAMP was detected. 
The rates of reaction of { (TI 6-arene)Ru(en)X)' towards cGMP decreased in the 
order: THA > biphenyl > DHA > p-cymene > benzene, suggesting that N7-binding 
is promoted by favourable arene-purine hydrophobic interactions. Such arene-purine 
hydrophobic interactions may influence the kinetics of DNA binding. These findings 
will aid the design of more effective anticancer complexes, as well as new site-
specific DNA reagents. 
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Abbreviations: 
Cisplatin 	 cis-[PtC12(NH 3 )2], cis-DDP 
NAMI-A 	[trans-Ru(ffl)C14(DMSO)Im] [ImH] 
Tm 	 imidazole 
Ind 	 indazole 
cdta 1, 2-cyclohexanediaminotetraacetate 
AO acridine orange 
Eth ethidium bromide 
Tf transferrin 
HMG high-mobility-group 
LMCT ligand-to-metal charge tranfer 
NMR nuclear magnetic resonance 
COSY 2D correlation spectroscopy 
IISQC heteronuclear single quantum coherence 
DQF double-quantum filtered 
NOESY 2D nuclear Overhauser effect spectroscopy 
NOE nuclear Overhauser effect 
TOESY total correlation spectroscopy 
HPLC high performance liquid chromatography 
UV ultraviolet spectroscopy 
WATERGATE water suppression by gradient-tailored excitation 
en ethylenediamine 
AD adriamycin 
IC50 50% inhibitory concentration 
Bip biphenyl 
THA 1, 4, 9, 10— tetrahydroanthracene 




5'-GMP guanosine 5'-monophosphate 
9EtG 9-ethylguanine 
Guo guanosine 
cGMP 3', 5'-cyclic-GMP 
5-IMP inosine 5-monophosphate 
mo inosine 
5-AMP adenosine 5'-monophosphate 
Ado adenosine 
cAMP 3', 5-cyclic-AMP 
5'-CMP cytidine 5-monophosphate 
5'-TMP thymidine 5'-monophosphate 
TSP sodium trimethylsilyl-d4-propionate 
Cp 
DMSO dimethyl sulfoxide 
DMF N, N-dimethylformamide 
THF tetrahydrofuran 
Ca. circa (about) 
xl" 
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1.1 Introduction 
Interest in the biological activity of ruthenium complexes, as well as the 
possibility of discovering ruthenium-based drugs active in the treatment of human 
malignancies, is mainly due to the antineoplastic activity of cisplatin.' Approaches to 
the design of new active ruthenium complexes have rapidly evolved in recent years. 
Currently, ruthenium is probably second only to platinum in the number of 
complexes that exhibit anticancer activity. 2 A potential advantage over platinum is 
that it is generally less toxic. The fate of Ru compounds in the body appears to be 
different from that of many other transition metals, probably attributable to its own 
unique structural features and chemical behaviour. 3  Finding new ruthenium-based 
anticancer drugs will be aided by understanding existing metal agents with a view 
toward developing new modes of attack. 
1.2 Ruthenium Chemistry 
Ru (atomic number 44, atomic weight 101.07, Kr5s'4d7), along with Os, Rh, 
Id, Pd and Pt, forms the so-called platinum metals group. Ru has seven stable 
isotopes, ranging from 96 to 104, with 102 R being the most abundant at 31.6%. In 
medicinal inorganic chemistry, Ru compounds are often active against Pt-resistant 
turnouts. 3  Likely reasons for this are the differences in the geometric structure of the 
generally square-planar platinum(II) compounds and the ruthenium(II1III) species, 
which are nearly always six-coordinate, low spin octahedral. The most relevant 
oxidation states for bioinorganic chemistry are Ru II, III, TV. 4 The three (t2 g)d 
oribitals are filly populated in Ru(II) complexes and have a single electronic 
vacancy in Ru(III) species. 5 ' 6 The difference of a single electron between the two 
oxidation states significantly affects their chemistry, so that Ru(II) usually behaves 
as a relatively "soft", 7 it-donor metal ion and Ru(III) as a borderline "hard" metal 
ion, which can function as a n—acceptor of ligand eletrori density. 8 
2 
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Ru(II) complexes with n-acceptor ligands invariably exhibit intense metal-to-
ligand charge-transfer transitions in their optical spectra due to the strong back-
bonding interations, while Ru(III) complexes with it-donor ligands such as R-S and 
imidazole, usually show strong ligand-to-metal charge transfer transitions. The 
reduction potential for the Ru(IIJIII) couple is a strong function of the ligand 
environment. 9,10,11,12  The effect of back donation of electron density is somewhat 
more prominent in stabilizing the lower valence state of Ru than for most other 
metals. The coordination of n-acceptor ligands such as carbonyl or pyridine increases 
the reduction potential while the addition of anionic or good electron-donor ligands 
causes it to decrease. 8,13 
The hypothesis of "activation by reduction", proposed by Clarke based on his 
systematic study of the anticancer activities of ammine-ruthenium complexes, 
suggests that Ru(III) complexes may serve as prodrugs, which are activated by 
reduction in vivo since Ru(ll) coordinates more rapidly to biomolecules.14lS In vivo 
reduction of Ru(JII) to Ru(II) can occur by single-electron-transfer from proteins 
which exist in both the mitochondrial electron-transfer chain and in microsomal 
electron-transfer systems, with microsomal proteins being the more efficient ) 6 
Oxidation of Rq(TI) back to Ru(III) can occur by reaction with molecular oxygen, 17 
cytochrome oxidase,' 7 ' 8 and other oxidants. 
As reduction of Ru(JII) to Ru(II) fills the d orbitals, the n-donor ligands are 
no longer able to bind sufficiently strongly to remain intact. In the case of Ru(ll) 
ammine complexes, acido ligands are lost fairly rapidly (k = 110 1)1920  Since 
most biological amines are protonated at neutral pH, potential biological ligands such 
as lysylamines or thiols on the surface of proteins at neutral pH do not readily 
coordinate to the Ru(II) species. 8 Consequently the lone pairs of electrons on the 
nitrogens of imidazole rings of histidine (on protein) and purines (on DNA) present 
the readiest binding targets to Ru(II). 
H3 N 
H3N,,,, 
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Being directly below Fe in the periodic table, and existing in both the +2, +3 
oxidation states in aqueous solution as does Fe, Ru may mimic some properties of 
Fe. Indeed, like Fe(III), Ru(III) appears to have a high affinity for the plasma protein. 
HPLC studies of the anticancer complex [Ru(III)Cl41nd 2]HJnd in the blood have 
shown that most of the complex is bound to albumin (80%) and the remainder to 
transferrin. 2 ' X-ray crystallographic studies of human lactoferrin have demonstrated 
that this indazole Ru(IJI) complex directly bound to the imidazole nitrogen of 
His253, one of the Fe  binding ligands in the N-lobe. 22 Significantly, the binding of 
Ru(III) to transferrin is reversible. The metal complex is released at pH 4-5 in the 
presence of a large excess of citrate or adenosine triphosphate (ATP). This suggests 
that transferrin can serve as a mediator to deliver Ru(III) anticancer complexes. 
Transferrin uptake appears to an important mode for the specific uptake of Ru(III) by 
tumour cells, 23,24  which is probably linked to the potential selective cytotoxity. 
Transferrin may lower ruthenium toxicity by preventing it from binding to other 
biomolecules or uptake until it has been delivered to the tumour cells. 25 Ru-Tf 
complexes offer a potential new family of less toxic and more effective antitumor 
agents. 
1.3 Ruthenium Antitumour Agents 
Ru-ammine complexes were the first group of Ru complexes to undergo 
screening for antitumor activity. 26 Fac-[Ru(llI)C] 3 (NH3 )3] (1) showed the best 
activity but its low solubility makes it unsuitable as a drug. 27  Clarke's hypothesis of 
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Trans-[Ru(II)C12(dmso)4J (2), selected for its good solubility, exhibits 
significant activity against solid tumour metastases, and, interestingly, much higher 
than the activity against the primary tumour. 28,29 
The introduction of heterocyclic ligands to Ru(JII) complexes has been 
shown to improve their solubility as well as antitumor activity. 30 ' 3 ' The indazole 
complex, trans-[Ru(III)Cl4Jnd2] - (3) has become a candidate for clinical trial. This 
complex has been shown to enter cancer cells by transferrin-mediation 32 '2 ' and it has 
been cocrystallized with apolactoferrin by Baker et al. and analysed through X-ray 
crystallography. 22 
3 	 4 
Trans- [Ru(III)Cl4(dmso)Imr (NAMI-A) (4), which contains both dmso and a 
heterocyclic ligand, became the first Ru(III) antimetastic complex to be introduced 
into clinical trials. 33  Sava et aL have shown that NAMI-A exhibits excellent 
antimetastic activity 34 at doses genuinely devoid of toxicity through the novel 
mechanism of action distinguished from the traditional ones of DNA binding, 35,36,37 
which establishes a new generation of anticancer agents. 
61 
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Cis-[Ru(IV)(edta)Cl2] (5) (cdta = 1 ,2-cyclohexanediaminotetraacetate) was 
reported as the first example of an active Ru(IV) antitumour complex. 38,39  RU  
polyamino-polycarboxylate complexes constitute a relatively new group of 
anticancer agents. 
Ru-polypyridyl complexes have shown effective intercalative binding and 
groove-binding to DNA and have been widely used for probing DNA structure. 40 
Mer-[Ru(terpy)C1 3 ] (6) has been shown by Reedijk et alto exhibit good antitumour 
activity against human cervix carcinoma Hela and murine L1210 cell lines. 41 
CII.N 
cl_*~ I ~~N~a 
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1.4 Di/tri-nuclear Metal Complexes 
1.4.1 Diltri-nuclear Platinum Complexes 
The development of polynuclear metal complexes represents a promising 
approach in the design of new anticancer agents. The platinum dimers and trimers 
developed by Farrell and his coworkers  42  provide very stimulating precedents in this 
direction. The first representative of this new class, 1,0,1/t,t,t or BBR3464 (Figure 
1.1) is now advanced to phase-TI clinical trials after a highly promising Phase I trial 
indicated responses in colon and pancreatic cancers . 43 This trinuclear cationic 
compound shows potent cytotoxicity against both cisplatin-sensitive (L1210) and - 
resistant (L1210/CDDP) murine leukemia cell lines, and it is 30 times more cytotoxic 
Chapter 1 Introduction 
than cisplatin. 44  Also, a wider spectrum of tumours are sensitive to this agent. Within 
18 human tumour xenografts studied, BBR3464 also maintains high antitumour 
activity in a subset of 6 tumours classified as mutant p53. 
CI\ , NH3 HSN\ /I
/Pt\ Pt 
	
CI 	NH2(cH2)nH2N cI 
2,2/c,c 
— 1 2+ 	 2+ 
Ci 	NH3 	H3N 1,71 
H3 N /CI 	Ci\ 	NH3 
Pt 	 Pt 
,,, 
/\ /\ 




ci ,ci 	Ci 	 CI 	CI 
H3N' 	 )6H2N "NH2(CH2 	
" 	
NH2(CH2)6H2N 	'" NH3 
2,2,21c,c,c 
1 + 
NH3 Pt /NH2(CH2)6HZN\ 	NH3 	NH3 	ci 
\ ,/ 
Pt 	 Pt 
Ci 	"NH3 	H3N' " \ NH2(CH2)5H2N 	NH3 
1,0,11t,t,t (BBR3464) 
Figure 1.1 Structures of some dinuclear and trinuclear platinum anticancer 
compounds .42 
The choice of BBR3464 as a clinical candidate arose from systematic studies 
on the broad class of dinuclear and trinuclear Pt compounds. The structures in Figure 
1.1 represent a formal array of potential DNA-binding modes from bifunctional to 
hexaflinctional. The 2,21c,c compound was first reported in 1988 and consists of two 
7 
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cis-{PtCl2NII3)) units linked by a flexible diamine chain. 45 The use of cisplatin as a 
synthon was further demonstrated by extension to trinuclear systems 2,2,2/c,c,c 
(Figure 1.1).46  Most recently, extensive investigation has focused on the distinct 
biological activity of the pair of dinuclear isomers 1,1 /c,c and 1, 1/t,t (Figure 1.1) 
derived from their mononuclear counterparts, cisplatin and transplatin respectively. 47 
(Pt, Pt) lnterstrand 	(Pt, Pt) Intrastrand 	(Pt, Pt) Intrastrand 
Cross-link 	 Cross-link 	 Cross-link 
(Pt, Pt) DNA-protein 	(Pt, Pt) DNA-protein 
Cross-link 	 Cross-link 
Figure 1.2 Schematic limiting modes for possible DNA-DNA and DNA-protein 
cross-linking induced by dinuclear platinum complexes. 47 
Unlike the mononuclear case, where one isomer (cisplatin) is antitumour-
active and the other (transplatin) is not, it has been found that both dinuclear isomers 
of 1,1/c,c and I,I/t,t are as active as cisplatin against conventional tumour lines and 
the 1,1/t,t derivatives are markably active against tumour lines resistant to cisplatin. 48 
Sequencing studies 49,50,51  on template double-stranded DNA binding of 1,1/c,c or 
I;] 
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1,1/t,t have indicated that both isomers are very efficient with formation of 
interstrand cross-links (Figure 1.2), and, additionally, the 1,1/t,t derivatives are 
capable of forming (Pt, Pt) intrastrand cross-links to the adjacent guanines of a 
d(GpG) sequence . 49 The excision repair UVrABC52 '53 complex also recognizes 
bis(Pt)-DNA adducts formed either by 2,21c,c or 1,1/t,t complexes. The 
polyfunctional nature of the his-Pt complexes suggested that the availability of 
multiple coordination sites (> 2) can be used to induce covalent cross-linking of 
protein to platinated DNA (Figure 1.2). These results suggest that improved 
antitumour activity of bis-Pt complexes could be related to the formation of DNA 
adducts structurally unique from those formed by cis and trans-DDP and the more 
efficient protein-DNA cross-linking than cis and trans-DDP. The DNA adducts will 
be affected by geometry and nature of the coordination sphere as well as chain length 
and steric effects within the linker group. 47 
Further studies based on the 1,1/t,t series have shown that, in general, in vivo 
antitumour activity as well as the enhanced activity in cisplatin-resistant cancer cells 
are seen with longer chain lengths (n > 4) and are greater with the straight-chain-
diamine (n =.47,54  Steric effects within the diamine linker were examined by 
replacing butane-1,4-diamine with the sterically hindered cis-cyclohexane-1,4-
diamine, which produced very disappointing cytotoxicity. 5° It is likely that the 
sterically hindered compound binds more slowly to DNA, especially in the second 
bifunctional step. 
Straight-chain flexible diamines linking two trans-{PtC1(NH 3 )} moieties 
gave consistently better antitumour activity in cisplatin-resistant cells and the 1,1/t,t 
(n = 6) complex was the most potent compound which can readily span a four-base 
pair segment of DNA .41  1,O,l/t,t,t (BBR3464) was thus developed by linking a 
precursor central molecule, a non-covalent tetra-amine 
[Pt(NH3)2{H2N(CH 2)6NH2 } 2] 2  to two equivalents of a target terminal platinum 
I!' 
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coordination sphere, trans- {PtC1(NH3) 2 }, 5 ' in which the central Pt unit is capable of 
hydrogen-bonding interactions with DNA. The overall charge of +4 greatly enhances 
DNA affinity, characterised by long-range interstrand cross-linking up to six base 
pairs apart with significant unwinding and efficient, irreversible conversion of B- to 
Z-DNA. 55 '56 '57  The adducts terminate DNA synthesis in vitro. Therefore, BBR3464 
became the first genuinely new platinum anticancer agent not based on the 
"classical" cisplatin structure to enter clinical trials and its success is encouraging the 
development of other polynuclear metal anticancer agents. 
1.4.2 Di/tri -nuclear Ruthenium Complexes 
The development of heterodinuclear (Ru, Pt) metal compounds provides an 
alternative approach to the design of a new type of anticancer agents. This is driven 
by the hypothesis that alteration of the antitumour activity of drugs will be achieved 
by modification of the mode of DNA-DNA or DNA-protein binding in comparison 
to cisplatin and this mode will vary with alterations in the coordination sphere. 58 
Me2OS 
Me20SN I /SOMe2 H3 N\ /CI 







ci 	ci 	 ci 	ci 
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The Ru-Pt dinuclear complex [{cis,fac-(RuCl2(Me 2 SO)3 )p-NH2(C}12)4N}12-
{cis-Pt(NH3 )C12 }] (7) has been designed 58,53  to incorporate two inequivalent 
coordinations, the octahedral sphere of Ru(II) and square-planar Pt(II). This 
combination is capable of selective reaction at the Ru centre and effective cross-
linking of DNA repair protein to DNA. Unfortunately, the hydrolytic activity, 
photosensitivity, and dissociation of Ru from this complex result in nonspecific 
biopolymer binding. 58 Analogous complexes of the type [(bpy)2M(dpb)PtCl 2]C12 
(where M = Ru(II) or Os(II) and bpy = 2,2'-bipyridine, dpb = 2,3-bis(2-
pyridyl')benzoquinoxaline) have been synthesised to couple a chromophoric metal 
(Ru or Os) site to the cis-dichloride platinum site which provides a system with two 
potential modes of binding to DNA, intercalative and covalent. 59 
With the success of NAMI-A as the first Ru(III) antimetastic complex to 
enter into clinical trials, currently, dinuclear Ru complexes based on NAMI-A are 
being developed . 60 The dinuclears Na2[{trans-RuC1 4(Me2 SO-S)} 2(p-L)} and 
[{zner,cis-RuCI 3 (Me2 SO-5)(Me2SO-0)} 2(u-L)], where L = pyrazine, pyrimidine, 
4,4-bipyridine, 1 ,2-bis(4-pyridyl)-ethane (etbipy) or 1,3-bis(4-pyridyl)-propane, 
have been synthesised with the aim of accessing their neoplastic activity. They have 
been found to maintain their dimeric structures in solution and undergo aquation 
reactions similar to those of the monomeric analogues. This indicates that they might 
behave as bi- or even tetra-functional agents and might maintain the antineoplastic 
activity of the closely related mononuclear species but with some different, and 
possibly enhanced, selectivity or specificity. The preliminary in vitro test data 6 ' have 
shown that these dimers effectively reduce the number and the weight of lung 
metastases; in particular, the complex Na2[{trans-RuCl4(Me2SO-S)}2(p-etbipy)] (8) 
was as effective as NAMI-A in inducing spontaneous metastases at a dosage which is 
about 3.5 times lower compared to that normally used for NAMJ-A. 
11 
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Ru-red, [(NH3)5Ru ... 0Ru"(NH 3)4Ru ... (NI-T 3 )s] 6 ,62 is a representative of 
another type of 0-bridged mixed-valent metal complexes which have been studied 
for their interesting biological activity. This agent has been used as a cytological 
stain and a tumour imaging agent with 103Ru-red. Ru-red also inhibits tumour 
growth, which may arise from its ability to interact with calcium metabolism. The 
dimeric complex [p-0-{(fl2O)2(bpy) 2Ru ... } 2] 4 , related to Ru-red, has also been 
studied for its biological properties and found to bind stereoselectively to calf thymus 
DNA. Irreversible thermal denaturation of DNA with this complex covalently bound 
indicated the formation of an interstrand biadduct. 63 
1.5 DNA Binding 
Substantial progress has been made over the past years in the fundamental 
characterization of a variety of drug-DNA interactions. Structure-based design 
strategies have yielded new DNA-binding agents with clinical promise. 
Cross-linking/Covalent Binding 
The success of cisplatin in cancer chemotherapy derives from its ability to 
crosslink DNA and alter the structure. Most cisplatin-DNA adducts are intrastand 
d(GpG) and d(ApG) crosslinics. The structural information about the principal DNA 
adducts of cis-DDP have been provided by NMR structural analysis, crystallographic 
studies, molecular mechanics and dynamics modeling. The X-ray crystal structures 
of cisplatin adducts with short single-stranded deoxyoligonucleotides such as cis-
[Pt(N113)2 {dpGpG}],64 '65 and cis-[Pt(NH3)2{dCpGpG}], 66 have shown that the 
adjacent two N7-platinated guanine rings are oriented in a head-to-head manner and 
destacked with the dihedral angle being 80-84°. The X-ray structure of a site-
specifically platinated double-stranded deoxyoligonucleotide with the sequence 
d(CCTCTG*G*TCTCC).d(GGAGACCAGAGG) ,  where G*G*  represents the cis- 
12 
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Pt(NH3)2-d(GpG)-N7(G6), N7(G7)11 intrastrand crosslink, has revealed 
67 that the 
duplexes are bent (bend angle 39-55°) towards the major groove with the bend locus 
near the site of platination. The dihedral angle between the G6 and G7 guanine 
planes is 26°. A projection of this DNA structure, based on the X-ray coordinates, is 
shown in Figure 1.3. A similar structure had been found in solution with an early 
NMR structural analysis of a cisplatin-modified duplex decamer, cis-
[Pt(NH3)2 {d(TCTCG*G*TCTC).d(GAGACCGAGA)} Recently a 16-base-pair 
double-stranded deoxyoligonucleOtide containing a single cis- [Pt(NH3)2-{d(GPG) 
N7(G8), N7(G9)}] intrastand crosslink was crystallized as a 1:1 complex with the 89-
amino-acid domain A of HMG1 from rat, affording the first detailed picture of any 
Figure 1.3 The X-ray structure of the GpG platinated DNA duplex 
d(CCTCTG*G*TCTCC)/d(0GAC ) where G*G* represents the cis-
[Pt(NH3)2- { d(GpG)-N7(G6), N7(G7) q67 Colour code of cis- [Pt(NH3)2- { d(GpG)-
N7(G6), N7(G7)}] : Pt (yellow), N of NH3 (blue), G6 and G7: (green). 
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complex between a structure-specific HMG domain and a DNA substrate. 69,70  This 
revealed how intrastrand crosslinking unwinds and bends the duplex to facilitate the 
binding of proteins that contain one or more high-mobility-group (HMG) domains. 
Such interaction with HMG therefore blocks the cisplatin-DNA adducts from 
recognition by the repair apparatus, enhancing the cytotoxic properties of the drug. 
This provides a rational basis for the design of new chemotherapeutic strategies and 
of molecules with an increased affinity and specificity for cisplatin-modified DNA. 
Such agents could enhance the cytotoxic effect of cisplatin and related compounds 
by shielding damaged DNA from intracellular repair. 
In contrast to the situation for cisplatin, the trans isomer, transplatin has been 
found to be therapeutically inactive. Transpiatin cannot, for stereochemical reasons, 
link two adjacent guanine bases in DNA. Instead, alternative lesions, namely 1,3-
intrastand (GNG) cross-links '48  are formed which tend to rearrange into bifunctional 
interstrand adducts. 7 ' Furthermore interstrand cross-links between N7 of guanine and 
N3 of cytosine of the same base pair (GC) have been detected in vitro. 72 ' 73 Possibly 
these adducts made by transpiatin in vivo disrupt the duplex more profoundly than 
the intrastrand cross-link cis-[Pt(NH 3 )2 {d(pGpG)}], and may therefore be more 
readily recognized and repaired by the cell. 64 
Intercalation 
Intercalative binding is a noncovalent stacking interaction resulting from the 
insertion of a planar heterocyclic aromatic ring between the base pairs of the DNA 
helix. The flat intercalator is held rigidly in a well-defined orientation perpendicular 
to the axis of the helix. This DNA binding mode was first proposed by Lerman to 
explain the strong affinity for DNA of certain heterocyclic aromatic dyes such as the 
aminoacri dines . 74 Intercalators are of interest owing largely to their ability to inhibit 
nucleic acid synthesis in vivo, leading to their activity as mutagens, antibiotics, 
14 
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antibacterials, trypanoci des, schistosomicides and antitumour agents. Examples of 
intercalators 75 ' 76 are given in Figure 1.4. 
R2 
R( .(It 11 N 	 R 1 
Ph 	Et 
Proflavin : R1 = NH2 R2 = H 
Ethidium 	 Acridine Orange: R1 = N(Me) 2 , R2 = H 
9-Aminoacridine: R 1 = H, R2 = NH2 








OH 0 	NH(CH2 ) 2NH2(CH2 )20H 
Rhodamine 123 	 Mitoxatrone 
Figure 1.4 Structures of DNA intercalators and dyes. 
Intercalation stabilizes, lengthens, stiffens and unwinds the DNA double 
helix. 74 ' 77 ' 78 The binding energy for intercalation derives both from electrostatic and 
aromatic stacking interaction between the intercalator and DNA. Although this 
binding mode results in high affinities of the ligand for double-stranded DNA, the 
majority of the interactions are with the aromatic surfaces of the bases rather than 
with the distinctive functional groups in the DNA grooves. Consequently, many 
intercalators, such as ethidium and acridine, are relatively nonspecific DNA binding 
agents Sequence Sequence-specific DNA binding can be improved when the aromatic ring is 
substituted with special ancillary groups. One example is the acridine-4-
carboxamides which have a N-(2-dimethylamino)ethyl)-4-carboxami de side chain 
15 
Chapter 1 Introduction 
(Figure 1.5). This type of agent inhibits both topoisomeraseS I and 11•80,8L82 The X-
ray structure of one derivative of 9amino-6-bromO-DACA (DACA = N42-
(dimethylaminO)ethY1)acfld1ne4arb0h11de) complexed to the d(CG(5-
BrU)ACG)2 duplex shows that two molecules intercalate between the d(CG)2 base 
pairs and the terminal NMe2H group of the side chain H-bonded to N7 of one of the 
two guanines at the intercalation site and the neutralized N site of acridine H-bonded 
to the carbonyl group of the carboxamide (Figure 1.5). 83  Such specific major groove 
interactions together with the "DNA-induced" side-chain orientation which therefore 
blocks the groove are the major features for this type of DNA intercalator, and are 
likely to be important contributors to topoisomerase inhibition. 
_. 
NH2 
N 	 Br 




Figure 1.5 X-ray structure of 9amino-6-bromo-DACA intercalated into the DNA 
duplex d(CIG(5BrU)ACIG), where I indicates insertion. 83 Colour code of 
intercalator: 0 (red), N (blue), brown (Br), C (grey), H (white). 
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Another class of noncovalent DNA-binding agents is the groove binders, 
which fit into the DNA minor groove causing little perturbation of the DNA 
structure. One example of this class is the hairpin polyamides, designed as drugs that 
can target specific sequences in the DNA minor groove.  84  The NMR structure of the 
duplex oligonucleotide d(CGCTAACAGGC)'d(GCCTGTTAGCG) bound by a six-
ring hairpin polyamide ImPyPy-y-PyPyPy-J3-Dp (where Im = imidazole; Py = 
pyrrole; Dp = dimethylamino-propylarnide) has shown that the hairpin polyamide 
molecule fits in the minor groove and covers its five base pair recognition site (51 











HET = 2-hydroxyethanethiolato 
1 
[Pt(bipy)(en)] 2 
bipy = 2,2-bipyridine 
en = ethylenediamine 
[Pt(o-phen)(en)] 2 
o-phen = ortho-phenanthroline 
Figure 1.6 Structures and abbreviations for platinum intercalators. 
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Metal complexes also may bind to DNA by intercalation. It has been shown 
that square planar platinum(II) complexes containing a heterocyclic aromatic ligand 
(Figure 1.6), such as terpyridine (terpy), phenanthroline (phen), or bipyridine (bipy), 
bind to the helix noncovalently, inserting between the base pairs of the 
polynucleotide. 86 ' 878' 89' 9°  The crystal structure of {Pt(terpy)(HET)] bound to 
(dCpG)2 revealed that the flat metal cation intercalates symmetrically between base 
pairs with the hydroxyethaflethiolato chain projecting into the major groove of this 
miniature DNA helix. 9 ' These Pt metallointercalators have been utilized as electron-
dense probes in X-ray diffraction experiments on nucleic acids. 92,93,94 
A-a-[Rh(R, R-Me2trien)Phi] 3 
Figure 1.7 X-ray structure of the rhodium complex Aa[Rh(R,R-Me2triefl)Phi1
3 
bound to the duplex 5 1 -G(d1U)11 (iL'AAL-5 o11gonue1euL1u vv111 
insertion. 98  Colour code of rhodium complex : Rh (purple), Phi (yellow), N (light 
blue), C of Me2trien (grey). 
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Metal lointercalation has been extended to three dimensions by Barton using 
octahedral Co, Zn, Ru, Os or Rh complexes containing multi heterocyclic aromatic 
ligands such as phenanthroline (phen), 9,1 0-phenanthrenequinone diimine (phi) or 
[3,2-a :2,3 '-cjphenazine (dppz). 95 ' 96 '97 The application of octahedral 
metallointercalators has permitted the targeting of specific DNA sites by matching 
the shape, symmetry, and functionalities of the metal complex to that of the DNA 
target. The crystal structure of A-a-[Rh(R, R-Me2trien)Phi] 3 ((R, R-Me2trien = 2R, 
9R-diamino-4,7-diazadecane) bound to 5'-GTTGCAAC-3' duplex DNA revealed that 
the phi ligand is deeply inserted into the DNA base pair stack from the major groove 
at the site of 5t-GC-3' and the axial amine is located in a specific position to H-bond 
to the exocylic oxygen of the G base with a close contact of N•••O 2.9 A. The methyl 
group of the ligand is a comfortable 3.5-4.1 A distance from the thymine methyl 
carbon (Figure 1.7). Those interesting binding features may contribute to the DNA 
site recognition ability of this Rh intercalator. 98 Moreover, these metallointercalators 
possess interesting photophysical, photochemical, and redox properties and therefore 
are being developed as powerful agents for probing and targeting nucleic acids. 97 
Simultaneous Covalent and Intercalative Binding 
A recent development has been the design and synthesis of complexes in 
which an intercalator and a chemically reactive platinum functionality are covalently 
linked. The interactions of these and other multifunctional molecules with nucleic 
acids are of interest since they introduce potentially new modes of binding and can 
yield information on the mutual interactions of functional groups held in close 
proximity. 
Planar aromatic ligands such as doxorubicin (dx), 99 ' °° acridine orange 
(AO),' ° ' 9-aminoacridine (9-AA), 102  and ethidium bromide (Eth)' °3 have been 
incorporated into Pt complexes as potential intercalators (Figure 1.8). For 
Ff1, 
P'A 
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[Pt{AO(Cll2)6en}Cl21 complex, there is a hexamethylene chain linking the reactive 
platinum moiety {Pt(en)C1 2 } to the acridine orange; '°' for cis-[Pt(NH 3 )2(N9-9-
AA)Clf, the platinum moiety is bound directly to an intercalator.' °2 The DNA 
binding and modelling studies have shown that these Pt-intercalator complexes can 
react with DNA covalently and intercalatively, and the DNA platination can be 
sensitive to sequence-dependent local DNA structure modulations such as those 
+ 





H 	 + 
HA 	NH 
HA xcl 
[Pt{AO(C H 2 )6en}C I2 ] 	 cis-[Pt(N H 3 ) 2 (N9-9-AA)CI] 
AO = acridine orange 9-AA = 9-aminoacridine 
H 
cis-[Pt(tba)(dx)C 1 2] 
tba = tert-butylamine 
dx = doxorubricin 
Figure 1.8 Structures and abbreviations of platinum complexes covalently linked to 
DNA intercalators. 
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accompanying intercalator binding. ' 02 " 03 " 04 Although the toxicity of many Pt-
intercalator complexes precludes their use as drugs, antitumor activity has been 
reported for [Pt {AO(CH2)6en } Cl 2J,' °5 cis-[Pt(tba)(N3-dx)C12] ( tba = tert-
butylamine), 99 and for platinum complexes of mitoxantrone. 106 
Planar aromatic ligands have also been introduced into transplatin, trans-
[PtC12(NH3 )2], for development of a new class of anticancer drug (Figure 1.9). When 
the ammine is changed to a planar aromatic N donor ligand such as pyridine, thiazole 
or quinoline as in trans-{PtC] 2(NH3)L] (L = planar aromatic N donor), the 
cytotoxicity of the trans complex is dramatically enhanced.' °7 ' 48 This has been 
attributed to the interaction of the planar aromatic ligand with the DNA duplex, 
perhaps partially by intercalation. 108,109  The transplatin derivative trans-[PtC1(PyAc-
N,O)(NH3 )J (PyAc = pyridin-2-yl acetate) also exhibits enhanced cytotoxicity and 
appears to produces its biological activity via a "pseudobifunctional" mechanism 
(covalent/intercalative 10 





CI 	NH3 	Ci 






trans.[PtCI(PyAc-N, 0)(NH 3)] 
PyAc = pyridin-2-yi-acetate 
Figure 1.9 Structures and abbreviations for type trans-[PtCl 2(NH3)L] complexes. 
1.6 Project Aims 
Ruthenium compounds provide a particularly promising and versatile path 
toward the development of new antitumour drugs. Finding Ru compounds more 
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potent than cisplatin with a broad spectrum of tumor sensitivity but low toxicity is a 
general aim of the research. The Ru(III)-chemotherapeutic agents designed on the 
basis of the "activation by reduction" hypothesis have often yielded good results."' 
The determination of the modes of tumour uptake and DNA binding by Ru 
complexes in actual biological organisms still forms a challenge for future research. 2 
On the other hand, the success of NAMI-A against 12  will stimulate more 
innovative studies in testing metal compounds in cell and animal systems. 
Our laboratory has been investigating Ru(II) arene complexes as a potential 
new class of chemotherapeutic agents. The recent research results have been 
encouraging. The goal is to find compounds that may be active against a broad 
spectrum of turnours that do not respond, or acquire resistance, to cisplatin. To 
achieve this goal intensive research efforts are required. The aims of my project were 
as follows. 
The design and synthesis of a series of novel (q 6_polycyclic arene)Ru(II) 
complexes as potential anticancer agents as well as investigation of their anticancer 
activities. 
Design and synthesis of di-nuclear Ru(II)(arene) complexes as potential 
bifunctional DNA cross-linking agents. The increased DNA binding is expected to 
lead to a distinct and unique profile of anticancer activity. 
Investigation of the structure-activity relationships among these mono- and di-
nuclear Ru(II) arene anticancer agents, including studies of their binding to 
nucleobases, nucleotides and polynucleotides. 
22 
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Chapter 2 Experimental Methods 
2.1 Instruments 
2.1.1 NMR Spectroscopy 
NMR spectra were recorded on either Bruker DMX 500 ('H, 500.13 MHz; 
' 3C, 125.72 MHz; ' 5N, 50.66 MHz; 31 P, 202 MHz) or Bruker DMX 360 ('H, 360.13 
MHz) Varian UIIILYJ2Y0vA  (H, 599.82 MHz; ' 5N, 60.80 MHz) NMR spectrometers 
using TBI ['H, 13C, XI  or triple resonance [ 1 H, 13C, ' 5N] probeheads, respectively, 
and equipped for z-field gradients. All spectra were acquired in 5 mm NMR tubes 
using standard sequences. All data processing was carried out using XWIN-NMR 
version 2.0 (Bruker U.K. Ltd.). 'H NMR chemical shifts were internally referenced to 
1, 4-dioxane (3.77 ppm), or to the methyl singlet of sodium trimethylsilylpropionate 
(TSP, 0 ppm) in aqueous solutions, or to CD2HCOCD 3 (2.06 ppm) in acetone-d6 
solution, or to (CD2R)2S0 (2.50 ppm) in dmso-d6 solution. 1 5  N resonances were 
referenced to 1 M 15NH4CI in 1.5 M HCl (external) at 0 ppm and 31P resonances to 
85% 113PO4 (external) at 0 ppm. NMR work was carried out with the aid of Dr John 
A. Parkinson. 
2.1.2 X-ray Crystallography 
X-ray crystallography studies were carried out on a Bruker SMART-APEX 
CCD or a Stoe Stadi-4 serial diffractometer equipped with Oxford Cryosystems low-
temperature devices by Dr Simon Parsons, Dr Robert 0. Gould, Dr Robert A. Coxall, 
lain Oswald and James Davidson. XP 5.1 was used for drawings of crystal structures. 
2.1.3 CHN Analysis 
CHIN analysis were performed by the CHIN Service at the University of 
Edinburgh. 
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2.1.4 High Performance Liquid Chromatography 
The following equipment was used: Hewlett-Packard Series 1100 
Chemstation, HP 1100 series quaternary pumps, HP 1100 series vacuum degasser, 
HP variable wavelength D2 lamp UV/Vis detector, HP enhanced integrator, 
Rheodyne sample injector with 25 - 100 j.xl loops, Hamilton microlitre syringes. All 
water for HPLC was purified using a Millipore Elix 5 system, followed by an 
Elgastat UHQ II deioniser, and filtered using PK50, 0.45, 47 mm nylon 66 
membranes from Anachem. The data were analysed using HP chemstation for 
Windows '95. The column and mobile phase used was dependent on the system 
being studied. The HPLC analysis was carried out with the aid of Dr Fuyi Wang. 
2.1.5 Ultraviolet and Visible Spectroscopy 
Ultraviolet and visible absorption spectra were obtained on a Perkin-Elmer X 
16 UV-Vis recording spectrophotometer using 1 cm pathlength quartz cuvettes. The 
temperature was controlled using a PTP1 Peltier Temperature Programmer. Spectra 
were normally referenced to solvent alone. Spectra were processed with UVWinlab 
for Windows '95. 
2.2 Nuclear Magnetic Resonance Spectroscopy 
The basic theory and concepts of NMR are given in detail in textbooks such 
as Mason 1 and Evans 2.  The nuclei used in this study and their magnetic properties 
are given in Table 2.1. 
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Table 2.1 NMR properties of nuclei studied in this thesis. 
Nucleus Spin Natural Abundance Magnetogyric Ratio NMR Frequency 
(I) (%) 7/107  rad T' at 11.74 T (MHz) 
'I-I 1/2 99.98 26.75 500.13 
31 p 1/2 100 10.80 202.4 
15 N 1/2 0.37 -2.71 50.66 
2.2.1 Exchange Effects in NMR Spectroscopy 
The term "chemical exchange" in NMR refers to any process in which a 
nucleus exchanges between two or more different environments in which its NMR 
parameters (e.g. chemical shift, scalar coupling, or relaxation) differ. 3 The process 
may be intra- or intermolecular, involving one or several species, respectively. 
Typical examples are isomerization or ligand exchange processes. The effect of the 
exchange process on the NMR spectrum depends upon its rate, relative to the 
magnitude of the accompanying change in NMR parameters. For example, if an 
ionization process is accompanied by a change in chemical shift of 250 Hz, an 
exchange rate of > 1000 sec' would be regarded as fast, one of 250 see - ' as 
intermediate, and one of< 100 sec 1 as slow on the "NMR time scale". Each of these 
regions of exchange leads to characteristic effects on the NMR spectrum (Figure 2.1). 
In slow exchange, separate resonances are seen for the nucleus of interest in each of 
the two states A and B. By contrast, in fast exchange a single averaged resonance is 
observed. In the intermediate exchange region, there is a complex series of changes 
in appearance of the spectrum as the separate signals coalesce into one. 
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T << 	- 
t 114 (u 
112 (UA - ¶33) 
= 213 (u - 
= 121 (tA - ¶33) 
t>> l/(u ¶33) 
'JA 	 VB 
Figure 2.1 Change in chemical shifts and linewidths in the presence of chemical 
exchange between two equally populated environments. Bottom to top: increasing 
exchange rates as labelled (from ref 3). r : exchange time; v : resonance frequency. 
For 'H NMR experiments detecting interconversion between two isomers, 
isomers A and B appear at two resonance frequencies VA  and VB. 
A-B 
If it is assumed that this exchange process obeys the first-order kinetics and depends 
on temperature, their exchange rate constants and activation parameters can be 
obtained from the temperature dependence of the resonance lines. 4 If the coalescence 
temperature T0 at which the two signals just coalesce is detected, the rate constant /c 
is given by: 
k2.22Av 
Here Lw is the separation in Hz between the two signals in the absence of exchange. 
It is determined experimentally from spectra recorded at temperatures which are as 
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far below the coalescence temperature as posssible. This equation applies only if the 
exchange process is first-order kinetically, if the two singlets have equal intensity, 
and if the exchanging nuclei are not coupled to each other. An important fact of ic is 
that it is determined by the magnitude of At', which is in turn proportional to the 
resonance frequency. Thus T is not a constant, but depends on the observation 
frequency. 
For a pH titration experiment, 
A+ H' 	- AH 
the proccess of protonationldepronation is usually very fast with respect to the 
difference in chemical shift between the two species A and AFI. Thus a single 
resonance is observed, whose chemical shift is the weighted average of the chemical 
shifts of the deprotonated species A and protonated species AH t , 3 
8ohsd = 6A (XA) + öfijj (X,), where XA and XfiJ-j are the fractional populations 
of species A and AH, respectively, with XA + XAH = 1. 
From the chemical shift data derived from pH titrations, pKa values of 
deprotonation can be calculated according to the following formula. 5 
8A8AH < 
5obsd = 	 + 
2.2.2 Ruthenium NMR 
Ruthenium has a very broad coordination chemistry with its oxidation states 
varying from -II up to + VII. The most relevant oxidation states for bioinorganic 
chemistry are Ru II, III, and W. Among these, the +111 state cannot be readily 
detected by conventional high-resolution NMR methods because of its 
paramagnetism. The paramagnetic nature of low-spin, d 5 Ru(III) strongly affects the 
NMR spectra of its coordinated ligands. 6 For example, the resonances of protons are 
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generally severely shifted and broadened by Ru(ffl). The paramagnetic effects 
generated by the metal centre can be used to assist in assigning the geometry of the 
complex. 7 The Ru complexes studied in this thesis contain diamagnetic Ru(ll) and 
they have all been readily studied by using 'H, 31 P, and ' 5N NMR. 
Table 2.2 NMR parameters of 99Ru and ' ° 'Ru. 
Nucleus Spin Natural Abundance Receptivity relative Quadrupole 
(I) (%) to ' 3 C moment, 10.28 Q 
in 2.A 
99 R 5/2 12.72 1 	0.83 0.076 
101 R 1 	5/2 17.07 1 	1.56 0.44 
Although not a technique utilised in this thesis, it is interesting to consider the 
potential of using ruthenium NMR. Ruthenium has two magnetically active isotopes 
(Table 2.2): 99Ru (natural abundance = 12.7 %) and ' ° 'Ru (natural abundance = 17.1 
%). Both isotopes have I values of 5/2, but 99Ru has a much lower quadrupole 
moment than ' ° 'Ru and hence gives narrower spectral lines .8  This makes 99Ru more 
preferable than ' ° 'Ru despite the higher receptivity of the latter. 99Ru and 101Ru NMR 
in solution was first reported for Ru04 in 1981. These nuclei are also useful for 
solid state NMR,' ° for example, for investigating magnetic properties of ruthenium 
oxides." 99Ru has a large range of the chemical shift, for example, from —1270 ppm 
for RuCp2 (in CH202 solution) to +7821 ppm for [Ru(NTh)6] 2 (in aquaous 
solution) ' 2 and is sensitive to the environment around the metal centre which allows 
study of subtle electronic changes at the Ru moiety. 13 99Ru NMR provides a 
powerful tool for structural analysis and for distinction of isomers in enantiomeric 
mixtures. ' 4" 5 For examples, mer- and fac- isomers of [Ru(2,3-dpp) 3 1[PF6] 2 (2,3-dpp 
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= 2,3-bis(2-pyridyl)pyrazine) in acetonitrile solution were distinguished by 99 R 
NMR at 4510 and 4499 ppm, respectively. 14  Generally, 99Ru NMR is sensitive to the 
species and requires high symmetry and high concentration (50-500 mm). Therefore 
it was not investigated in this thesis since the Ru(arene) complexes have low 
symmetry. 
2.2.3 31 P NMR 
31 P is spin V2, 100% abundant and has a receptivity relative to the proton of 
0.0663. In consequence, this is an easy nucleus to observe. 31 P NMR has a large 
chemical shift, ranging up to 1362 ppm in Bu'P{Cr(CO) 5 } 2, but a range from —224 
ppm (P4S3) to +326 ppm (P4010) is more typical. 16  The chemical shift is sensitive to 
the coordination environment. 31P NMR is a general method to investigate the 
reaction of phosphate groups with metal anticancer complexes.' 7" 8 "9 The pH effect 
on the chemical shift is obvious when deprotonation/protonation process happens to 
the phosphate group. Thus, the curve of 31 P NTvIR chemical shift as a function of pH 
can provide the pKa values of phosphate groups. In this thesis, 3 'P NMR has been 
used to investigate the direct coordination of Ru(ll) to phosphate groups of DNA 
nucleotides or phosphate buffer (Chapter 6) and to detect the possible fl-bonding 
interactions between the amino NH and phosphate 0 group (Chapter 5). In particular, 
the case of direct binding leads to a large 31 P NMR downfield shift (up to 5 ppm), 
whilst fl-bonding only leads to a small 3 'P NMR downfield shift (less than 1 ppm). 
2.2.4 15N NMR 
14 N NMR spectroscopy can be useful for ammine and amine complexes, 20,21 
but ' 4N is a quadrupolar nucleus (I = 1, 99.6% natural abundance), and quadrupolar 
relaxation is dominant when the environment of 14N has a low symmetiy. 22 This can 
lead to very broad lines and a consequent reduction in sensitivity 
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' 5N has spin 1/2 and is recently the isotope of choice for the observation of 
nitrogen, despite its low natural abundance (0.37%) and low NMR sensitivity. Its 
receptivity as compared to 'H is only 3.85 x 10' 6 . The sensitivity of detection can be 
improved by the use of multipi ise techniques and inverse detection technology. 23,24,25 
For example, the sensitivity of ' 5N can be greatly improved by the use of inverse 
detection methods ('H-detected 15N), by a theoretical maximum of 306 
I 'yH I / 7N I )5/2) with respect to directly detected ' 5N, such that signals can be 
detected in aqueous solutions at concentrations of physiological relevance (5 tM). 2 ' 
'H-detected inverse methods are applicable to any system which contains a 15N atom 
with a measurable spin-spin coupling to 'I-I (i.e. 'J(' 5N, 'H)) in ammine, primary and 
secondary amines, but not tertiary amines although a longer range coupling can 
sometimes be utilised. In practice the best applications are for those systems with 
large one-bond couplings (e.g. Ca. 73 Hz for ' 5N3) 
The protons bonded to ' 5N can be selectively detected by these methods with 
natural abundance ' 5N, but it takes several hours of instrument time and requires high 
concentrations of complexes (> ca. 30 mM in a 5-mm tube). By enriching complexes 
with >95% 15 N, it is possible to work at low millimolar concentrations, and even 
approach micromolar concentrations of physiological relevance. Much work has 
recently been done to apply ' 5N-edited 'H NMR and 2D ['H, ' 5N] heteronuclear 
single/multiple quantum coherence (HSQC/HMQC) NMR spectroscopy to the direct 
detection of ammine and amine N-H resonances of ' 5N-labeled platinum complexes 
in aqueous solution. 26,27,28 [lfl, 15N] HSQC (see section 2.3) NMR has proven to be 
a powerful method for studying DNA platination reactions by cisplatin and other 
platinum complexes. The technique requires the use of ' 5N-labeled compounds and 
allows observation of all platinated species at low (micromolar) concentrations. The 
work in this thesis has involved ' 5N NMR studies of ' 5N in natural abundance for 
characaterization of mono Ru(arene) diamine and dinuclear bis-Ru(arene) diamine 
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complexes (Chapter 4) and 15N-labeled Ru compounds for reactions with DNA 
nucleobase derivatives (Chapters 5 and 6). 
2.2.5 Water Suppression 
NMR spectra for biomolecules are normally obtained from aqueous media, 
such as D20 (99.9%) or H20/D20 (90%: 10%, v/v). For metal anticancer complexes, 
such as Pt am(m)ine complexes, the Pt-NH 'H NMR resonances cannot be readily 
detected in D20 solutions because the half-life for H-P exchange is only a few 
minutes at ambient temperatures. 29,11  In H20 solutions, the intense 1120 peak causes 
severe dynamic range problems. For the Ru(arene) diamine complexes studied in this 
thesis, similarly, the Ru-NH 'H NMR resonances cannot be detected within minutes. 
Therefore all the studies in aqueous media were carried out in H20/D20 (90%: 10%, 
v/v). Special techniques are needed to suppress the large HOD (or 1120) signal. 
"Presaturation" and "WATERGATE (WATER suppression by GrAdient Tailored 
Excitation)" were used in this study. 3 ' The former method is applied by irradiation at 
frequency of the HOD (1120) resonance during the relaxation delay between pulses, 
before the observe pulse in an experiment. The disadvantage is that exchangable NH 
protons can also be saturated resulting in loss of intensity. The WATERGATE 
method uses selective 180° pulse field gradients to select different coherence 
pathways, and yields a superior water suppression. 
2.2.6 Two Dimensional NMR 
Heteronuclear Single-Quantum Correlation (HSQC) 
The heteronuclear experiments allow identification of the chemical shifts of 
protons and X-nuclei that are directly coupled. One obvious use of this correction 
information is to allow assignments already made for one nuclear species to be 
transferred to the other. A more important but less obvious use is in overcoming 
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problems caused by overlap in the proton spectrum: in the heteronuclear 2D spectrum 
the proton resonances are spread out according to the shifts of the heteronuclei to 
which they are coupled. 
The heteronuclear single quantum coherence (HSQC) technique belongs to 
the family of indirect (or inverse) detection techniques. An important feature of the 
experiment is that the proton magnetisation which is detected during t2 originated as 
proton magnetisation at the start of the sequence. The main advantage of this 
technique is the enhanced sensitivity, a theoretical maximum of [I7HI/IyxI]512  (306 for 
with respect to direct detection, and relatively short repetition time according to 
the T 1 of the protons and not of the X-nuclei. 32 Therefore it is possible to detect 
species at concentrations of physiological relevance (mM or even .LM) in D20 or 
aqueous solution (90% H20/10% D 20) where labile NH protons can be observed. By 
means of selective labelling ' 5N, this technique can also simplify a complicated 
spectrum in which only those protons directly attached to 15N atoms are detected. The 
basic HSQC pulse sequences is shown in Figure 2.2. 
7t/2 	iv 	n12 	it 	n/2 	it 
it 	it/2 	 7cI2 	it 
I II tj III 
Figure 2.2 Basic HSQC pulse sequences. The delays A and t are '/4J and 'AJ 
respectively, where J is the one-bond HX coupling constant. 
The Pt- 15N11 protons can be detected selectively by the use of ['H, ' 5N] single 
quantum coherence (HSQC) pulse sequences. A 1D 1H spectrum containing only 
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resonances from Pt-' 5NH species is obtained by acquiring only the first increment in 
a two-dimensional experiment; resonances for CH and OH (including water) are 
eliminated. This is particularly useful in studies of body fluids or cell culture media, 
where only the signals from platinum complexes are detected and thousands of other 
overlapping 'H resonances are filtered out. If ' 5N decoupling is employed during 
acquisition (e.g. the GARP method), then each type of Pt-NH resonance appears as a 
singlet. In practice the water resonance is so intense that it is usually necessary to use 
additional solvent suppression techniques (e.g. presaturation). The addition of an 
H20 T2 relaxation agent (e.g. 0.5 M (NH 4)2SO4) can also be helpful to detect NH 
peaks very close to the H2O peak. A large improvement in water suppression is 
achieved by the use of pulsed field gradients for coherence selection, for example, by 
use of the HSQC sequences of Stonehouse et al. 33 
COrrelation SpectroscopY (COSY) 
COSY is a two-dimensional homonuclear (H, H)-correlated NMR 
experiment which is used to correlate the chemical shifts of 'H nuclei which are J-
coupled to one another. It is the standard 2D experiment that can be used to identify 
pairs of protons that have a scalar spin-spin coupling connectivities. Two types of 
COSY sequences were used in this thesis: magnitude COSY 34,35 and double-
quantum filtered (DQF-) COSY 36. Their basic pulse sequences are shown in Figure 
2.3. The 2D spectrum acquired in these magnitude COSY experiments has line-
shapes in both Fl and F2 that have both absorption and dispersion contributions. This 
means that it is not possible to phase the spectrum so that the peaks are purely 
absorptive, and the spectrum must be displayed in magnitude mode. A typical 
resolution is 3 Hz/pt. This is sufficient for resolving large couplings, but not for 
resolving small ones. In order to resolve small J-couplings, it is necessary to use fine 
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digital resolution and this requires a significant increase in the experiment time. In 
general, if higher resolution is desired, it is desirable to use DQF-COSY. 
More favourable lineshapes can be obtained by using the double-quantum 
filtered COSY sequence (DQF-COSY) (Figure 2.3b). This experiment is phase-
sensitive, i.e. the cross peaks of the DQF-COSY spectrum can be displayed with pure 
absorption line-shapes in both Fl and F2. A phase-sensitive spectrum has a higher 
resolution than an otherwise equivalent magnitude spectrum because the magnitude 
lineshape is broader than the pure absorption lineshape. The DQF-COSY sequence 
has two significant advantages. First, partial cancellation of the diagonal peaks in a 
DQF-COSY spectrum means that the diagonal ridge is much less pronounced in a 
DQF-COSY spectrum than it is in a normal COSY spectrum. This makes it easier to 
observe cross peaks between signals which are close together in chemical shift. The 
double quantum filter elimnates the strong signals from, e.g., solvent 11s  that do not 
experience homonuclear J-coupling. These signals would otherwise dominate the 
spectrum and possibly be a source of troublesome ti noise. 
ir/2 
dl ri 1 [Jac 
it/2 
dl [1 , ri d2 
Figure 2.3 Pulse sequences for two-dimensional (a) COSY and (b) DQF-COSY. 
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Nuclear Overhauser Effect SpectroscopY (NOESY) 
The NOESY experiment 37,38  is often used to identify pairs of protons that are 
undergoing cross-relaxation, i.e. protons that would show an NOE in 1D 
experiments. Most commonly, NOESY is used as a homonuclear 'H technique. In 
NOESY, direct dipolar couplings provide the primary means of cross-relaxation, and 
so spins undergoing cross-relaxation are those which are close to one another in 
space. Thus, the cross peaks of a NOESY spectrum indicate which 'H's are close to 
which other 'H's in space. 
The characteristic feature of the NOESY pulse sequence (Figure 2.4) is the 
mixing time t (the time during which cross relaxation occurs). The cross-peaks are 
generated by magnetisation transfer that takes place during the mixing time so the 
length of this delay must be chosen according to the rate of the transfer process. In 
contrast to the COSY experiment, both cross-peaks and diagonal peaks in NOESY 
spectra can be obtained with absorption-mode lineshapes. The experiments are 
therefore eminently suitable for studying macromolecules. If presaturation is used in 
a NOESY experiment it is usually also necessary to irradiate the solvent during the 
mixing time. A complicated factor is that the NOESY pulse sequence cannot 
distinguish between magnetisation transfer caused by cross-relaxation and 
magnetisation transfer by chemical exchange. In macromolecules, both give cross-
peaks of the same sign as the diagonal. 
acq. 
dl 	I I 	ti I 	I 'Em 
Figure 2.4 2D NOESY pulse sequence. m  is the mixing time. 
TOtal Correlation SpectroscopY (TOCSY) 
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TOCSY provides a different mechanism of coherence transfer than COSY for 
2D correlation spectroscopy. 39 ' 4° In TOCSY, cross peaks are generated between all 
members of a coupled spin network. An advantage is that the "net" coherence 
transfer produced can be arranged to create pure absorption mode spectra with 
positive intensity peaks (rather than "differential" coherence transfer which causes 
spectra with equal positive and negative intensities). In traditional COSY, cross-
peaks have zero integrated intensity and coherence transfer is restricted to directly 
spin-coupled nuclei. In TOCSY, oscillatory exchange is established which proceeds 
through the entire coupling network so that there can be net magnetization transfer 
from one spin to another even without direct coupling. The isotropic mixing which 
occurs during the spin-lock period of the TOCSY sequence exchanges all in-phase as 
well as anti-phase coherences. The basic pulse sequence is shown in Figure 2.5. 
The coherence transfer period of the TOCSY sequence occurs during a 
multiple-pulse spin-lock period. The multiple-pulse spin-lock sequence most 
commonly used is MLEV-17. The length of the spin-lock period determines how 
"far" the spin coupling network will be probed. A general rule of thumb is that 1/(10 
JHH) should be allowed for each transfer step, and five transfer steps are typically 
desired for the TOCSY spectrum. The TOCSY spectrum can be phased so that all 
cross peaks and diagonal peaks have positive intensity. 
702 	Spin lock 
q. 
dl ri 1E'M _ 	 It2 
Figure 2.5 2D TOCSY pulse sequence 
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3.1 Introduction 
Cisplatin is an effective clinical anti-tumour drug, however, it also has many 
side-effects, such as nausea, neuropathy and loss of high frequency hearing.' Our 
laboratory has been developing organometallic Ru(II)(arene) complexes as novel 
anticancer agents. A series of nine Ru(arene) complexes with different substituted 
aromatic rings, has been synthesised in this laboratory2 and assessed against the 
human ovarian cancer cell line, A2780, and drug resistant sub-clones by the 
Oncology Unit, Western Gemeral Hospital. The IC 50 values for the Ru(II) 
compounds in A2780 cells ranged from 6-200 RM, compared to 0.6 RM for cisplatin 
and 6 1iM for carboplatin. The two most active compounds, [(11 6 
biphenyl)Ru(en)Cl][PF 6] (7, IC50 6 j.tM, where en = ethylenediamine) and [(Ti 6-p-
cymene)Ru(en)C1J[PF6] (IC50 8 11M) were evaluated in cisplatin-resistant A2780cis 
cells and multi-drug resistant 2780 (AD = adriamycin) cells. Both compounds 
were non-cross resistant in A2780cis, whereas cross-resistance was observed in 
A2780AD . 3 
These preliminary cytotoxicity tests indicated that more potent activity was 
associated with chemical stability and increased hydrophobicity of the compounds. 4 
The aromatic ligand is likely to exert a larger effect on the anticancer activity, and 
thus, introducing variety into the arene ring allows investigation of structure-activity 
relationships for the Ru(arene) complexes. 
In this Chapter, polycyclic ring systems are introduced into Ru(II) complexes 
to allow investigation of their anticancer activity. A range of novel 
tetrahydroanthracene (THA, C 14H 14) chloro (TI  complexes (1, 2 and 3) 
and dihydroanthracene (DHA, C14H12) chloro ( 6-C 14H 12)Ru(II) complexes (4, 5 and 
6) were synthesised (Scheme 3.1) and characterised by 'Fl NMR, X-ray 
crystallography and CHN analysis. They show interesting structural properties which 
may lead to exciting biological activities. The details of the synthesis and 
50 
Chapter 3 (ij6-polycyclic arene)Ru(II) Complexes 
characterisation for the ethylenediamine complexes [(il 	(1) 
and [(TI 	(4) will be reported in Chapter 5, but their structures 
are described here for comparison with other Ru(arene) complexes. In addition, the 
three aqua Ru(arene) complexes [(9 6-arene)Ru(en)(0H2)][PFd2 (arene = Bip 
(biphenyl), 8; THA, 9; DHA, 10) were also prepared and characterised by 'H NMR 
and X-ray crystallography. Their structural features are compared with their parent 
chloro complexes 7 ([(T1 6-Bip)Ru(en)Cl][PF 51), 1 and 4. 
3.2 Experimental Section 
3.2.1 Materials and Methods 
The complex [(ij 	(7) was prepared as previously 
decribed. 2  Ethylenediamine was freshly distilled over Na, and ethanol and methanol 
were dried over P205. Tetrahydrofuran (THF) was dried by distillation from Na-
benzophenone. 
3.2.2 Preparation of Chloro Ru(arene) Complexes 1-6 
1,4,5,8,9,1 0-Hexahydroanthracene (C 14H16) 
Anthracene (C 141­1 10, 4.0 g, 22.4 mmol) was dissolved in freshly dried TFIF 
(200 mL) and ethanol (40 mL). This mixture was added to liquid NH 3 (500 mL) 
which had been condensed under argon into a I litre flask equipped with a Dewar 
condenser, cooling bath (dry-ice/acetone) and mechanical stirrer. Sodium (10.40 g, 
0.45 mol) was added in small pieces over a period of 20 mm. After a further 50 mm 
stirring at —60°C, the cooling bath was removed and the ammonia was allowed to 
evaporate under an argon flow with stirring. To the residue was added 50 mL water 
slowly to decompose the excess of sodium and then a further 150 mL. This was 
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Scheme 3.1 Preparation of (A) {( 6-C 14Hj4)Ru} 2 complexes 1, 2 and 3, and (B) 





	 4, Lithium/NH3 
000 C14HI6 	 CICO 
Ru(III)Cl 3 xHO 
	
4, 
I [(°-C14H 14)Ru(en)CIJ[PFJ 
	
4 [(Tl6-C14H12)Ru(en)CIJLPF6J 
2 (( 6-C14H 14)Ru(DMSO)Cl2] 
	
5 ftq 6-C 14H 12)Ru(DMSO)C121 
3 [(ln6-C14H14)Ru(NCCH3)2C1][PF5] 
	
6 (( 6-C 14 H 12)Ru(NCCH 3 )2CI][PFJ 
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with saturated NaCI solution (2 x 250 mL) and dried over MgSO4. Removal of 
diethyl ether on a rotary evaporator afforded a white solid, which was recrystallised 2 
x first from benzene/chloroform (1:1), and then from benzene to yield a white needle 
product, 98% pure by 'H NMR. This was used for preparation of dimer [(6 
C14H,4)RuCl2]2. Yield: 1.54 g, 8.36 mmol, 37.3 %. 'H NMR (CDCI3) 8: 5.68 (s, 
411), 2.51 (s, 8H), 2.37 (s, 4H). 
I ,4,9,1O-Tetrahydroanthracene (C14H14 6 
9,10-Dihydroanthracene (C14H12, 6.5 g, 36.1 mmol) dissolved in 540 mL 
THF was added to refluxing ammonia (I 100 mL) which had been condensed under 
argon into a 2 litre flask equipped with a Dewar condenser, cooling bath (dry-
ice/acetone) and mechanical stirrer. Li wire (0.66 g, 95.1 mmol) was added in small 
pieces over a period of 20 mm. After refluxing for 2.7 h with stirring, 60 mL ethanol 
was added to the reaction mixture and then 130 mL water, and the ammonia allowed 
to evaporate overnight. This was extracted with diethyl ether (3 x 250 mL) and the 
combined ether layers washed with saturated NaCl solution (1 x 500 mL) and dried 
over MgSO4. Removal of ether on the rotary evaporator afforded a light yellow solid 
which was recrystallized 5 x from benzene to remove of the hexahydroanthracene 
(C141-116) as white needles. The residue (3.3 g) contains the starting material C141112 
(18.6%) and C141-114 (81.4%). This mixture was directly used for preparation of dimer 
[( 6-C14H,2)RuC12]2 'H NMR (CDC],) of C1411,4 6: 7.11 (m, 411), 5.78 (s, 211), 3.25 
(s, 4H), 2.70 (s, 4H). 
((1 6-C14H14)RuCI212 and [(ii 6-C14H12)RuCl2]2 
[( 6-C14H14Ru(en)CIJ[PF 5] ( I) and [( 6-C14 Hi2)Ru(en)CI][PF 6] (4) 
For details of preparations, see Chapters. 
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[(1 6-C14H 14)Ru(dmso)C1 2] (2) 
[( 6-C14Hi4)RuC12]2 (0.05 g, 0.07 mmol) was dissolved in dimethyl sulfoxide 
(2 mL) and filtered to yield a deep red solution. Slow diffusion of diethyl ether into 
this solution resulted in the formation of brilliant red crystals suitable for X-ray 
diffraction. The crystals were collected and washed thoroughly with diethyl ether (4 
x lOmL). 
Yield: 0.03 g, 0.07 mmol, 49.5%. Anal. Calcd for C16H20C12ORuS (432.37): C, 
44.45; H, 4.66. Found: C, 44.41; H, 4.51. 'H NMR (CDCI3) 8: 5.74 (s, 2H), 5.68 
(m, 2H), 5.50 (m, 2H), 3.50 (m, 211), 3.00 (m, 2H), 2.65 (m, 4H), 3.15 (s, 611). 
[(11 6-C 1 4H 14)Ru(NCCH 3 )2C11[PF51 (3) 
[('I 6-C,4H,4)RuC 12I2 (0.10 g, 0.144 mmol) was suspended in 10 ml, 
acetonitrile. NH4PF6 (47.1 mg, 0.288 mmol) in 2 mL acetonitrile was added in one 
portion. The reaction was stirred at 60°C without special precautions to exclude air. 
After 48 h the pale brown precipitate was filtered off and orange filtrate evaporated 
to yield an orange solid. This was recrystallized from acetonitrile/ether to yield 
orange crystals. 
Yield: 0.13 g, 0.238 mmol, 82.8%. Anal. Calcd for C18H20CIF6N2PRu (545.86): C, 
39.60; H, 3.69; N, 5.13. Found: C, 39.17; H, 3.48; N, 5.47. 'H NMR (Acetone-d 6) 6: 
5.95 (s, 2H), 5.80 (m, 4H), 3.28 (s, 4H), 2.87 (d, 4H), 2.71 (m, 614) 
[(ti 6-C14H12)Ru(dmso)C12] (5) 
I(TI 	(0.05 g, 0.07 mmol) was dissolved into dimethyl 
sulfoxide (1 mL) and filtered to yield a rose red solution. Slow diffusion of diethyl 
ether into this solution resulted in the formation of brilliant red crystals suitable for 
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X-ray diffraction. The crystals were collected and washed thoroughly with diethyl 
ether (3 x 10 mL). 
Yield: 0.025 g, 0.058 mmol, 41.4%. Anal. Calcd for C16H,8C12ORuS (430.35): C, 
44.65; 11, 4.21. Found: C, 44.08; 11, 4.18. 1 H NMR (CDCI3) 8: 7.25 (m, 4H), 5.75 
(m, 4H), 4.25 (d, 2H), 3.80 (d, 2H), 2.97 (s, 611). 
1(T,
6-C14H12)Ru(NCCH3)2C 1][PF6] (6) 
101 6-C14H12)RuCI212 (0.10 g, 0.142 mmol) was suspended in 10 mL 
acetonitrile. NH4PF6 (48.6 mg, 0.298 mmol) in 2 mL acetonitrile was added in one 
portion. The reaction was stirred at 60°C without special precautions to exclude air. 
After 25 h the pale brown precipitate was filtered off and orange filtrate evaporated 
to yield an orange solid. This was recrystallized from acetonitrile/ether to yield 
orange crystals. 
Yield: 0.125 g, 0.23 mmol, 81% . Anal. Calcd for C15H,8CIF6N2PRu (543.85): C, 
39.75; H, 3.34; N, 5.15. Found: C, 39.42; H, 3.33; N, 5.14. 'H NMR (Acetone-d6) 8: 
7.39 (m, 4H), 6.15 (m, 4H), 4.05 (m, 411), 2.85 (s, 3H), 2.45 (s, 3H). 
3.2.3 Preparation of Aqua Ru(arene) Complexes 8-10. 
A solution of AgPF6 (1.3 mol equiv) in H20 was added to a solution of [(TI 6 
arene)Ru(en)Cl][PF5], complex 7 (100 mg, 0.20 mmol), complex 1 (49.4 mg, 0.09 
mmol) or complex 4 (61 mg, 0.12 mmol), in 20 mL H20, giving a yellow-orange 
solution and an immediate precipitate of AgCl (Scheme 3.2). This mixture was 
stirred over night at 40°C (protected from light) and was then filtered to remove 
AgC1. Evaporation of the solution to dryness gave a dark-yellow product. This was 
recrystallized from water to afford a crop of fine yellow crystals. Further 
recrystallization from water at 4°C afforded yellow needles which were suitable for 
X-ray structure determination. 
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Rr1 6-biphenyl)Ru(en)(0H2)11PF61 2 (8), yield: 31.0 mg, 24.6%. 'H NMR (10% D20, 
pH 7.6): 8 7.80 (m, 2H), 7.618 (m, 3H), 6.116 (d, 211), 5.991 (t, 211), 8 5.844 (t, 111), 
5.967 (broad, 2H), 3.768 (broad, 2H), 2.455 (m, 2H), 2.390 (m, 2H). 
[(1 6-THA)Ru(en)(0H2)1[PF6]2 (9), yield: 49.0 mg, 83.6%. 'H NMR (10% D 20, pH 
4.5): 6 6.057 (broad, 211), 5.863 (s, 211), 5.808 (m, 211), 5.729 (m, 211), 4.045 (broad, 
2H), 3.357 (q, 2H), 3.015 (q, 2H), 2.760 (s, 411), 2.448 (m, 211), 2.368 (m, 2H). 
[(1 6-DHA)Ru(en)(0H2)11PF6 1 2 (10), yield: 30.0 mg, 39.5%. 'H NMR (10% D20, 
pH 6.7): 7.473 (m, 211), 7.407 (m, 211), 5.954 (m, 211), 5.857 (m, 2H), 5.737 (broad, 
211), 3.98 (q, 211), 3.864 (q, 2H), 3.654 (broad, 211), 2.10 (m, 211), 2.011 (m, 211). 
3.3 Results and Discussion 
(i 6-Ci4Hi4)Ru(ll) Complexes 1-3 
The THA (C 14H, 4) complexes, [(i6-C,4H14)Ru(en)Cl][PFd  (1), [(6 
C 14H, 4)Ru(DMSO)C1 2] (2) and [(TI  (3), were 
synthesised by reaction of the dimer [(11 6-C14H1 4)RuCl2] 2 with three different ligands: 
ethylenediamine, DM50 and acetonitrile (Scheme 3.1). The preparation of the dimer 
[016-C14H,4RuCl2]2 began with anthracene (C,4H, 0) which was first reduced using 
sodium metal in liquid ammonia to give 1,4,5,8,9,10-hexahydroanthracene (C, 4H, 6).5 
Then, reaction between C 14H,6 and hydrated RuCI3 in refluxing ethanol afforded the 
yellow-brown dimer [( 6-C 14H, 4)RuC12]2 , 7 a member of the well-known chloro-
bridged polyruthenium family, where the C 14H,5 skeleton is aromatized in one outer 
ring by dehydrogenation and binding to Ru as a n-bonding arene. 
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Table 3.1 Crystallographic data for [(q 6-C141114)Ru(CNCH3)2C1][PFd (3), [(6_ 
C14H12)Ru(DMSO)C12] (5), [(11 6-C14R12)Ru(CNCH 3 )2C1] [PFd (6), [(TI 6 
Bip)Ru(en)(0H 2)] [( 6-Bip)Ru(en)(OH)][PF6] 3 (8), [(q 6-C14H14)Ru(en)(0H 2)] [PF6]2 
H2O (9) and [(n 6-Ci 4Hi 2)Ru(en)(OFI 2)][PFd2 2H20 (10). 
3 	 5 	:': 	6 	 8 	 9 	 10 
Empirical 
formula 
C20H23 CIF6N3PRu C,6H 1 8Cl2ORuS - C20H2iCIF6N3PRu C2iIi39F18N402P3Ru2 C,oH25F13N203P1Ru C16H10Fi3N203P2ku 
Molar mass 586.90 430.33 584.89 1100.68 669.40 685.40 
Crystal 
system 
Incline monoclinic triclinic monoclinic triclinic triclinic 
Crystal size 
/mm 
0.84 x 0.66x 0.08 0.80 x 0.20 x 0.14 0.74 x 0.43 x 0.18 0.43 x 0.21 x 0.09 0.28 x 0.24 x 0.18 0.30 x 0.14x 0.12 
Space group P-I P2,1c P.! C21c P-i P-i 
Crystal habit yellow lath orange block orange lath orange plate yellow block orange block 
a /A 6.8697(18) 10.947(5) 6.921(3) 14.400(4) 9.3030(17) 11.586(3) 
b iA 12.706(3) 12.405(5) 12.813(5) 16.011(5) 9.8849(18) 13.319(4) 
/ A 14.722(4) 12.543(5) 14.613(5) 17.049(5) 13.086(2) 16.241(4) 
a /deg 115.235(15) 90 64.514(18) 90 85.585(3) 98.663(4) 
3 /deg 96.606(16) 10836(3) 78.041(18) 106.881(4) 88.262(3) 94.970(4) 
y / deg 93.916(15) 90 84.800(18) 90 85.679(3) 91.094(4) 
T/K 150(2) 220(2) 220(2) 150(2) 150(2) ISO 
Z 2 4 2 4 2 4 
R[F>4 
(F)]' 0.0305 0.0343 0.0305 0.0524 0.0562 0.0936' 
R,)' 0.0768 0.0799 0.0762 0.1254 0.1409 0.0772 
GoP 1.020 1.054 1.057 1.055 1.034 1.117 
p max and 
mm, I A. - 0.65, -0.87 +0,58, -0.83 -'- 0.69, -0.83 + 1.64, 	-1.12 +1.31, -1.02 +2.28, -1.21 
a  R = IIF0i - IFcIIIEFF0I. b 	= [ w(F02 - F)2IWF02)f"2. c  GOF = [w(F02 - 
F 2)2/(n-p)], where n = number of reflections and p = number of parameters. d 
Refinement based on F with 7242 data with F > 6a(F). 
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Table 3.2 Selected bond lengths (A) and angles (deg) for complexes 3, 5, 6, 8, 9 and 
10. 
Bond(s) 	3 	 5 	 6 	 8 	 9 	lOt 
Rut-Cl 2.176(3) 2.255(5) 2.179(3) 2.207(6) 2.224(5) 2.235(7) 
Rul-C2 2.185(3) 2.217(5) 2.180(3) 2.188(6) 2.180(5) 2.176(7) 
Rul-C3 2.173(3) 2.171(5) 2.174(3) 2.164(7) 2.175(5) 2.174(7) 
Rul-C4 2.166(3) 2.181(5) 2.176(3) 2.162(7) 2.156(5) 2.164(7) 
Rut-05 2.198(3) 2.178(5) 2.196(3) 2.173(7) 2.146(5) 2.210(7) 
Rul-C6 2.208(3) 2210(5) .2 2.202(3) 2.201(6) 
2.216(5) 




2.073(3) 2.113(5) 2.111(4) 2.138(7) 
Rul-N2 
2.078(3) 
(Ru I-N ID) 2.076(3) 2.130(5) 2.115(5) 2.135(6) 
Rut-GIl 2.4072(9) 2.3935(15) 2.4041(11) 
Rul-C12 2.4087(14) 




(N I A-Rut-NIB) 













82.9(2) 87.6(2) 81.9(2) 




a.  For atom labels see Figures 3.1, 3.2 and 3.3. b.  01 has an occupancy factor of 0.7 
C.  Refers to molecule 1 (Rul). The data for molecule 2 (Ru2) are not listed. 
RK 
Chapter 3 (176-polycyclic arene)Ru(II) Complexes 
CIO Cg i 	
Ca 	tv 	C6 	 C4 
Cl 
J3 -7.5° 
WE X 	..42 C2E 
(A) Cation I 
0 31.4° 
Figure 3.1 X-ray structures and atom numbering schemes for [(ij 
C 14FI i4)Ru(CNCH3)2C1] in complex 3 (B), with the C 14H 14 ring conformation 
compared to that for [(TI  in complex 1 (A, from Chapter 5), at 
30% probability thermal ellipsoids. The PF6 counter-ion has been omitted for clarity. 
The hinge bending angle 13 is defined as in Table 3.3. 
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Complex 5 	 CIM 
CS 	p,2r' 	C3 
W '7'  mr,4 AS
CH 
Cation 6 
Figure 3.2 X-ray structures and atom numbering schemes for [(is-
C 14H 12)Ru(DMSO)C1 2] (5, B) and [(i 6-C14H12)Ru(NCCH3)2C1f in complex 6 (C), 
with the C 1 4H12 ring conformation compared to that for [( 6-C14Hi4)Ru(en)Cl] in 
complex 4 (A, from Chapter 5), at 30% probability thermal ellipsoids. The PF 6 
counter-ion has been omitted for clarity. The hinge bending angle P is defined as in 
Table 3.3. 
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Crystals of 1 (Chapter 5) and 3 suitable for X-ray analysis were obtained 
through ether diffusion into an ethanol solution of 1 and an acetonitrile solution of 3. 
The structures of cations 1 (from chapter 5) and 3 are displayed in Figure 3.1. The 
crystallographic data of 3 are shown in Table 3.1, and selected bond lengths and 
angles listed in Table 3.2. Figure 3.1 shows interesting structural features of 
complexes 1 and 3. In 1, the coordinated tricyclic-ring system is nearly flat and the 
outer ring is slightly tilted up from the Ru centre about C7-C14 by 7.2 ° . The Ru-
centroid distance of 1.675 A is normal; the two ring-junction carbons Cl and C6 are 
slightly further away from the metal centre than C3 and C4. In 3, the planarity of the 
coordinated tricyclic-ring system is lost, and the outer ring is twisted down from the 
Ru centre about CS and C14 by 31.4 ,  but the two ring-junction carbons CS and C14 
are still slightly further away from the metal centre than C2 and C3. The Ru-centroid 
distance of 1.614 A is 0.061 A shorter than that of!; the Ru-Cl distance of 2.4072(9) 
A is slightly longer than 2.4033(16) A distance found in 1. The Ru-NCCH 3 linkage 
is linear and the Ru-N distances are actually equal, 2.078(3) A. The crystal structure 
of complex 2 has been reported '7  and the planarity of the coordinated tricyclic-ring 
system is lost too. The outer ring is significantly tilted up from the Ru centre by 
23 ° and the other structural features are similar to those of 1 and 3. 
(1 6-C 14H 12)Ru Complexes 4-6 
An analogous polycyclic series of DHA (C14H12) complexes [(6 
C 14H12)Ru(en)Cl][PF6] (4, Chapter 5), [(1 6-C14R12)Ru(DMSO)C12] (5) and [(6 
C 14H 12)Ru(NCCH3 )2C1][PF6] (6) was prepared via a similar method to that for the 
synthese of (1 6-C 14H 14)Ru complexes 1-3. The dimer [(rl  was 
obtained by reaction between 1,4,9,10-tetrahydroanthracene (C 1 4F1 14) and hydrated 
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RuC13 during which the outer diene ring was dehydrogenated and aromatized 
(Scheme 3.1). 
Their structures were all confirmed by X-ray diffraction studies and are 
displayed in Figure 3.2. Crystallographic data of 5 and 6 are shown in Table 3.1 and 
selected bond lengths and angles are listed in Table 3.2. These three molecular 
structures exhibit the familiar piano-stool geometry similar to those of complexes 1, 
2 (ref. 7) and 3 (Figure 3.1). An interesting feature is that the coordinated C14H1 2 ring 
adopts three different conformations in these three complexes in the solid state. It is 
of interest to examine the nature of the C141 ­1 12  ring in different environments. 
As previously reported, 5 ' 9" 0 there are two preferred conformations for the 
C 14H, 2 molecular skeleton, either folded with a dihedral angle (defined as the angle 
between the planes of the two benzene rings) close to 146.2 ° (sample standard 
deviation 9.2 ° ), or planar (or very nearly so); the individual values depend on the 
nature of the substituent. For the structures of these three (TI  complexes, 
the coordinated C 14H 12 rings are all folded through the central rings, exhibiting a boat 
conformation (Figure 3.2). In complex 4, the ring system is twisted down towards the 
Ru-centre and the central ring forms a dihedral angle of 139.3 ° ; in complex 5, the 
ring system is tilted up from the Ru-centre and has a dihedral angle of 154.2° ; and in 
complex 6, the ring system is twisted down again with a dihedral angle of 
145.2 ° . These can be compared with free C1 4H12 in the solid state, which has a 
folded shape with a dihedral angle of 144.7 0 , while C 14H, 2 2(TNB) was found to be 
virtually planar." It seems that the marked conformational change in our cases is 
due to the effect of metal coordination on the C 14H 1 2 ring but is still within the 
normal range. 
On the basis of the intriguing structures of these 6 complexes, particularly 
the conformational mobility of the polycyclic ring, which in the case of complex I 
can be planar, there could be several possible modes of DNA binding: (1) covalent 
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binding by the loss of Cl, (2) partial intercalation with DNA due to the flatness of 
polycyclic ring,' 2 and (3) groove binding by the polycyclic arene ring which is rich 
in electrons and flexible in structure.' 3,14 
Aqua Ruthenium Arene Complexes 
Since the ethylenediamine complexes [(ii 6-arene)Ru(en)Cl] show the 
promising anticancer activities 15  and their aqua species are potential reactive 
intermediates inside cells,' 6 it is of interest to study the chemistry of [(6 
arene)Ru(en)(OH 2)] 2 complexes. The coordinated chloride ligands can be effectively 
removed from the chloro Rurene complexes 7, 1 and 4 by addition of a soluble Ag 
salt, eg. AgNO 3 , AgPP6, accompanied by precipitation of AgCl (Scheme 3.2). The 
Scheme 3.2 Preparation of aqua Ru(arene) complexes as PF 6 salts. 
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resultant aqueous solutions were found to be acidic with pH values of 3-6. For 
preparation of crystalline aqua Ru arene complexes 8-10, AgPF6 was used instead of 
AgNO3 , to avoid the possibility of the coordination of the nitrate ligand to Ru, as 
reported in preparation of crystalline structures of a-[Ru(azpy) 2(NO3 )2]' 7 and cis-
[Pt(NH3)2(NO3)21 18 
Crystallographic data for aqua ruthenium arene complexes 8, 9 and 10 are 
listed in Table 3.1, and selected bond lengths and angles in Table 3.2. Comparisons 
of their conformations with those of their parent chloro-complexes 7, 1 and 4, 
respectively, are listed in Table 3.3. The structures of cations 8, 9 and iDa are shown 
in Figure 3.3, and cation lOb shown in Figure 3.4. 
For crystal 8, the ratio of Ru to PF 6 in the unit cell is 8 : 12, thus its 
formulation is determined as [(u1 6-Bip)Ru(en)(0H2)][(n 6-Bip)Ru(en)(OH)][PF6]3 (or 
[(11 6-Bip)Ru(en)(0H2)0.5(OH)o5][PF6]1.5) This suggests that the 0 atom attached to 
Ru can be assigned to a 1:1 mixture of 0112 and OH, probably due to the partial 
deprotonation of the coordinated OH2 molecule. Similar situation was found in a 
single crystal of complex 9, where the 0 atom attached to Ru again can be assigned 
to a 1:1 mixture of OH2 and OH (data not shown). Another single crystal from the 
same batch of 9 was selected for data collection and it was found that its formulation 
is [( 6-T11A)Ru(en)(OH 2)J[PF51 2 •H20. There is no deprotonation of the coordinated 
OH2 molecule for this crystal, but this OH2 molecule was disordered over two 
positions 01 and 01' with occupancy factors of 0.7 and 0.3 respectively. For 
complex 10, the crystallographic data showed that its formulation is [(q 6-
DHA)Ru(en)(0H 2)][PF6] 2 .2(I-120) and without deprotonation of the coordinated OH2 
molecule. 
(I.., 	. 
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(B) cation 9 
Figure 3.3 X-ray structures and atom numbering schemes for (A) ([(Il 
Bip)Ru(en)(OH2)05 (OH)o. 5]' 5 in complex 8, (B) [(q 6-THA)Ru(en)(H 20)] 2 in 
complex 9, and (C) [( 6-DHA)Ru(en)(H20)] 2 (lUa) in complex 10, at 30% 
probability thermal ellipsoids. Cation lOb is shown in Figure 3.4. 
oil 
Chapter 3 (q6-polycyclic arene)Ru(II) Complexes 
(A) Cation lOb 	 (B) Cation lOa (open)/lOb(solid) 
RUM 
- 	Os 
-" --f- - 
(C) H-bonding 
Figure 3.4 (A) X-ray structure and atom numbering scheme for [(6 
DHA)Ru(en)(H 20)] 2 (cation lOb) in complex 10. (B) Comparison of the 
conformations of cation lOa (open) and lOb (solid). Alignments are based on a 
superposition of the labelled atoms (Ru, Ni and N2 of en). (C) Intermolecular 
hydrogen bonding involving en NH and 0(w) in the crystal of complex 10. 
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Table 3.3 Comparison of the Conformations of Aqua Ru Arene Complexes 8-10 
(Figures 3.3) and Their Parent Chloro-Complexe? 7, 1 and 4. X = H20 or Cl. 
NH 




I r'VYB'YC' / A'Ru 
\C). kA -) 





Biphenyl Complex 4 (1-120) and I (Cl). 
8(F120) 	
.7 frpa 
Bip orientation, a (I), [Aa] ° 	23.3(3) [-3.5] 	 26.8(2) 
(deg) 
Bip propeller twist, x, []C 	45.3(3) [+19.1] 	 26.2(4) 
(deg) 
Ru-coordinated ring 	1.663 (3) 	 1.663(3) 
(centroid), A 
TI-Lk Complexes 9 (H 20) and 1 (Cl) and DHA Complexes 10 (H20) and 4 (Cl). 
9 (1-120) 	1 (CJ). 	10 (1-120) 	4 (C 
63.7(2) 	45.12(6) 	325(3)f [-31.59] 	64.09(8) 
[+18.58] 355(3)2 [-28.6] 
-1.8(3) 	-7.53(12) 	+ 31.8(4)' [-8.85] 	+40.65(16) 
[+5.73] + 38.4 (4)2  [-2.25] 
1.664(2) 	1.676(3) 	1671(3)d 	1.667(3) 
1.678(3 )e 
THA/DI-IA orientation, a (II), [Aa]t 
(deg) 
Hinge bending angle, 0 (III)', [Ax ]e 
(deg) 
Ru-coordinated ring (centroid), A 
a  See Chapter 5. b : twist of pendent phenyl ring (B) with respect to coordinated 
phenyl (A) of Bip. C  The change of torsion angles for 8 compared to 7. d  The hinge is 
defined by C7A - C  OA, see Figure 1. A + ye sign for 3 indicates movement towards 
Ru-X. e  The change of torsion angles for 5 and 6 compared to 2 and 3, respectively. 
cation lOa. g  cation lOb. 
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For the Bip complex 8, the propeller twist of the pendant phenyl with respect 
to the coordinated phenyl of the Bip ligand is 45.3°, which is 19.1° larger than that 
for the chloro complex 7 (Table 3.3). The long axis of Bip is rotated away from the 
Ru-O vector by 23.3°, which is 3.5° smaller than that for complex 7. The distance 
from Ru to the centroid of coordinated phenyl (A) is 1.66 A, similar to that in 
complex 7. 
For the THA complex 9, the tricyclic ring system (THA) is nearly flat. The 
outer ring (C) is slightly bent up away from the 0 atom (hinge bending) by ca. 1.8°, 
similar to that (7.5°) in complex 7. The long axis through the THA ligand is rotated 
away from the Ru-O vector by 66.62°, which is 21.5° larger than that in complex 7. 
The distance from Ru atom to the centroid of coordinated ring (A) is 1.66 A, similar 
to that in complex 7. 
For the DHA complex 10, there are two kinds of independent cations (two 
lOa cations and two lOb cations, Figures 3.3 and 3.4) in the asymmetric unit. The 
structures of these two cations lOa and lOb differ significantly only in the orientation 
and hinge bending of the DHA ring (Figure 3.4). The outer ring (C) is bent down 
towards the 0 atom by 31.8° in cation 10a, and by 38.40  in cation lOb, comparable to 
that (40.65°) in complex 4. The long axis through the DHA ligand is rotated away 
from the Ru-U vector by 32.5° in cation lOa and by 35.5° in cation lOb, which are 
ca. 30° smaller than that in complex 4. The distance from the Ru to the centroid of 
coordinated ring (A) is 1.67 A in both lOa and lOb, similar to that in complex 4. 
There are interesting chains of intermolecular hydrogen-bonds: 
040103050206 and en NH ... 04/06, involving both cations lOa and lOb 
in the crystal packing (with the distances of U4"01 2.650 A, 0103 2.805 A, 
0105 2.952 A, 0502 2.726 A, 0206 2.702 A, 04N12 3.272 A and 
O& N14 3.096 A, Figure 3.4). 
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The X-ray structures of 8-10 revealed that an Ru-O bond length for 
coordinated water of 2.1-2.2 A, within the range reported for other aqua Ru arene 
compounds! 9 The coordinated OH2 molecule showed the acidity through 
protonation/deprotonation as found in the solid state of complexes 8 and 9. In each 
case, the coordinated OH 2  molecule is deprotonated in about 50% of the unit cell to 
provide charge nuetrality. There is an interesting arene conformation for each aqua 
compound as shown in Figure 3.3 and Table 3.3. Noticeably, the propeller twist of 
the biphenyl in 8 is 19.10  larger than that in chloro complex 7. For aqua THA 
complex 9, the small hinge bending of 1.8° away from the 0 atom shows that 
tricyclic ring system is still rather flat as in chloro THA complex 1. For the aqua 
DHA complex 10, the outter ring (C) is significantly bent down toward the 0 atom 
by 31.8° (38.4'), comparable with the hinge bending of 40.65° in the chloro-complex 
4. Such large hinge bending toward the 0 or Cl atom in the DHA complexes 10 and 
4 may impose a steric constraint to hydrolysis of Ru-Cl and may also influence the 
rate of G N7 coordination in reactions with DNA. 
3.4 Conclusion 
A series of novel chloro (i 6-C14H14)Ru(I) complexes (1, 2 and 3) and (6 
C12H12)Ru(II) complexes (4, 5 and 6) was synthesised with the aim of investigating 
their anticancer activity. The preliminary cytotoxicity data of these six complexes 
against A2780 human ovarian cancer cells show that, the two ethylenediamine 
complexes, [(TI  (1) and [(11 6-DHA)Ru(en)Cl][PF6] (4), 
obtained the increased cytotoxicity with IC50 values 0.5 RM for 1 and 2 PM for 4, 
compared with 6 .xM for [(Tj  (7) (see Appendix Table). The 
dimethyl sulfoxide and acetonitrile complexes, 2, 3, 5 and 6, however, recorded IC 50 
values greater than 100 jiM and were defined essentially as inactive. 20 Noticeably, 
these four compounds alone contain more reactive monodentate ligands, dimethyl 
MM 
Chapter 3 (if-polycyclic arene)Ru (II) Complexes 
sulfoxide and acetonitrile, in comparison to the more stable chelating en ligand in 1 
and 4. Those preliminary data suggest that stable bidentate ligands, a more 
hydrophobic arene ring and a single leaving group (Cl) are associated with the 
increased cytotoxicity. 15 
The aqua complexes [(TI 	(8) [( 6-THA)Ru(en)(OH 2)] 2 
(9) and [( 6-DHA)Ru(en)(OH2)] 2 (10), potentially reactive intermediates inside 
cells, were also prepared from the chloro complexes 7, 1 and 4, respectively, by 
removal of the Cl ligand with Ag. Their molecular structures were determined by X-
ray crystallograghy. These showed interesting features, particularly in the 
conformation of the polycyclic rings, as compared with their parent chloro 
complexes. This maybe relevant to the biological activities for these novel chloro and 
aqua Ru(arene) complexes and will be discussed further in Chapters 5 and 6. 
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4.1 Introduction 
Organometallic 	ruthenium(II) 	complexes 	of the 	type 	[(p 6- 
arene)Ru(II)(en)Cl][PF61 (en = ethylenediamine) have high and reproducible in vitro 
or in vivo anticancer activity. The activity increases with increase in size of the 6 
arene. For example, complexes which contain 11 6-tetra- or di-hydroanthracene rings 
(THA, DHA) or biphenyl (Bip) have much higher activities than compounds 
containing a single ring such as 6-benzene (Ben) or 6—cymene (Cym)." 2 A 
potential target for these organometallic Ru(II) complexes is DNA and the preferred 
binding site appears to be guanine. 2 The structures of guanine adducts of THA, DHA 
and Bip complexes show stereospecific hydrogen-binding of en NH with G 06, and 
strong arene-nucleobase stacking, both in the solid state by X-ray crystallography, 
and in solution by NMR methods (Chapter 5). These studies have revealed several 
DNA recognition features and suggested a potential DNA-binding mode, involving 
simultaneous intercalation and covalent coordination with DNA for organometallic 
Ru(II) complexes. The diamine NH group and hydrophobic arene group as well as 
the Cl leaving group may therefore all play important roles in anticancer activity. 
These studies have stimulated the design of multi-functional arene-Ru(II) antitumour 
agents. One approach involves the formation of dinuclear his Ru(arene) agents by 
linking two Ru(arene) units with a tetraamine ligand, where each Ru centre would 
behave similarly to the active mononuclear species. This type of dimeric species 
would be a potential bifunctional agent and facilitate the formation of DNA 
interstrand crosslinks or DNA-protein crosslinks leading to a distinct and unique 
profile of antitumour activity. 
There are precedents which have exploited a similar concept. The platinum 
dimers and trimers developed by Farrell, et al '3  one of which, the trinuclear 
compound BBR3464,4 ' 5 ' 6 is currently in phase-TI clinical trial, represent a very 
stimulating precedent in this sense. Dimers such as 
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[(PtCl(NH3)2)2(NH2(CH2)4NH2)] 2 ,7 derived from cis-[PtCl 2(N}1 3 )2 1 upon 
replacement of one ammonia with a bridging aliphatic diamine, maintain structure 
motifs and coordination environments very similar to those of the monomeric parent 
compound (cisplatin). They are as active as cisplatin against conventional tumour 
lines, but are remarkably active also against tumour lines resistant to cisplatin, 
apparently because the co-ordination-induced modifications of DNA are different 
from those induced by the mononuclear complex. 8 ' 9 Currently, due to the success of 
NAMI-I in clinical trials against solid tumour metastasis, the antineoplastic activity 
of the dimers Na2[{trans-RuCl 4(Me2 SO-S) 2(u-L))] and [{tner,cis-RuCI 3 (Me2 SO-
S)(Me2SO-0)} 2(p-L)] where L is pyrazine, pyrimidine, 4,4-bipyridine, 1,2-bis(4-
pyridyl)-ethane or 1 ,3-bis(4-pyridyl)-propane, based on NAMI-A, are being 
investigated. 10,11 
Chart 4.1 The structures of dinuclear his Ru(arene) complexes compared with their 
mononuclear Ru(arene) analogues. 
+ o_o 	 2+ 
RU*_-NH2 	 RUs..4j CI .'V'/'NH cI__ H2&._) H2N 
5 




H2N..) 	 H2N...) 
In this chapter, the design and synthesis of the bifunctional ligand of N, N'-
bis-(2'-aminoethyl)- 1 ,6-diaminohexane (4, H2N(C112)2N1-1(CH2)6NH(CH 2)2NF12, 
Scheme 4.1), and its reactions with the dimers [(Tl 	and [(6_ 
C 14H 14)RuCl 2 ] 2 , 	respectively, to form 	two dinuclear 	complexes [((TI 6 
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biphenyl)RuCI)2(H2N(CH2)2N11(CH2)6NH(CH 2)2NH2-N,N',N'çN")][PF5 ] 2  (5), and 
[ 6-C14Hi4)RuCl)2W2N(CH2)2NH(CH2)6NH(CH2)2NII2-N,NN'N")] [PP6]2 (6) are 
described. Their structures have been studied by 2D ['H, 1 H] TOCSY, COSY, 
NOESY, and ['H, ' 5N] HSQC NMR methods. In addition, the mononuclear complex 
ftq 6-biphenyl)Ru(Et-en)Cl][PF 6] (7, where Et-en = N-ethylethylenediamine, 
H2N(CH2)2NH(CH 2CH3)) was also synthesized for comparison, due to the similarity 
of its structure to each unit of the dinuclear complex 5. This mono Ru compound was 
characterised by X-ray crystallography and 2D ['H, 'H] COSY and NOESY and ['H, 
' 5N] HSQC NMR methods. It exhibits interesting diastereomerism as compared with 
complex 5. 
4.2 Experimental Section 
4.2.1 Materials and Methods 
	
The starting materials [( 6-biphenyl)RuC1 2]2 and [(TI 	were 
prepared as previously described (Ref 2 and Chapter 5). Ethylenediamine, 
triethylamine and N-ethylethylenediamine were freshly distilled over Na. 
Tetrahydrofuran (THF) was dried by distillation from Na-benzophenone. 
triphenylmethyl chloride (99%) and adipoyl chloride (98%, CICO(CH2)4COCI) was 
purchased from the Arcos Chemical Co. All other chemicals were AR grade and 
were used as received. 
Scheme 4.1 i) TrCI, C112C12 , r.m., 12 h; ii) Adipoyl chloride, triethylamine, CHCI3, 
reflux, 2 h; iii) LiAIFI4-THF, reflux, 25 h; iv) 6.0 M HCI, reflux, 3 h. 
9 	¶1 r- m 




iii 	!— 	 iv 
-*-Tr-HN 	NH-(CH2 )6 -HN 	NH-fl -ø-H 2N 	NH-(CH2 )6 -HN 	NH24 HCI 
3 	 4 
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4.2.2 Preparation of N,N'-bis-(2'-aminoethyl)-1 ,6-diaminohexane 
N-tritylethylenediamine (1) 
A solution of trityl chloride (5.57 g, 20 mmol) in dichloromethane (25 mL) 
was slowly added to a solution of ethylenediamine (8 mL, 120 mmol) in 
dichloromethane (75 mL) with stirring at room temperature. The addition was 
accomplished within 1 h and the reaction stirred overnight. The white salt was 
filtered off and the filtrate washed with water and dried over anhydrous sodium 
sulphate. Dichloromethane was removed by rotary evaporation and the residue 
dissolved in methanol (30 mL). A white precipitate begun to form after shaking for a 
while and the mixture kept in the fridge for 5 h and then filtered off. The methanol 
filtrate was reduced in volume to 10 mL and kept in the fridge overnight. A white 
solid precipitated. This was collected as the desired product, and washed with diethyl 
ether and dried in vacuo. 
Yield: 4.5 g, 14.88 mmol, 74.4%, mp 96 °C. 1 R NMR (CDC1 3) 5: 7.10-7.49 (m, 
15H, aromatic H), 2.80 (t, 211, CR2), 2.20 (t, CR2). 
N,N-bis(2'4rityIaminoethyI)-1,6-diamidohexane (2) 
N-Tritylethylenediamine (1.5 g, 4.96 mmol) and triethylamine (1.0 g, 7.29 
mmol) were dissolved in chloroform (35 mL) and cooled in an ice bath. To this 
solution was added adipoyl chloride (0.36 mL, 2.48 mmol) in chloroform (10 mL) 
slowly with stirring. After addition, the mixture was refluxed for 2 h and cooled to 
room temperature. This was filtered to gave a clear chloroform filtrate (see below). 
The filtered precipitate was dissolved in dichloromethane (100 mL). This was 
washed with water and then saturated NaC1 solution and dried over anhydrous 
sodium sulphate. Removal of the solvent by rotary evaporation gave a white product. 
The chloroform filtrate was also washed with water and saturated NaCl solution, and 
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dried over anhydrous sodium sulphate. After removal of chloroform, a further crop 
of product formed. 
Yield: 1.40 g, 1.91 mmol, 77% mp 200-202 °C 
Anal. Calcd for C4811502N4•H20 (732.96) : C, 78.66; H, 7.15; N, 7.64. Found: C, 
78.81; 11, 6.73; N, 7.55. 'H NMR (CDCI3) 8: 7.15-7.50 (m, 15H, aromatic H), 3.23 
(q, 4H, 2CH2), 2.22 (m, 811, 4CH2), 1.63 (m, 4H, 2CH2). 
(c) N,N'-bis(2'4ritylaminoethyl)..1 ,6-diaminohexane (3) 
Into a solution of N,N-bis(2'-tritylaminoethyl)-1,6-diamidohexane (1.3g, 1.82 
mmol) in dry THF was added a suspension of LiAIH4 (0.69 g, 18.18 mmol) in dry 
THF (20 mL) under argon with vigorous stirring. After the addition, the reaction was 
maintained under gentle reflux with stirring for 25 h. This was cooled to 4°C. The 
reaction product and excess of hydride were decomposed by the dropwise addition of 
H20 (0.69 mL), followed by 15%(w/v) NaOH solution (0.69 mL) and 1120 (2.07 
mL) in succession. After vigorous stirring for 30 mm, the mixture was filtered by 
suction and the resulting cake was washed thoroughly with dichloromethane. The 
combined filtrate was concentrated to dryness on a rotary evaporator and the 
resulting light-yellow residue dissolved in dichloromethane (50 mL). This was 
washed with water and then saturated NaCl solution, and dried over anhydrous 
sodium sulphate. Removal of dichioromethane on a rotary evaporator afforded a 
colorless, waxy solid. 
Yield: 1.20 g, 1.75 mmol, 96%. 'H NMR (CDCI3) 8: 7.10-7.49 (m, 15H, aromatic 
H), 2.71 (t, 4H, 2CH2), 2.50 (t, 4H, 2CH2), 2.28 (t, 4H, 2CH2), 1.49 (m, 4H, 2C112), 
1.32 (m, 411, 2CH2). 
(d) N,N'-bis(2-aminoethyl)-1 ,6-diaminohexane tetrahydrochloride (4) 
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A mixture of N,N-bis(2'-tritylaminoethlyl)- 1,6-diaminohexane (1.0 g, 1.45 
mmol) and 6 M HC1 (30 mL) was refluxed for 3 h. Then the mixture was filtered and 
the filtrate was concentrated to about 3 mL in vacuo. Addition of methanol into the 
concentrated solution afforded a white salt. 
Yield: 0.46 g, 1.32 mmol, 92%. m.p. 244°C (decomp.). Anal. Calcd for 
C,0H26N44HCl (348.09): C, 34.48; H, 8.68; N, 16.09. Found: C, 34.26; H, 8.77; N, 
16.24. 
'H NMR (1320) 8: 3.35 (m, 8H, 4CH2), 3.10 (t, 4H, 2CH2), 1.69 (m, 4H, 2CH2), 
1.40 (m, 4H, 2CH2). ' 3 C NMR (D20) 6: 25.9, 35.0, 44.5, 48.2. 
4.2.3 Preparation of Dinuclear Bis Ru(arene) Complexes 
[((11 6-biphenyl)RuCI)2(H2N(CH2)2NH(CH2)6NH(CH2)2NH2-N,N;NtN"1][PF6]2 (5) 
[(
1
1 6-biphenyl)RuC12I2 (0.106 g, 0.162 mmol) in 10 mL water was refluxed 
for 2.5 h and then cooled to 50°C. Into this suspension was added a methanol 
solution of N,N'-bis(2-aminoethyl)-1,6-diaminehexane (0.162 mmol) which was 
obtained by the treatment of N,N1bis(2ami noethyl)1,6diaminohexane 
tetrahydrochloride (4, 56.39 g, 0.162 mmol) with 1.294 ml 0.501 M KOH-MeOH. 
The mixture was heated to reflux for 1.5 h. This was filtered while hot. NH4PF 6 
(0.175 g, 1.07 mmol) was added into the bright yellow filtrate to yield a bright 
yellow precipitate, which was recrystalized from methanol/ether. 
Yield: 0.10 g, 0.093 mmol, 57.5% 
Anal. Calcd for C34H46C12F,2N4P2Ru2 (1073.74): C, 38.03; H, 4.32; N, 5.22. Found: 
C, 37.86; H, 4.25; N, 5.20. 'H NMR (DMSO-d6): 67.80 (m, 4H), 7.50 (m, 6H), 
6.95, 6.7 (broad, Nil), 6.31, 6.25, 6.20 (m, 4H), 6.00, 5.93, 5.87, 5.78 (m, 6H), 4.60, 
6.65, 3.80 (broad, Nil), 3.3-1.0 (broad, CH2) MS (FAB) (M-H) +  : m/z 783.11630 
(Calc. m/z 783.11988, Dev.4.50 ppm) 
Vt] 
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[((n 6-C14H14)RuCI)2(H2N(CH2)2NH(CH2)6NH(CH2)2NH2-N, N N', N")J[PF 6]2 (6) 
[(1 6-C14Hi4)RuCl2]2 (0.15 g, 0.213 mmol) in 10 mL methanol was stirred 
under argon at 60°C. Into this suspension was added a methanol solution of N,N'-
bis(2-aminoethyl)-1,6-diaminohexane (0.213 mmol), which was obtained by 
treatment of N,IP-bis(2-aniinoethyl)-1 ,6-diaminohexane tetrahydrochioride (4, 73.97 
g, 0.213 mmol) with 1.697 mL 0.501 M KOH-MeOH solution. The mixture was 
adjusted to pH 6.5 and stirred at 60°C for a further 1.5 h. This was filtered while hot 
and concentrated to 6 mL. Addition of NFI4PF6 (0.25 g, 1.53 mmol) into the 
concentrated solution afforded a yellow precipitate. This was recrystalized from 
methanol/ether. 
Yield: 0.09 g, 0.0796 mmol, 37.4%. Anal. Calcd for C33H54C12F12N4P2Ru2 (1129.85): 
C, 40.39; H, 4.81; N, 4.95. Found: C, 40.30; 11, 4.49; N, 4.21. 'H NMR (DMSO-d6): 
8 6.82, 6.35 (broad, NH), 5.72 (s, 4H), 5.6, 5.45 (m, 8H), 4.52, 3.80, 3.72 (broad, 
NH), 3.15 (m, 811), 2.65 (m, 8H), 2.87, 2.70 (broad, CH2), 2.5-1.2 (broad, CH2). MS 
(FAB) (M-H)+ : m/z 839.18129 (Cale. m/z 839.18248, Dev. —1.42 ppm) 
4.2.4 Preparation of [( 6-biphenyI)Ru(Et-en)CIJ[PF61 (7) 
[( 6-biphenyl)RuC12]2 (0.10 g, 0.158 mmol) was refluxed in water (10 mL) 
for 3 h and then cooled down to 80°C. To this suspension was added N-
ethylethylenediamine (37 mg, 0.42 mmol). The brown suspension immediately 
became dark green. This was then slowly heated to reflux again for a further 1.5 h 
and filtered while hot. NFI4PF6 (0.2 g, 1.23 mmol) was added to the yellowish filtrate 
and the flask briefly shaken. A yellow precipitate began to form almost immediately. 
After standing at 4°C overnight, the precipitate was collected, washed with a little 
methanol followed by diethyl ether and dried in vacuo. This was recrystallised from 
methanol/ether. 
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Yield: 0.08 g, 0.153 mmol, 48.3%. Anal. Calcd for C16H22CIF5N2PRu (523.85): C, 
36.68; 11,4.23; N, 5.35. Found: C, 36.00; H, 4.37; N, 5.24. 
4.2.5 X-ray Crystallography 
Diffraction data were collected for isomers 7A and 7B with Mo K. radiation, 
= 0.71073 A. For isomer 7A, a Stoë Stadi-4 serial diffractometer was used at 220 
K, and absorption corrections were made using w-scans. For isomer 7B, a Bruker 
Smart Apex ccd diffractometer was used at 150 K, and absorption correction made 
using the program SADABS.' 2 Both structures were solved by combined Patterson 
and direct methods (DIRDIF' 3). All hydrogen atoms were placed in calculated 
positions and allowed to ride on the nitrogen or carbon atoms to which they are 
bonded. All non-hydrogen atoms were refined with anisotropic displacement 
parameters. In both isomers, the refined displacement parameters suggest a slight 
disordering of the PF5 ions. 
4.2.6 NMR Spectroscopy. 
'H NMR spectra were acquired on a Bruker DMX 500 ('H = 500 MHz ) 
NMR spectrometer using TBI ['H, ' 3C, X] or triple resonance [lfl,  ' 3C, ' 5N] probe-
heads, respectively, and equipped with z-field gradients. 
1D 'H NMR spectra were typically acquired with 32 transients into 32 K data 
points over a spectral width of 6.0 kHz using a double pulsed-field gradient spin-
echo pulse sequence. Typically, 2D ['H, 'H] NOESY NMR spectra were acquired 
with 8 transients for each of 512 t, increments (TPPI). The mixing time was 1 s, and 
the relaxation delay was 2 s. 2D ['H, '11] COSY and DQFCOSY spectra were 
acquired with 32 tranisients for each of 512 t1 increments (TPPI). 2D ['H, 1 H] 
TOCSY spectra were acquired with 16 transients into 4096 complex data points 
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(acquisition time 0.51 s) for each ti increments. A spin-lock time of 60 ms was 
employed. 
2D ['H, ' 5N] HSQC NMR spectra (optimised for 'J) = 73 Hz) were 
acquired using the sequence of Stonehouse et. aL 14 A GARP decoupling sequence 
was used for ' 5N decoupling during acquisition. 2D ['H, ' 5N] HSQC NMR data were 
acquired with 140 transients into 2048 data points over a 'H (172) spectral width of 5 
kHz (10 ppm centred at 5 ppm) for each of 512 t1 increments (TPPT), and over a 
(F 1) spectral width of 3.04 kHz (60 ppm, centre at —10 ppm) using a relaxation delay 
of 2 s between transients. The NH proton resonances from sample 5 (90 mM) and 7 
(40 mM) in DMSO-d6 solutions were observable within a few hours with ' 5N at 
natural abundance. Typically, 2D ['H, 15N] NMR HSQC spectra were acquired over 
a15 hperiod. 
All data processing was carried out using XW1IN-NMR version 2.0 (Bruker 
U.K. Ltd.). 'H NMR chemical shifts were internally referenced to (CD2H)2S0 (2.5 
ppm) in DMSO-d6 solution. 15N resonances were referenced to 1 M ' 5NH4CI in 1.5 
M HO (external) at 0 ppm. 
4.3 Results and Disccusion 
4.3.1 [( 6-biphenyl)Ru(Et-en)CI][PF 6] (7) 
The reaction of [(r-biphenyl)RuC12}2 with N-ethylethylenediamine yields 
complex 7 as a mixture of diastereomers which exhibit chirality both at the metal 
centre and at the substituted N atom of the N-ethylethylenediamine ligand (Figure 
4.1). 
X-ray Structure of Complex 7 
The X-ray structures of diastereomers 7A and 7B for complex 7 are shown in 
Figure 4.1. These two diastereomers crystallised in the same batch but in two 
ii 
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Table 4.1 Crystallographic data for the two diastereomers 7A and 7B of complex 
[( 6-biphenyI)Ru(TEt-en)Cl] [PF6]. 















































R [F >4c(F)I' 	0.0682 
0.1960 
GOFC 	 1.022 
zip max and mm, / +1.988, -1.329 
ek3 
a  R = IIF01 - IFII/tF0I. b 	= [ w(F02 - F2)2/wF02)]1/2. C  GOF = [Ew(F02 - 
F 2)2/(n-p)J"2 , where n = number of reflections and  = number of parameters. 
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Table 4.2 Selected Bond Lengths (A) and Angles (deg) for the two diastereomers 7A 
and 713 of complex [(il  
atoms 7A 7B 
Rul-N1A 2.112(6) 2.109(7) 
Rul-N2A 2.142(6) 2.148(6) 
Rul-CIl 2.392(2) 2.408(2) 
Rul-Ci 2.220(7) 2.223(7) 
Rul-C2 2.193(8) 2.175(8) 
Rul-C3 2.147(7) 2.186(8) 
Rul-C4 2.159(8) 2.192(8) 
Rul-05 2.178(9) 2.181(9) 
Rul-C6 	 2.181(7) 	 2.175(8) 
Ru-(centroid) 
1.667 	 1.669(4) coord-ring 
NIA-Rul-N2A 	79.4(3) 	 79.8(3) 
NIA-Rul-CIl 	83.29 (19) 	83.0(2) 
N2A-Rul-Cl1 	87.22 (18) 	83.26(18) 
Bip propeller twist 	19.5 (5) 	 35.6(4) 
Rotation of bip from 
29.44 	 46.1(3) 
Ru 1-Cl I 














Figure 4.1 X-ray structures and atom numbering schemes for (A) cationic 
diastereomer 7A and (B) cationic diastereomer 7B in complex [(11 6_Bip)Ru(Et-
en)Cl] +, at 30% probability thermal ellipsoids. Their enantiomers 7K (SRUSN) and 
7W (RRU SN) are not shown. Chiral centres are indicated by * 
M. 







Figure 4.2 Projections of the diastereomers 7A and 7B of [(TI  
along the Ru-centroid axis of the arene group, showing the relative disposions of 
the biphenyl rings and CI I, NIA and N2A bearing the ethyl substituent, which are 
compared with [(q 6-Bip)Ru(en)Cl] (ref 2). 
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independent single crystals. These two single crystals showed different appearances: 
orange lump for 7A and yellow flake for 7B, and thus both were selected for X-ray 
data collection. The absolute configurations of 7A and 7B can be assigned 15  as 
RRURN and SRURN. Their corresponding enantiomers 7A' (SR USN) and 713' (RRU SN) 
were also present in their respective unit cells (not shown). Crystallographic data for 
both isomers 7A and 7B are listed in Table 4. 1, and selected bond lengths and angles 
in Table 4.2. In 7A, the pendant biphenyl ring is twisted out of the plane of the 
coordinated ring by about 19.5 °, and in 7B, by 35.6 0 (Table 4.2), compared with 
26.8 ° in [(ij  (Chapter 5). The distance from Ru atom to the 
centroid of the coordinated phenyl is 1.667 A for 7A, very similar to that for 7B 
(1.669 A). The Ru-CI distance for 7A is 2.392 A, a little shorter than that for 7B 
(2.408 A), and the distances of Rul-NIA (2.112 A) and Rul-N2A (2.142 A) are 
close to those of 7B (2.109, 2.148 A). 
The pyramidal conformation of Rul-Cli, -NIA and -N2A for both isomers is 
an interesting feature (Figure 4.2, Table 4.2). The angles of NIA-Rul-Cli (83.29) 
and N2A-Rul-NIA (79.4 0) angles in 7A are comparable with values of 83.0 ° and 
79.8° respectively, found in 7B, while the angle of N2A-Rul-Cl1 (87.22 °) in 7A is 
larger than that of 7B (83.0°). Noticeably, the long axis of the biphenyl ligand is 
rotated away from the Ru-Cl! vector by 29.4 ° for 7A while 46.1 ° for 713, compared 
with 26.2 for the structure of [(il 6  -biphenyl)Ru(en)Cl] +  (Chapter 5). This suggests 
that the three legs of Rul-Cli, Ru!-NIA and Rul-N2A are much more staggered 
with the Ru-C bonds for 7A, similar to the case for [(TI  but are 
much more eclipsed for lB (Figure 4.2). In addition, the ethyl substituent on the 
N2A atom (chiral) points down towards the Cl atom for 7A, while it is tilted up 
away from the Cl atom for 7B. As a result, the NH proton on N2A atom points up 
toward the coordinated phenyl ring in 7A while it points down away from the 
M. 
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coordinated phenyl ring in 78. This represents the most distinguishing feature for 
these two diastereomers. The conformation of the pendant-down ethyl group as well 
as the staggered legs as found in isomer 7A may be energetically favourable, 
compared with the conformation in 7B with the tilt-up ethyl group as well as the 
eclipsed legs, and therefore acounts for the high stereoselectivity for formation of 
isomer 7A in DMSO-d5 (0.737 0.263 equilibrium ratio for 7A 7B, based on the 
intensity of NH cross-peak in 2D ['H, ' 5N] HSQC NMR spectrum of complex 7, 
Figure 4.5A). 
NMR Structure of Complex 7 
The 'H NMR spectrum of 7 was acquired immediately after dissolving the 
sample in DMSO-d6, and did not change over a period of more than 10 days at 
ambient temperature. It contains two sets of signals, indicating the presence of two 
diastereomers in solution as found in crystals. 2D ['H, ' 5N] HSQC, 2D [ 1 H, 'H] 
COSY and NOESY spectra were also acquired and thus allowed signal assignment 
for both diastereomers. 
The 2D ['H, ' 5N] HSC spectrum contains two sets of cross-peaks for the Et-
en NH resonances, accountizg for two diastereomers (Figure 4.5A). There are three 
cross-peaks at 6 6.6251-24.183, 6 3.8041-24.183 and 6 6.9401-7.130 for NH 11 ,, NHd, 
and NH112 of isomer 7A and another three cross-peaks at 6 6.6231-28.171, 6 4.522/-
28.171 and 6 3.864/10.746 for NH11 1, NHd,' and NHd2' of isomer 7B. These two sets 
of cross-peaks have the intensity ratio of 0.737 : 0.263. According to previous NMR 
studies for structures of the type ((Tl  the high frequency signal is 
for NH11 proton which points up toward the phenyl ring, whereas the low frequency 
signal is for NHd proton which points down away from the phenyl ring. In the 2D 
COSY spectra (Figure 4.3), the Et-en region (A) shows the correlations of lidI-HI, 2, 
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Figure 4.3 2D DQFCOSY 1 1-1 NMR spectrum of [( 6-bipbeny1)Ru(Et-en)C1f (7) in 
DMSO-d6, showing assignment of (A) Et-en and (B) biphenyl resonances for the 
two diastereomers 7A (solid lines) and 7B (dashed lines). In (A), the DOH signal is 
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at 5 3.35 (4); and H4 and Hi are overlapped with the (CD2IJ2SO signal at 52.5 (*) 




(A (NRU N) 
3.4 
 
8.0 	 7.0 	
'H 	
6.0 	 81H 
Figure 4.4 NOE data for [(TI 	(7). (A) Structure with NOEs 
for the two diastereomers 7A and 7B indicated by dotted lines. (B) Regions of the 2D 
NOESY 1 H NMR spectrum in DMSO-d5 at 298 K. 
PM 
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and the aromatic region (B) shows the correlations of H—Hd, H g-Hf, HeHd and HCHf 
for 7A and of Hg H/, H'Hd', He'Hd' for 7B. 2D NOESY spectra (Figure 4.413) 
show that, for isomer 7A there are strong NOEs between the protons NH., and NH 112 
of the Et-en ring and the protons c, d, e, f and g of the coordinated phenyl ring, while 
the NOEs between NHdI and the coordinated phenyl ring are very weak; for isomer 
711 there are strong NOEs between Et-en NHi' and the phenyl protons c', d, & and f, 
and between the ethyl protons 5 and the phenyl protons g', f and e', and but no NOEs 
between Et-en NHdI', NH d2  and the phenyl protons, indicating that the proton 1-15' 
together with proton NHj' points up towards the phenyl ring and the protons NHdI' 
and NHd2' point down away from the phenyl ring. These NMR studies reveal that the 
solution structure of two isomers 7A and 711 (Figure 4.4A) are largely consistent 
with the conformations found in the solid state (Figure 4.1). Noticeably in both solid 
and solution state, the chiral N atom which bears the ethyl substituent has one NH 
proton which points up toward the coordinated phenyl ring and appears at high 
frequency for isomer 7A, while the proton points down away from the coordinated 
phenyl ring and appears at low frequency for isomer 7B. 
4.3.2 Dinuclear Bis Ru(arene) Complexes 5 and 6 
Synthesis of Linear Tetraamine Ligand 
The route used for the preparation of the linear tetraamine ligand, N, N'-bis(2-
aminoethyl)-1,6-diaminohexane, was similar to that previously reported for the 
synthesis of hexaamine ligands.' 7 The general aim was to assemble a ligand in a 
convergent fashion by C-N bond formation via nucleophilic displacement at a 
terminal N of amino group. 18 The route shown in the Scheme 4.1 was proved to be 
mild, efficient and easy to handle, and may be generally useful for the preparation of 
this type of tetraamine ligand with a variety of chain lengths. In addition, this method 
will be applicable to the preparation of 15N-labeled bis(2-aminoethyl)-1,6- 
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diaminohexane based on the availability of 15N(en) obtained via the use of 15N-
glycine in our laboratory. It is well known that 15N-labelled amine ligands are useful 
in the study of the interaction between metal-amine complexes and DNA via ['H, 
' 5N] 2D NMR methods. 19 Therefore, this new synthetic method has potential 
applications related to biological research. 
Preparation of Dinuclear Complexes 5 and 6 
The two dinuclear his Ru(arene) complexes 5 and 6 were prepared via 
reaction of [(rl  or [( 6-C14H,4)RuCl2]2 with a stoichiometrically 
equivalent amount of N,N'-bis(2'-aminoethyl)-1,6-diaminohexane, obtained by 
treating its tetrahydrochioride salt 4 with four molar equivalents of KOITI in MeOH 
solution. FAB mass spectra were obtained for each of the complexes 5 and 6 and 
confirmed the composition of the molecular ions, [((6 
biphenyl)RuCI) 2(H2N(CH2)2NH(CH2)6NH(CH2)2NH2 -N,N',N'çN")] 24  (5), and [((1 6 
C 14H,4RuCI)2(H2N(C112)2NH(CH2)6NH(CH2)22 -NN',N'çN")] 24  (6). For cation 5, the 
peak at 783.116 is assignable to [5-H] (calcd m/z 783.119). For cation 6, the peak at 
839.181 is assignable to [6-H] + (calcd m/z 839.182) 
NMR Studies of Complexes 5 and 6 
'H NMR spectra of 5 and 6 were acquired immediately after dissolution in 
DMSO-d6, and did not change over a period of more than 10 days at ambient 
temperature. In each case, the spectrum is highly overlapped both in the aromatic 
region (ö 5.6-6.4) and in the linker CR2 region (8 0.9-3.4). This is complicated by the 
presence of more than one species in solution. Diastereomer formation is 
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Figure 4.5 Comparison of ['H, ' 5N] HSQC spectra of (A) [( 6-Bip)Ru(Et-en)Clf 
(7), and (B) [((1 6-Bip)RuCl)2(H2N(CH2)2NH(CH2)6NH(CH2)2NFI2-N,N',N",N")] 2 
(5) in DMSO-d6 solution. In each case, two sets of NH peaks can be identified due 
to their connectivities in COSY, NOESY and TOCSY spectra, and by integration, 
corresponding to two conformations of A and B (based on the conformations of 7A 
and 7B, Figure 4.4A). A and B cross-peaks for complex 5 have an intensity ratio of 
0.729: 0.271, consistent with that for lÀ and 7B of complex 7 (with a ratio of 0.737 
0.263). 
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unavoidable for this type of dinuclear complex. The linear tetraamine ligands 
themselves exhibit no chiral centres (Figure 4.8). However they contain two 
prochiral nitrogen atoms (N 1 , N2). These two amine nitrogens become chiral when
1. 
bound to two metal atoms, and correspondingly the two metal centres also become 
chiral too. Thus, there are, four chiral atoms (Ru 1 N 1 N2Ru2) in bis(Ru-arene)-
tetraamines complexes, resulting in a total of 16 possible configurations (Figure 4.8). 
In order to understand such 'interesting diastereomeration, NMR analysis for the 
dinuclear complexes was carried out in detail. First complex 5 was studied. 
The solid and solutidn studies of mononulear complex 7 provide a basis to 
understand the stereochemistry of dinuclear his Ru(Bip) complex 5. Specifically 
there is one NH proton on the chiral N atom (bearing the ethyl substituent) which has 
a characteristic chemical shift: to high frequency when in isomer 7A where NH (H2) 
points up toward the coordinated phenyl; to low frequency when in isomer 7B where 
NI-I (Hd2) points down away from the coordinated phenyl ring. This provides a 
fingerprint for analysis of the configurations of the Ru(Bip) units in complex 5. The 
dinuclear complex 5 can be treated as an assemble: two [(TI  units 
analogous to 7 linked by a 602CH2 chain through the ethyl side chain (Figure 4.4A). 
Since complex 7 is a mixture of two diaostereomers: 7A(RRURN/SR USN) and 
7B(SRURN/RRUSN), both Ru(Bip) units of 5 can treated as three combinations of AA 
(I), AB (II) or BB (III), see Figure 4.9. The A and B units can be treated to have the 
similar conformation as that for diastereomers 7A and 7B of complex 7, respectively 
(Figure 4.4A). The AA combination (I) consists of four configurations (based on the 
absolute configuration of au-N-N-Ru): RRRR, SSRR/RRSS and SSSS. The AB 
combination (II) consists of eight configurations: SRRJURRRS, RSRRIRRSR, 
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Figure 4.6 (A) The structures of three types of configurations I, II and III for 
dinuclear complex 5. (B) 2D TOCSY NMR spectrum of NH and linker CR2 region 
of Bis-Ru(Bip) in dmso-d6 solution (90 mM) suggested the presence of three spin-
systems for the linker. Cross-peak connectivities of 
NH2->a-*b-*c-*c-*b->a-4NH2 for I (thick solid line), NH2-*a-->b-4c---*c'--+b-> 
a'-NHd2 for II (thin solid line); and NHd2-3a'-3b'-4c-*c'--)b'--* a'-*NHd2' for III 
(dotted line). Note that each of the labels a, b, c, d, e, a', b', c', d' and e' represent a 
Pu 
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pair of protons on the same C. Each pair of protons are inequivalent and one appears 
at high frequency and the other at low frequency, but specific assignments were not 
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Figure 4.7 2D COSY 'H NMR spectrum of dinuclear complex 5, showing 
assignment of Nil and linker CH2 resonances for the three types of configurations I, 
II and III. The cross-peak connectivities: Nil2-*a, a-*b, b->c, c-->c, c-*b, b-*a, 
a-*NF1 112 (I, thick solid line) ; NH2-*a, a-*b, b-->c, c-+c', c'-W, b'-).a', a —*NHd2 (II, 
thin solid line); NHdf-*a', a'->b', b'->c', c'->c', c->&, &->a, a' — NHd2' (III, doffed 
line). For structures, see Figure 4.6. 
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Figure 4.8 Possible configurations for dinuclear complex 5. 
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Figure 4.9 The structures of the 16 possible configurations of dinuclear complex 5. 
Each structure can be a combination of AA, AB, or BB-type configurations. The four 
configurations RRRR, SSRR, RRSS and SSSS would show the identical NMR 
signals as type I since RRRR and SSSS, SSRR and RRSS are minor isomers and RR 
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and 85 on each end of molecule are mirror images. Each end has little influence on 
the other. Similarly, the eight configurations SRRRJRRRS, RSRR'RRSR, 
RSSSISSSR and SRSSISSRS (reversed in direction) would show identical NMR 
signals as type H, and the six configurations SRRS, SRSR'RSRS and RSSR would 
show the identical NMR signals as type III (Figure 4.6). 
RSSSISSSR and SRSSISSRS; and the BB combination (III) consists of four 
configurations: SRRS, SRSRIRSRS and RSSR. 
The 2D ['H, ' 5N] HSQC spectrum of complex 5 (90 mM in DMSO-d6) 
contains two major sets of cross-peaks, almost identical to that for complex 7 (Figure 
4.513). This suggests that complex 5 contains both A and B units either within the 
same molecule or in different molecules, and one Ru unit has little influence on the 
other Ru unit in solution. There are three cross-peaks at 6 6.6771-24.372, 6 3.809/-
24.372 and 6 7.011/-8.646 (average positions) for the NH,, NHd, and NIE12 of unit 
A, and another three cross-peaks at 6 6.7031-28.396, 8 4.5741-28.396 and 6 
3.70/9.155 (average position) for the NH,, NHa1' and NHd2' of unit B. This analysis 
is aided by studies of the NH signal on the chiral N atom: NH2 signal at high 
frequency as the marker for a conformation of 7A-type and the NIHd2' signal at low 
frequency as the marker for a conformation of 711-type. These two sets of cross-
peaks have an intensity ratio of 0.729 : 0.271, again consistent with that for complex 
7 (with a ratio of 0.737 0.263). 
The 2D ['H, 1 H] TOCSY spectrum shows that there are three spin-systems 
for the linkers, indicating that there are three major conformations (Figure 4.6): I 
(AA), II (AB) and III (BB) for complex 5. The cross-peak connectivities are 
NH02-*a--*b-->c-4c-4b-->a-->NH 112  for I, NH2-*a->b-4c---*c'--->b'--> a'->NHd2 for II; 
and NHd2-4--*b-W--*c-4b-> a->NH' for III. 2D ['H, 'H] COSY data (Figure 
4.7) show the coupling pathways for these three spin systems: (I) NH2-*a, a->b, 
b-*c, c-*c, c-*b, b-+a, a-*NH u2; (II) NH112-*a, a->b, b-*c, c-*c', c'->b', b-*a, 
a'->NHd2'; (III) NHd2'-*a, a'->b', b'->c', c'-+c', c'-W, b'->a', a'-3NHd2'. Therefore, 
DO 
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analysis of 21) 'H TOSCY and COSY cross-peak connectivities allowed "walks" 
from one Ru(Bip) unit through the alkylene linker to the second Ru(Bip) unit, and 
thus to the assignment of major conformations for dinuclear complex 5. The 
TOCSY NMR study for complex 6 gave very similar results as for complex 5. 
These NMR analyses reveal the diasterotopic nature for this type of dinuclear 
Bis Ru(arene) complex. The formation of 16 configurations is unavoidable during 
the preparations of 5 and 6 since no specific methods to control the nature of chiral 
centers was used. Since two Ru units on each molecule have little influence on each 
other, the four configurations of RRRR, SSRR, RRSS and SSSS would show the 
identical NMR signals as type I, the eight configurations of SRRR/RRRS, 
RSRRJRRSR, RSSS/SSSR and SRSS/SSRS would show the identical NIMR signals 
as type II, and the six configurations of SRRS, SRSRIRSRS and RSSR would show 
the identical NMR signals as type III (Figure 4.9). 
For complex 7, there are two diastereomers present in DMSO-d6 solution 
with 7A 73.7% and 711 26.3% at equilibrium. Based on this, the statistical ratio for 
the combinations of AA, AB and BB should be 67.32%, 24.07% and 8.60%. The 
observed ratios of conformations I, II and III are 67.7% : 24.0% : 8.3% in DMSO-d5 
solution, based on the cross-peak intensities of I, II, and III in the TOCSY spectrum. 
This result is consistent with the statistical ratios of I(AA), II(AB) and III(BB), 
suggesting that it is energetically unfavourable for the Ru(Bip) unit to adopt the B-
type configuration in which the NH proton on the chiral N points down away from 
the coordinated phenyl ring while the ethyl substituent points up towards it. 
4.4 Concluding Remarks 
A new method has been used for synthesis of the bifunctional ligand N,N'-
bis(2'-aminoethyl)-1,6-diaminohexane. Two novel dinuclear his (Ru-arene) 
complexes 5 and 6 were prepared with this tetraamine ligand, as potential DNA 
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cross-linking agents. They are presently undergoing cytotoxity tests. The cytotoxity 
data against A2780 cell lines are promising. They are at present under study as 
potential DNA interstrand cross-linking agents. 
NMR studies of the dinuclear complex 5 revealed diastereotopic behaviour. 
This can be understood with the aid of studies of complex 7, the mono chiral 
Ru(arene) complex. Each end of the dinuclear complex 5 was found to have a 
similar stereo-chemistry as the two diastereomers 7A and 7B, and would therefore 
have a similar chemical behaviour to complex 7. Thus, further investigations of DNA 
binding for the two diastereomers 7A and 7B will be interest. It will be interest to 
investigate the influence on DNA binding of the steric hindrance from the 
ethylenediamine aliphatic substituent in isomers 7A and 7B, in comparison with the 
analogue species [(TI  
In view of the importance of steric-selectivity in biochemistry, eg. chiral 
recognition of DNA by drugs, 20  the resolution of diastereomers of the dinuclear 
complexes S and 6 is also of interest. For the resolution of the isomeric mixture, an 
efficient FIPLC method or fractional crystallization could be. used . 2 ' Selective 
crystallization of one diastereomer 22 of the dinuclear complexes could also be 
attempted. 
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5.1 Introduction 
Ruthenium complexes offer potential for the design of anticancer drugs.' The 
ammine complex fac-[Ru(III)Cl 3 (NH3)3], has long been known to be active, but its 
poor aqueous solubility has prevented its clinical use. 2 Recently other Ru complexes 
such as trans-[Ru(II)C12(DMSO) 4], trans-[HIn][Ru(III)C1 4(Jnd)2] (Ind = indazole), 
mer-[Ru(III)(terpy)C1 3 ] (terpy = 2, 2': 6', 2"-terpyridine), cx-[Ru(azpy) 2]Cl2 (azpy = 
2-(phenylazo)pyridine) and [Ru(W)(cdta)C1 2] (cdta = 1, 2-
cyclohexanediaminetetraacetate) have also been reported to be highly active. 3 Trans-
[HJm][Ru(1II)C14(DMSO)(Jm)} (In-i = imidazole) (NAMI-A) recently became the 
first Ru complex to enter clinical trials. NAMI-A is relatively non-toxic, but active 
against tumour metastases. 4 Ru(III) antitumor complexes may serve as prodrugs 
which are reduced to active Ru(II) species in vivo. 5 We have found that 
organometallic Ru(TI) complexes of the type [( 6-arene)Ru(II)(en)Cl][PF 6] (en = 
ethylenediamine) exhibit anticancer activity both in vitro, 6,7  and in vivo, 8 including 
activity against cisplatin-resistant cancer cells. 
A potential target for these organometallic Ru(II) complexes is DNA and in 
initial studies we observed strong selective binding to N7 of guanine (G) bases on 
DNA oligomers. 7 It is now important to elucidate potential modes of interaction of 
these Ru arene complexes with DNA and, in particular, to investigate whether 
monofunctional binding induces significant structural changes in DNA. Such 
understanding will be aided by investigations of interactions with mononucleobase 
derivatives. However, to date only one X-ray crystal structure of a Ru arene adduct 
with a G derivative, that of [(q 6-C6H6)Ru(JI)(9EtG-N7)2(H20)][CF350 3 ] 2 2H20, 
appears to have been reported. 9 Also there are very few reported X-ray 
crystallographic studies of other Ru(II) and Ru(III) -nucleobase, -nucleoside, or - 
nucleotide complexes. 
lOB 
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Hydrophobic interactions between the arene ligand in [(71 6 
arene)Ru(II)(en)Cl] and DNA could produce a driving force for DNA binding. 10 
Such interactions have already been shown to be of importance in the biological 
activity of some platinum anticancer agents. Planar aromatic ligands such as 
doxorubicin," acridine orange, 12  9-aminoacridine,' 3 and ethidium bromide 14  have 
been incorporated into Pt complexes as potential intercalators. Also earlier studies of 
the binding of [Pt(terpy)C1f to calf thymus DNA revealed intercalation as well as 
covalent interactions. 15 The high antitumor activity of trans-[PtC12(NH3)L] (L = 
planar aromatic N donor such as pyridine, thiazole or quinoline) in comparison with 
transplatin, trans-[PtCl2(NH3)2], 16" 7 has been attributed to the interaction of the 
quinoline ligand with DNA duplex, perhaps partially by intercalation,' 8,19  and the 
cytotoxic transplatin derivative trans-[PtCI(PyAc-N, O)(NH3)] (PyAc = pyridin-2-yl-
acetate) also appears to exhibit "pseudobifunctional" behavior (covalentlintercalative 
binding). 20 Hydrophobic interactions with nucleobases play a key role in 
determining the recognition of cisplatin-modified DNA by the high-mobility group 
protein (HMG 1), 2 ' and also contribute to formation of stereoselective GG intrastand 
crosslinks on DNA by the anticancer drug cis-[PtC12(NH 3)(2-picoline)]. 22 The 
presence of intercalator ligands in coordinatively-saturated octahedral Ru(II), Os(II), 
and Rh(III) complexes increases DNA affinity and gives rise to highly specific 
recognition of DNA base sequences via shape selection. 23  Also the introduction of 
aliphatic amine ancillary ligands into Rh(III)(phi) complexes (phi = 9, 10-
phenanthrenequinone diimine) has optimised site-recognition through specific H-
bonding and van der Waals contacts between the ancillary ligands and DNA bases. 24 
Hydrogen-bonding plays an important role in modulating the DNA sequence 
recognition of platinum am(m)ine complexes and stabilization of platinated 
adducts .25  Pt-am(m)ine NH protons are often involved in H-bonding with an oxygen 
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of the 5'-phosphodiester linkage or with G 06.26  The diamine ligand in [(6_ 
arene)Ru(ll)(en)Clf complexes has potential for H-bonding interactions. 
The aim of this work is to gain insight into the factors which influence the 
interaction of [(TI 6_arene)Ru(Il)(en)] 2  with guanine derivatives, including covalent 
Ru binding to N7, hydrophobic interactions of the arene ligand, and en NH hydrogen 
bonding. The molecular structures of the parent chloro anticancer complexes [(Il 
arene)Ru(en)C1][PF 6], where arene = biphenyl (Bip, complex 1), 1, 4, 9, 10-
tetrahydroanthracene (THA, 2), and 9, 1 0-dihydroanthracene 
Chart 5.1 Ligands and complexes studied in this work and NMR numbering scheme 
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Table 5.1 Structural studies of [(il 	complexes reported in this 
work. For structures and abbreviations, see Chart 5.1. 
4&rene X Complex Stnictijrea 
No. 
Bip Cl I X-ray NOESY (DMTF-d6)" 
9EtG 4 X-ray NOESY (acetone do)b 
Guo 5 X-ray NOESY (10% D20 in 1120)b 
5'-GMP 8C NOESY (10% D20 in H20) " 
THA Cl 2 X-ray NOESY (DMSOd6)b 
9EtG 6 X-ray C 
5-GMP 9C C 
DHA Cl 3 X-ray 
9EtG 7 X-ray C 
5'-GMP lO' C 
a All crystals studied as PF5 salts. b  Solvent for NMR. C  Arene resonances too broad 
for NOESY studies. C  Since the charge on 5'-GMP is dependent on pH, no overall 
charge is assigned to the 5'-GMP adducts discussed in this chapter. 
(DHA, 3), and those of their 9-ethylguanine (9EtG), guanosine (Guo) and guanosine 
5'-monophosphate (5'-GMP) adducts (Chart 5.1), have been studied, where possible 
both in the solid state by X-ray crystallography and in solution using NMR methods 
(Table 5.1). These studies will aid optimisation of the design of this new class of 
anticancer agents. 
5.2 Experimental Section 
5.2.1 Materials 
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9-Ethylguanine (Sigma), guanosine hydrate (9-[-D-ribofuranosylguanine) 
(Aldrich) and Na2-5'-GMP (Aldrich) were used without ftrther purification. 
15N112(CH2)2 15NF12 ("N-en) '21  1, 4, 5, 8, 9, 10-Hexahydroanthracene (C14H 1 6),28 1, 
4, 9, 10-Tetrahydroanthracene (C14H14), 29 [( 6-biphenyl)Ru(en)Cl}PF 6 (1) and [(TI 6_  
biphenyl)Ru(' 5N-en)Cl]PF6 (' 5N-1)7 were prepared according to the published 
procedures. Other complexes were prepared as described below. 
5.2.2 Preparation of Complexes 
101 6 -C14H14)RuCl2] 2. 30  1, 4, 5, 8, 9, 10-ilexahydroanthracene (1.0 g, 5.43 
mmol) was added to a solution of RuCl33H 20 (0.84 g, 3.18 mmol) in dry ethanol (60 
mL) and refluxed under Ar for 48 h. Filtration of the hot reaction mixture gave a 
yellow-brown solid which was washed with fresh ethanol (2 mL) followed by diethyl 
ether (4x10 mL) and dried under vacuum. Yield: 0.96 g (85.5 %). 'H NMR (DMSO-
d5): 8 5.83 (m, 211), 5.71 (s, 2H), 5.61 (m, 211), 3.21 (m, 2H), 3.05 (m, 2H), 2.5 (m, 
4H). 
[(11 6-C14H14)RuCI(en)I[PF6] (2). [( 6-C j4Hi4)RuCl2 ] 2 (0.205 g, 0.289 
mmol) was stirred in dry methanol (25 mL) under Ar at 333 K. Ethylenediamine (48 
RL, 0.75 mmol) was added in one portion. The reaction was stirred for 3 It and 
filtered, and NR 4PF6 (0.4 g, 2.45 mmol) added. The volume was reduced to ca. 6 ml, 
on a rotary evaporator. After standing at 277 K overnight, a yellow microcrystalline 
precipitate formed, which was collected by filtration, washed with fresh methanol 
(0.5 mL), followed by diethyl ether (5 mL) and dried in vacua. Yellow crystals 
suitable for X-ray diffraction were obtained by recrystallisation from ethanol/ether. 
Yield: 0.1 g (32.9%). Anal. Calcd for C, 6H22C1F6N2PRu (523.85): C, 36.68; H, 4.23; 
N, 5.35%. Found: C, 36.20; H, 4.17; N, 5.34%. 1 H NMR (DMSO-d6): 8 6.29 (broad, 
TOP 
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211), 5.75 (s, 211), 5.61 (m, 211), 5.50 (m, 211), 4.10 (broad, 2H), 3.18 (m, 411), 2.62 
(s, 411), 2.32 (m, 2H), 2.23 (m, 2H). 
E(
11
6-C14H12)RuCl2I2. 1, 4, 9, 10-Tetrahydroanthracene (0.45 g, 2.49 mmol) 
was added to a solution of RuC1331 ­120 (0.48 g, 1.83 mmol) in dry ethanol (45 mL). 
The reaction was heated to reflux under Ar for 48 h. Filtration of the hot reaction 
mixture gave a brown solid which was washed with fresh ethanol (1 mL) followed 
by diethyl ether (4x10 mL) and dried under vacuum. Yield: 0.57 g (88.5%). 'H NMR 
(DMSO-d6): 8 7.27 (m, 4H), 5.89 (m, 411), 3.92 (m, 411). 
[(16-C14H12)RuCI(en)][PF6] (3). [( 6-C, 4F1 j 2)RuC12]2 (0.10 g, 0.142 mmol) 
was stirred in dry methanol (10 mL) under Ar at 333 K. Ethylenediamine (24 j.tL, 
0.359 mmol) was added in one portion. The reaction was maintained at 333 K with 
stirring for 5 h and filtered. The volume was reduced to ca. 4 mL with a rotary 
evaporator and to this solution was then added a solution of NH 4PF6 (0.20 g, 1.227 
mmol) in methanol (2 mL). On shaking, a yellow solid precipitated. This mixture 
was allowed to stand overnight at 277 K. The precipitate was then collected by 
filtration, washed with fresh methanol (0.5 mL), followed by diethyl ether (5 mL), 
and dried under vacuum. Recrystallisation from benzyl alcohol / ether gave yellow 
crystals suitable for X-ray diffraction studies. Yield: 0.1 g (67.5%). Anal. Calcd for 
C16H20CIF6N2PRu (521.83) : C, 36.82; H, 3.86; N, 5.37%. Found: C, 36.50; 11, 3.85; 
N, 5.38%. 111  NMR (DMSO-d6): 8 7.20 (m, 411), 6.19 (broad, 2H), 5.70 (m, 4H), 
3.95 (m, 4H), 3.86 (broad, 211), 2.22 (m, 211), 2.05 (m, 211). 
L(TI 6-biphenyI)Ru(en)(9EtG -N7)][PF6]2IMeOH) 	(4). 	[(1 6W 
biphenyl)Ru(en)Cl][PF6] (1) (0.10 g, 0.20 mmol) was dissolved in water (30 mL) and 
9EtG (37.63 mg, 0.21 mmol) was added. The mixture was stirred for 2 d at 313 K. 
109 
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After filtration, the volume was reduced to 8 mL and then NH 4PF6 (0.2 g, 1.2 mmol) 
was added. A precipitate was obtained overnight at 277 K. Recrystallization from 
methanol gave yellow crystals suitable for X-ray diffraction studies. Yield: 0.12 g 
(73.5 %). Anal. Calcd for C22H31 F 12N702P2Ru (816.55): C, 32.36; H, 3.83; N, 
12.01%. Found: C, 32.19; Fl, 3.80; N, 12.34%. 
[( 6-biphenyJ)Ru(en)(Guo-N7)J[PF6]2.3.75(H 20) (5) was prepared by 
reacting [(il  (1) (89.7 mg, 0.18 mmol) with Guo (53.8 mg, 
0.19 mmol) in water (20 mL) at 313 K for 4 d. The solution was filtered and then 
NH4PF6 (0.16 g, 1.0 mmol) was added. After shaking, the reaction mixture was then 
kept at 277 K overnight. The precipitate was recrystallised from water. Slow 
evaporation of the aqueous solution gave yellow-green crystals suitable for X-ray 
diffraction studies. Yield: 80.0 mg (48.1%). Anal. Calcd for C24H385F12N70875P2Ru 
(956.11): C, 30.15; 11,4.05; N, 10.60% Found: C, 30.17; H, 3.86; N, 10.42%. 
[(11 6-C14H14)Ru(en)(9EtG-N7)J[PF6]2.(MeOH) (6). [( 6C 14H i4)Ru(en)Cl]-
[PF61 (2) (70.68 mg, 0.14 mmol) was reacted with 9EtG (26.34 mg, 0.147 mmol) in 
water (30 mL) at 313 K for 2 d under At. The mixture was then filtered. The 
volume of the filtrate was reduced to 10 mL and NH 4PF6 (0.16 g, 1 mmol) was 
added. Yellow crystals suitable for X-ray diffraction studies were obtained on 
recrystallization of the precipitate from MeOH. Yield: 62.0 mg (52.4 %). Anal. 
Calcd for C24H35F12N702P2Ru (844.60): C, 34.13; Fl, 4.18; N, 11.61%. Found: C, 
34.28; H, 4.62; N, 11.96%. 
[(1 6-C14H12)Ru(en)(9EtG-N7)][PF 6]2.2(MeOH) 	(7). 	ftq 6-C1 4H 1 2)- 
Ru(en)Cl][PF6] (3) (34.8 mg, 0.067 mmol) was reacted with 9EtG (12.0 mg, 0.067 
mmol) in water (15 mL) at 313 K for 2 d under At. The mixture was then filtered. 
110 
Chapter 5 Ru(arene)-guanine Adducts 
The volume of the filtrate was reduced to 4 ml, and NH4PF6 (0.16 g, I mmol) was 
added. Recrystallisation of the precipitate from Me011 gave the yellow crystals 
suitable for X-ray diffraction studies. Yield: 32.5 mg (55.5 %). Anal. Calcd for 
C25H37F12N703P2Ru (874.63): C, 34.33; H, 4.26; N, 11.21 %. Found: C, 34.35; H, 
4.55;N, 11.69%. 
5.2.3 Preparation of NMR Samples 
[( 6-biphenyl)Ru(en)(5'-CMP-N7)] (8). A solution containing this 
complex was prepared by mixing [(q 6-biphenyl)Ru(en)Cl][PF6] ( 1) (2.43 mg, 4.9 
jimol) with an aliquot (122.3 j.iL) of a stock solution of Na25'-GMP (40 mM) in 10% 
D20 I 90% H20 (total volume 700 ML). This solution was kept at 310 K for 16 h. The 
final Ru concentration was 7.0 mM and pH = 7.3. Then sodium 
trimethylsilyl[2,2,3,3-d4jpropionate (TSP, 2 ML of a 50 mM solution in D20) was 
added and the solution was filtered into a 5 mm NMR tube. 
(h6-biphenyl)Ru( 15N-en)(9EtG-N7)] 2 (15N-4), [( 6-biphenyl)Ru( 15N-
en)(Guo-N7)J 2 ( 15N-5) and [(r1 6-biphenyl)Ru( 15N-en)(5cGMPN7)] ( 15N-8) 
were prepared by the following procedure. Typically, [(q 6-biphenyl)Ru(' 5N-
en)Cl][PF5] (' 5N-1) (1.77 mg, 3.55 mmol) and 9EtG (0.636 mg, 3.55 mmol) or Guo 
(1.0 mg, 3.55 mmol) or Na25'-GMP (88.75 ML of a 40.0mM solution) were reacted 
in 10% D20 I 90% H20 (total volume 700 ML)zat 310 K for 24 h. The reaction was 
then complete and the mixture was filtered directly into NMR tubes. For the spectra 
in acetone-d6 or DMSO-d6, the filtrate was lyophilized and then redissolved in 
acetone-d6 or DMSO-d6 (700 ML). The final Ruconcentration was 5 mM. 
E01 6-C14H14)Ru(en)(9EtG -N7]2 	(6 	and 	15N-6) 	and 	[(6 
C14H14)Ru(en)(5'-GMP-N7)] (9 and 15N-9 ) were prepared by in situ reactions of 
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stoichiometric amounts of [(i 6-C14H14)Ru(en)ClJ[PF6] (2) (0.91 mg, 1.73 pmol) and 
9EtG (0.31 mg, 1.73 l.xmol) or Na25'-GMP (43.25 jiL of a 40.0 mM solution)) in 10% 
D20 I 90% 1120 (total volume 680 pt). The mixture was degassed by bubbling Ar 
for 10 mm, then sealed and kept at 310 K for 10 h. TSP (2 ML of a 50 m solution in 
D20) was added and the resulting mixture filtered into NMR tubes under Ar. To 
prepare ' 5N-6 and 15N-9, 15N-2 was used. The final Ru concentration was 2.5 ram. 
The pH of solution was 6.3 for 9EtG adducts, and 7.4 for 5'-GMP adducts. 
[(11 6 -C14H12)Ru(en)(9EtG-N7)] (7) and [( 6-C14Hi2)Ru(en)(5'-GMP-
N7)] (10) were prepared by in situ reactions of [(r1 6-C 14H12)Ru(en)Cl][PF 6] (3) (0.98 
mg, 1.88 .xmol) and 9EtG (0.34 mg, 1.88 jimol) or Na 25-GMP (47.0 tL of a 40.0 
mM solution) in 10% D20/90% H20 (total volume 740 tL) at 310 K for 10 h; then 
TSP (2 ML of a 50 mM solution in D 20) was added. The mixtures were filtered into 
NMR tubes under Ar. The final Ru concentration was 2.5 mM. The pH of solution 
was 6.2 for complex 7, and 7.1 for complex 10. 
5.2.4 Methods and Instrumentation 
X-ray Crystallography. All diffraction data were collected using a Bruker 
(Siemens) Smart Apex ccd diffractometer equipped with an Oxford Cryosystems 
low-temperature device operating at 150 K. Absorption corrections for all data sets 
were performed with the multi-scan procedure SADABS; 3 ' structures were solved 
using either Patterson or direct methods (SHELXTL 32or DJRDIF 33); all except 
complex S were refined against 172 using SHELXTL. For complex 2, all H-atoms 
were located in a difference map and refined freely. In other structures these atoms 
were placed in calculated positions, except those attached to nitrogen, which were 
refined freely. The difference in the strategy for H-atom treatment adopted for 2 was 
as a result of the rather unexpected non-planarity of the hydrocarbon ligand: the H- 
112 
Chapter 5 Ru(arene)-guanine Adducts 
atom positions were refined without difficulty, which gave confidence in the quality 
of the data set and the correctness of the model presented. We confirmed these 
structural features by repeating the structure determination of this compound using a 
different sample. All non-H atoms in all structures were modelled with anisotropic 
displacement parameters. In 4, one of the crystallographically-independent PF 6 
anions is disordered in an approximately 50:50 ratio about a common FPF axis. 
Similarity restraints were applied to the geometry and the displacement parameters 
for this ion. 
The crystal structure of 5 was complicated by both twinning and 
pseudosymmetry effects. Several crystals were investigated, and all showed 
significant multiplicity. The diffraction patterns were indexed using the program 
GEMINI, 34  and a sphere of data was collected. An absorption correction was applied 
(assuming point group 1) by the multi-scan procedure SADABS. The structure 
solved easily by direct methods, yielding the positions of a pair of 
centrosymmetrically-related [Ru(C 1 2H 1 0)(en)(Guo)] fragments and four PF 6 anions, 
again in two centrosymmetrically-related pairs. A rather noisy region of electron 
density was observed next to the N9 atoms of the guanine rings. The ribose sugar 
was used in a chirally-pure form in the synthesis of this material, and so the space 
group P-i is physically impossible. The true space group must be P1, but the 
difficulty in resolving the ribose fragments can be ascribed to the dominant effect on 
the phases of the centrosymmetric part of the structure. Two ribose fragments were 
eventually picked out of difference maps by ensuring that only peaks which 
corresponded to the known enantiomer of the sugar were selected. Further modelling 
revealed that while one pair of PF 6 anions (based on P1 and P3) conform closely to 
inversion symmetry, the other pair differ in orientation. At this stage, further 
difference peaks were assigned to water of crystallisation, to give a conventional R-
factor of 10%. It was clear at this stage that the centrosymmetric sub-structure could 
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be constrained by applying the inversion relationship as part of the model. The 
advantage of this procedure is that it effectively cures ill-conditioning of the least 
squares and minimises the number of parameters which need be refined against the 
rather weak data set obtained . 35 A refinement of this type was set up using the 
program CRYSTALS 36 for both fractional coordinates and displacement parameters. 
The ribose sugars, the PF 6 anions based on P2 and P4, and the water molecules were 
all refined independently. Analysis of poorly-fitting data at this stage revealed that 
most for which F. > F had h =0; the program ROTAX37 was used to identify the 
likely cause as twinning via a 2-fold rotation about the direct a-axis, which can be 
expressed by the matrix 
1 	00 
—0.045 —1 0 
—0.200 0 —I 
This was confirmed by re-analysis of the diffraction pattern using GEMINI. This is 
clearly not a symmetry operation of the lattice, and it accounts for the difficulty 
encountered in indexing the diffraction pattern prior to data collection. A recently 
introduced feature of CRYSTALS allows this kind of twin matrix to be input directly 
without the need to split overlapping data manually. H-atoms attached to N and C 
were placed by conventional methods and reidealised at the end of each refinement 
cycle. Coordinates for H-atoms attached to oxygen in the OH groups and water 
molecules were calculated using the program CALC-OH , 38 and thereafter allowed to 
ride on their parent atoms. Refinement was performed against F using 6014 data 
with F> 4a(P) and Chebychev polynomial weights. 39 The final R-factor was 6.65% 
(R = 6.95%) for 665 parameters. The final difference map showed no feature 
outwith ±1.8 eA 3. The twin scale factors refined to 0.66 and 0.44; the Flack 
parameter was not refined, but set at zero to avoid the need to model both non- 
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merohedral and racemic twinning; the known chirality of the sugar justifies this 
course of action. 
In the Tables of H-bonding data, esd's are given in cases where parameters 
have been refined. 
NMR Spectroscopy. 'H NMR spectra were acquired on either Bruker 
DMX 500 ('H = 500 MHz ) or Varian Unity INOVA ('H = 600 MHz) NMR 
spectrometers using TBI ['H, ' 3C, X] or triple resonance ['H, ' 3C, ' 5N] probe-heads, 
respectively, and equipped with z-field gradients. 
ID 'H NMR spectra were typically acquired with 64 transients into 32 K data 
points over a spectral width of 6.0 kHz using a double pulsed-field gradient spin-
echo pulse sequence. Typically, 2D ['H, 'H] NOESY NMR spectra were acquired 
with 32 transients for each of 1024 t, increments (TPPI). The mixing time was 1 s, 
and the relaxation delay was 2 s. 2D ['H, 'H] COSY and DQFCOSY spectra were 
acquired with 32 tranisients for each of 512 t, increments (States or TPPI) Water 
suppression was achieved by presaturation or by using a WATERGATE pulsed-
field-gradient sequence. 40 
Both 1D ' 5N-edited 'H NIMR spectra and 2D ['H, ' 5N] HSQC NMR spectra 
(optimised for 'J(NH) = 73 Hz) were acquired using the sequence of Stonehouse et. 
aL 4 ' A GARP decoupling sequence was used for ' 5N decoupling during acquisition. 
Typically, 1D 'H-{ 15N} data were acquired with 16 transients into 1024 data points 
over a spectral width of 2.5 kHz (5.0 ppm) with a relaxation delay of 2.0 s. 2D ['H, 
' 5N] HSQC NMR data were acquired with 4 transients into 1024 data points over a 
'H (172) spectral width of 2.5 kHz (5 ppm, centred at the water resonance) for each of 
256 t, increments (TPPI), and over a 15N (Fl) spectral width of 0.76 kHz (15 ppm, 
centre at —28 ppm) using a relaxation delay of 1.4 s between transients. Typically, 1D 
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'H-{' 5N} spectra were acquired over a 10 min period and 2D ['H, ' 5N] NMR HSQC 
spectra were acquired over a 30 min period. 
31 P NMR spectra were obtained on either Bruker DMX 500 (31 P = 202 MHz) 
or Bruker DMX 360 ('p = 146 MHz) NMR spectrometers at 298 K, using inverse-
gated 'H decoupling. Typical 1D 31p_  ( 1 H) NMR spectra at 202 MHz were acquired 
with 512 transients into 42 K data points over a spectral width of 40.7 kHz (200.8 
ppm) using a relaxation delay of 1.3 s. Typical 1D 31 P-{'H} NMR spectra at 146 
MHz were acquired with 256 transients into 32 K data points over a spectral width of 
14.6 kHz (100.28 ppm) using a relaxation delay of 0.5 s. 
All data processing was carried out using XWIN-NMR version 2.0 (Bruker 
U.K. Ltd.). 'H NMR chemical shifts were internally referenced to 1, 4-dioxane (3.77 
ppm) or to the methyl singlet of TSP (0 ppm) in aqueous solutions, of to 
CD2HCOCD3 (2.06 ppm) in acetone-d6 solution. ' 5N resonances were referenced to 1 
M ' 5NH4C1 in 1.5 M HCI (external) at 0 ppm, and 31P resonances to 85% H3PO4 
(external) at 0 ppm. 
pH Measurement. The pH values of NMR samples in 10% D20 / 90% 
H20 were measured at ca. 298 K directly in the NMR tube, before and after 
recording NMR spectra, using a Corning 240 pH meter equipped with an Aldrich 
micro combination electrode calibrated with Aldrich buffer solutions at pH 4, 7, and 
10. The pH values of samples were adjusted with dilute solutions of HCI and NaOH. 
No correction has been applied for the effect of deuterium on the glass electrode. 
Calculations of pKa values. The pH titration curves were fined to the 
Henderson-Hasselbalch equation using the program KALEIDAGRAPH, 42 with the 
assumption that the observed chemical shifts are weighted averages according to the 
populations of the protonated and deprotonated species. 
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5.3 Results 
5.3.1 General 
The molecular structures of the parent chloro anticancer complexes [(6 
arene)Ru(en)Cl][PF6], where arene = biphenyl (Bip, complex 1), 5, 8, 9, 10-
tetrahydroanthracene (THA, 2) or 9, 10-dihydroanthracene (DHA, 3) (Chart 5.1) and 
those of their 9EtG, Guo and 5-OMP adducts were been studied, where possible 
both in the solid state and in solution (Table 5.1). The X-ray structure of complex 1 
has been reported previously 7 and those of 2 and 3 are reported here. Yellow 9EtG 
and Guo adducts of {( 6-biphenyflRu(en)1 2 were successfully crystallized from 
MeOH and 1120, respectively. The structures of the chloro complex 1 and its 9EtG, 
Guo and 5'-GMP adducts (4, 5 and 8) in solution were studied by NMR methods, 
including 2D [ 1 H, ' 5N] HSQC NMR using ' 5N-en complexes, NOE measurements, 
pH and temperature dependences. For the anthracene derivatives, the 9EtG adducts 6 
and 7 were successfully crystallized, but NMR work in solution was limited to 1D '11 
and 2D ['H, ' 5N] NMR studies since broad resonances and slow chemical exchange 
processes complicated the interpretation of NOESY data. 
5.3.2 X-ray Crystal Structures of Biphenyl Complexes 
[(16-biphenyl)Ru(en)(9EtG-N7)][PF 6]2•(MeOH) (4). In complex 4, 
Ru(II) adopts the familiar "three-leg piano-stool" geometry. It is it-bonded to the 
hexadentate biphenyl ligand and c-bonded to the N atoms of ethylenediamine and 
N7 of 9EtG (Figure 5.1). Crystallographic data are listed in Table 5.2, selected bond 
lengths and angles in Tables 53A and 5.3C, and selected H-bonding interactions in 
Table 5.4A. The propeller twist of the pendent phenyl with respect to the coordinated 
phenyl of the biphenyl ligand is 137. The long axis of biphenyl is rotated away 
from the Ru-N7 vector by 136.00  (Table 5.5A) and therefore adopts the anti 
orientation with respect to the purine base. Atom 06 of 9EtG is strongly H-bonded 
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Figure 	5.1 	X-ray 	crystal 	structure 	of 	KTI 
 [PF6 ] 2 '(MeOH) (4). (A) The H-bond network of the dimer. The atom numbering 
scheme is shown for one cation. PF 6 ions are omitted for clarity. (B) Tetrameric 
aggregate in the unit cell (as viewed along the c axis). The core of this cyclic 
tetramer is filled by two PF6 ions and two MeOH molecules. The disordered PF 6 
ions are omited for clarity. Two pendent phenyl rings inside the unit cell stack onto 
the purine bases of adjacent cations . Color code: Ru purple, biphenyl yellow, N 
blue, 0 red, C of G and Me011 gray, H of G and MeOH white, F of PF 6 green and P 
of PF6 dark red. 
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Table 5.2 Crystallographic data for [(i 6-C14H14)Ru(en)C1][PF6] (2), [(6_ 
C14H12)Ru(en)Cl] [PFd (3), [(q 6-biphenyi)Ru(en)(9EtG-N7)] [PF6] 2 '(MeOH) (4), 
[1 6-biphenyl)Ru(en)(Guo-N7)] [PF 6] 2 3 .75(H20) (5), [(rj 6-C14H14)Ru(en)(9EtG-
N7)][PF6] 2• (MeOH) (6) and [( 6-C14Hj2)Ru(en)(9EtG-N7)][PF 6] 2 .2(MeOH) (7) 
2 3 4 5 6 7 
Formula C 16H22CIF6N2PRu C 15 F125CIF6N,PRu CnH3F i ,N702 P2Ru C24H35Fi2N7Og75P2Ru C24H,,FuN702P2Ru C25H37F11N703P2R 
Molar 523.85 521.83 816.55 956.11 844.60 874,63 
mass 
Crystal Monoclinic orthorhombic Monoclinic Triclinic Monoclinic Triclinic 
system 
Space P2 1 /c Pbca P2 1 /n P1 P2L/n P-I 
group 
Colour Orange Yellow Yellow Yellow Pale Yellow Yellow 
iA 12.171(3) 11.1220(18) 13.2927(14) 8.850(3) 16.6279(11) 10.6486(17) 
b/A 8.4733(18) 12.576(2) 15.9583(17) 11.543(4) 9.0528(6) 12.317(2) 
c / A 18.946(4) 25.593(4) 15.0878(16) 17.556(5) 21.5446(15) 13.006(2) 
a! deg 90 90 90 103.254(4) 90 73.957(2) 
fl/deg 103.854(3) 90 108.613(2) 92.885(4) 99.677(I) 79.483(2) 
r/ deg 90 90 90 90.983(4) 90 84.977(2) 
T/K 150(2) 150(2) 150(2) 150(2) 150(2) 150(2) 
Z 4 8 4 2 4 2 
R [F> 0.0230 0.0444 0.0895 0.0665 0.0593 0.0291 
4u(F)I' 
0.0625 0.1055 0.220 0.0695 0.1391 0.0768 
GOP 1.062 1.038 1.222 0.981 1.132 1.035 
zlpmax +0.722 ,-0.371 2.328, -2.190 2.00,-1.21 1.76,-1.84 1.12, -0.80 0.56, -0.45 
and mm 
/ ek' 
a  = IIF0I - IFcI1EW0I. bR = [Ew(F02 - Fc2)2IwFo2)]U2. 
C 
GOF = [Ew(F02 - 
F 2)2/(n-p)]'12 , where n = number of reflections and  = number of parameters. 
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Table 5.3 Selected Bond Lengths (A) and Angles (deg) for Complexes 1-7. 
Bond lengths (A) for biphenyl complexes 1, 4 and 5. 
atoms a 4 5 
Rul-NIB 2.110(5) 2.104(6) 2.099(6) 
Rul-N2B 2.121(5) 2.126(5) 2.133(6) 
Rul-N7/C11 2.408(15) 2.128(5) 2.120(5) 
Rul-CIA 2.244(6) 2.221(6) 2.240(6) 
Rul-C2A 2.185(6) 2.185(7) 2.181(6) 
Rul-C3A 2.160(6) 2.177(7) 2.158(7) 
Rul-C4A 2.152(5) 2.190(7) 2.194(7) 
Rul-05A 2.138(5) 2.168(7) 2.171(6) 
Rul-C6A 2.190(5) 2.205(7) 2.158(6) 
Ru-(centroid) 
1.663(3) 1.676(3) 1.667(3) 
a From ref 7. 
Bond lengths (A) for THA complexes 2 and 6 and DEJA complexes 3 and 7. 
Atoms 2 6 3 7 
Rul-NIB 2.1243(17) 2.119(3) 2.139(3) 2.1169(17) 
Rul-N2B 2.1307(18) 2.134(3) 2.134(3) 2.1189(16) 
Rul-N7/C11 2.405(6) 2.128(3) 2.407(9) 2.1173(15) 
Rul-CIA 2.2248(19) 2.221(4) 2.203(3) 2.2344(18) 
Rul-C2A 2.151(2) 2.173(4) 2.166(3) 2.1820(19) 
RuI-C3A 2.169(2) 2.184(4) 2.154(3) 2.1709(19) 
Rul-C4A 2.180(2) 2.169(4) 2.184(3) 2.1408(19) 
Rul-05A 2.197(2) 2.202(4) 2.181(3) 2.1965(19) 
Rul-C6A 2.2350(19) 2.226(4) 2.192(3) 2.2300(18) 
Ru-(centroid) 
coord. ring 
1.6769(10) 1.6831(17) 1.6596(14) 1.6783(9) 
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Bond angles (deg) for biphenyl complexes 1, 4 and 5 
4 	 5 
NIB-Rul-N2B 	79.20 (18) 	79.5(2) 	79.5(2) 
NIB-Rul-N7/Cll 85.60 (12) 87.2(2) 86.0(2) 
N2B-Rul-N7/Cl1 	82.88(11) 	86.3(2) 	86.8(2)_ - 
a Ref. 7 
Bond angles (deg) for THA complexes 2 and 6 and DNA complexes 3 and 7 
2 6 3 7 
NIB-Rul-N2B 	78.66(7) 79.22(13) 79.24 (10) 79.36(7) 
NIB-Rul-N7/Cl1 	84.59(5) 87.07(12) 85.66(8) 87.93(6) 
N2B-Rul-N7/Cll 	83.18(6) 84.41(12) 84.48(g) 84.44(6) 
to an en NH proton (NiB!) with a N1W"06 distance 2.761 A and N1B-H1B1 ... 06 
angle of 162.9° (Table 5.4A). Guanine-guanine pairing via two H-bonds between the 
G N2H and the G N3 (N2 ... N3 3.015 A, N2-H2X ... N3 172.00, Figure 5.1) is present. 
In addition, for each molecule, the second G N2 proton (H2Y) together with the G 
Ni proton (FIX)) forms two H-bonds to the 0 of MeOH (O1M) (N2 ... O1M 2.983 
A, Ni O1M 2.844 A, Figure 5.1). One PF6 counter anion is beneath the guanine 
plane and H-bonded to the en NH proton (H2B2) (N2R F4 2.952 A); the second 
PF6 ion (disordered) is above the guanine plane and its presence prevents 
intramolecular arene-purine stacking. 
In one unit cell, four molecules form a cyclic aggregate when viewed along 
the c axis (see Figure 5.iB). The core of this cyclic tetramer is filled by two PF ions 
and two solvent CH30H molecules. The pendent phenyl ring stacks onto the purine 
base of an adjacent cation with a centroid-centroid separation of 4.0 A and a dihedral 
angle of 4.5° (see space-filling model in Figure 5.2A). Tetramers are stacked on top 
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Table 5.4 Selected H-bonding Interactions for Complexes 4, 5, 6 and 7. O1M is 
Me011 oxygen. 
Complex 4 [( 6-biphenyl)Ru(en)(9EtG-N7)] [PF6] 2•(MeOH) 
fl-HA 	 WA (A) flA (A) zD-HA (deg) 
NIB-H18106 (intra) 1.868 2.761(8) 162.91 
N2-FI2XN3 (liner) 2.123 3.015(9) 171.96 
N2-H2YO1M 2.168 2.983(12) 151.25 
N1-HIXO1M 2.004 2.844(11) 155.19 
Complex 5 [Qi 6-biphenyRu(en)(Guo-N7)][PF 5 ] 2 .3.75(H20) (Cations I and II) 
Cation! Cation II 
1)-WA HA (A) fl'A (A) zD-WA D-FIHA HA (A) IY'A (A) /D-HA 
(deg) (deg) 
N14-H141061 1.8899 2.799(8) 158.97 N18-H181065 1.8899 2.799(8) 158.97 
(intra) (intra) 
N14-H142''065(I1) 2.5454 3.212(7) 127.28 N18-H182061(1) 2.5454 3.212(7) 127.28 
(inter) (inter) 
N24-H241052 2.7750 3.714(7) 169.28 N28-H281069(W) 2.1963 3.083(13) 154.72 
Nl1-1111029(W) 1.9772 2.841(16) 150.65 N15-1-115019(W) 2.0708 2.949(16) 153.63 
N21-H212029(W) 2.0335 2.861(17) 144.66 N25-H252'019(W) 2.2352 3.050(16) 143.47 
N21-H211'099(W) 2.2411 3.136(17) 156.44 N25-H251'032(1) 1.7916 2.715(11) 162.79 
(inter) 
Complex 6 [( 6-C 14ll 14Ru(en)(9EtG-N7)] [PF 6] 2.(MeOH) 
fl-HA WA (A) WA (A) zD-HA (deg) 
NIB-H1B106 (intra) 1.919 2.812(4) 163.30 
N2-1-12XN3 (inter) 2.349 3.105(4) 168.07 
N2-H2Y01M 2.403 3.085(5) 142.04 
N1-H1XO1M 2.161 2.829(6) 160.84 
Complex 7 [( 6-C14Hi2)Ru(en)(9EtG-N7)] [PF6] 2.2(MeOH) 
1)-HA HA (A) DA (A) zD-HA (deg) 
NIB-H1NB06 (intrà) 2.081 2.840(2) 163.09 
NIB-H1NA06 (inter) 2.237 3.031(2) 146.19 
N2-H2XN3 (inter) 2.299 3.085(3) 162.19 
N2B-H2NAOIM 2,112 2.895(3) 162.50 
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Table 5.5 Comparison of the Conformations of Guanine Adducts and their Parent 










c NFk  
Biphenyl Complexes 1, 4 and 5 
1 (Cl) 	4 (9EtG) 5 (Guo) 
Sip orientation, a (I), [Aaf, 26.8(2) 	136.0(3) 13.2(3) 
(deg) [+109.2] [-13.6] 
Bip propeller twist, f, [Ax]1' 26.2(4) 	13.7(5) 17.9(4) 
(deg) [-12.5] [-8.3] 
Ring B- G distance (A) 4.022(5) / 4.48(5) (Inter)' 3.80 1(4) / 23.8(4) (Intra)C 
/dihedral angle (deg) 4.199(4) / 23.0(6) 	(Inter)' 
a x:  twist of pendent phenyl ring (B) with respect to coordinated phenyl (A) of Sip. 1'  The change of 
torsion angles for 4 and 5 compared to I. ' Ring B and six-membered ring of 0 of an adjacent cation. 
Ring B and five-membered ring of 0 of the same cation. Ring B with six-membered ring of 0 of an 
adjacent cation. 
THA Complexes 2 and 6 and DHA Complexes 3 and 7. 
2 (Cl) 	6 (9EtG) 	3 (Cl) 	7 (9EtG) 
THAJDHA orientation, a (II), [Aa] t', 45.12(6) 	25.62(14) 	64.09(8) 	20.88(7) 
(deg) 	 [-19.5] [-43.2] 
Hinge bending angle, P (Ili)a, [AIj]b 	-7.53(12) 	+27.8(2) 	+ 40.65(16) + 31.95(9) 
(deg) 	 [+ 35.331 [-8.7] 
Ring C - 0 distance (A) 	 3.447(9) / 	 3.310(12) / 
/dihedral angle (deg) 3.30(17) (Intra)' 	 3.07(8) (Intra) ° 
hinge is defined by C7A - C1OA, see Figures 5.5 and 5.6. A + ye sign for P indicates movement 
towards Ru-X. b  The change of torsion angles for 6 and 7 compared to 2 and 3, respectively. C  Ring C 
and purine ring of 0 of the same cation. 
123 
Chapter 5 Ru(àrene)-guanine Adducts 
(A) Complex 4 
(B) Complex 5 
Figure 5.2 Space-filling models of [( 6-biphenyl)Ru(en)(9EtG-N7] 2 (4) and [1 6 .. 
biphenyl)Ru(en)(Guo-N7)] 2 (5). Colour code: phenyl ring yellow, Ru purple, 0 red. 
N blue, H white, C of G gray. Other parts of molecules not involved in this stacking 
are shown as stick models. (A) Stacking in complex 4 along the c axis: 
intermolecular stacking between pendent phenyl ring (yellow) and purine six-
membered ring (centroid-centroid distance 4.0 A, dihedral angle 4.5°). (B) Stacking 
in complex 5 along the a axis: intramolecular stacking between pendant phenyl ring 
and purine five-membered ring (centroid-centroid distance 3.8 A, dihedral angle 
23.8°), and intermolecular stacking between six-membered purine ring and pendant 
phenyl ring of an adjacent cation (centroid-centroid distance 4.2 A, dihedral angle 
23 . 00) . 
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of one another along the c axis. In the same layer, tetramers are connected by four 
sets of base pairs via H-bonds N2-H2X ... N3 along a and b axes. Figure 5.1A shows 
base-pairing along the b axis. 
[(r1 6-biphenyl)Ru(en)(Guo -N7)] [PF6]2'3.75H 20 (5) crystallizes with two 
independent [( 6-biphenyl)Ru(en)(Guo-N7)] 2 cations (I and H, Figure 5.3) in the 
asymmetric unit, which also contains four PF 6 counterions and nine water molecules 
(three with half-occupancy). The structures of these two cations differ significantly 
only in the orientation of the ribose ring. Selected bond lengths and angles are listed 
26 
Figure 5.3 Two independent cations (I and LI) of [TI  
in the asymmetic unit of the X-ray structure of complex 5, showing the atom 
numbering scheme and 30% probability thermal ellipsoids. H-bonding interactions of 
en NH with G 06 are indicated by dotted lines. 
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(A) cation 4 
	
(B) cation 5 
•111 
(C) cation 6 
Figure 5.4 Projections of the structures of cations. (A) [( 6-bipheny1)Ru(en)(9EtG-
N7)] 2 (4), (B) [( 6-biphenyl)Ru(en)(Guo-N7)] 2 (5), (C) [( 6-C 14H 14)Ru(en)(9EtG-
N7)] 2 (6), and (D) [( 6-C 14H 14)Ru(en)(9EtG-N7)] 2 (7) (30% probability thermal 
ellipsoids), showing arene (heavy line)-guanine base (light line) stacking in (B), (C) 
and (D) with the arene rings syn to G bases, whereas in (A), the arene ring is anti to 
the G base. 
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Table 5.6 Characterisation of the Ribose Ring Conformations (I and II) in 























Parameter 	Torsion angle (deg) 
%civ 	01'-C1'-N9-C8 




	 C4'-O 1 ,-C I'-C2' 
V1 
	 01'-Cl '-C2'-C3' 
Cl '-C2'-C3'-C4' 
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	 C2'-C3'-C4'-0 1' 
V4 
	 C3'-C4'-0 11' 
P 
12.505 	11.948 
aTorsion angles v0 - v4 and the pseudorotional parameters P and P, are defined 
according to the conventions of Ref. 43. bTheoretical:  C2'-endo (S type) P 
=144-190°, C3'-endo (N-type) P = 0 - 36°, C2'-exo/C3'-endo P = -36°0. 
in Tables 5.3A and 5.3C. The torsion angles vo-v4 and the pseudorotational 
parameters P and Ørn for ribose ring characterize the ring conformation 
43  and are 
listed in Table 5.6. In both these cations, the sugar puckers take the N- type (C2'-
exo/C3'-endo) conformation (P = -12.69° for cation I and -12.17° for cation II). 
The long axis of the biphenyl ligand is rotated away from the Ru-N7 vector 
by 13.2°. The propeller twist of biphenyl is 17.9 0 (Table 5.5A). When viewed normal 
to the plane of the purine base (Figure 5.4B), there is overlap of the pendent phenyl 
ring with the punne five-membered ring (distance 3.8 A, dihedral angle 23.8°, Table 
5.5A). The six-membered ring of the same purine stacks with a pendent phenyl ring 
of an adjacent cation (distance 4.2 A, dihedral angle 23.0°, Table 5.5A). Thus the 
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pendent phenyl ring is stacked alternately with the purine five-membered and six-
membered rings to form a columnar-type structure (as viewed down c, see Figure 
5.2B). 
Table 5.7 Possible Hydrogen Bonding Interactions' Involving Water' or Sugar 
Oxygens of [(TI 	[PF6]2.3.75(I-120) (5). 
interaction distance (A) interaction distance (A) 
022(1)'N35(11) 2.84(1) 026(11)016(II) 3.01(l) 
032(1)069(W) 3.08(2) 036(11) 059(W) 2.70(2) 
052(I)F19 3.08(2) 056(ll)016(II) 2.72(2) 
029(W) F15 2.87(2) 019(W) ... F3 2.85(1) 
029(W)N21(I) 2.86(l) 0I9(W)FI1 3.15(2) 
029(W) ... F20 3.22(2) 019(W) F16 3.09(2) 
039(W) F24 3.21(1) 049(W)F8 3.25(1) 
039(W) 089(W) 3.17(4) 049(W) F9 2.83(2) 
039(W)052(I) 2.89(1) 059(W) 099(W) 2.77(2) 
079(W)Fl0 3.14(2) 059(W) 022) 2.88(2) 
079(W) F12 3.26(2) 069(W)056(II) 2.88(2) 
079(W)"032(I) 2.55(2) 069(W) 049(W) 2.77(l) 
089(W)012(I) 2.81(3) 069(W) F7 3.20(l) 
099(W)"016(I1) 2.79(2) 069(W) "P8 3.28(1) 
099(W)"052(I) 2.76(2) 
aA generous maximum donor"  acceptor distance of 3.30 A is used as the cut-off. 
b Parentheses after atom labels designate oxygen from cation I or II or from 
water(W). C  Three water molecules (039, 079 and 089) are at half-occupancy. 
Selected H-bonds for 5 are listed in Table 5.413. For cations I and II, there is 
strong intramolecular H-bonding between an en NH and G 06, N14"061(I) 
(N18065(H)) distance of 2.799 A, and N14-H141"061(I) (N18-H181 ... 065(ll)) 
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angle of 159.00.  Intermolecular base-pairing between guanine bases of S is absent. 
Instead, N2H, N3 and N  H of Guo are H-bonded to PF 6 and H20. Most of the water 
molecules and PF6 ions are within H-bonding distances to the NH groups of en or 
0(5'), 0(3'), 0(2') and 0(1') atoms of the ribose ring, and thus form a complicated H-
bonding network (possible H-bonding interactions involving water molecules and 
ribose are listed in Table 5.7). 
5.3.3 X-ray Crystal Structures of THA and DHA Complexes 
[( 6-Ci4H i4)Ru(en)Cl][PF 6] (2) and [( 6-C1 4H i2)Ru(en)Cl][PF 6] (3). 
The structures of the cations of 2 and 3 are shown in Figure 5.5. The crystallographic 
data are listed in Table 5.2, and selected bond lengths and angles in Tables 5.313 and 
5.31). In the THA (C 14H14) complex 2, the tricyclic ring system is nearly flat. The 
outer ring (C) is slightly bent up away from the Cl ligand about the C7A-C1OA hinge 
by 7.5 ° . The long axis through the THA ligand is rotated away from the Ru-Cl 
(A) cation 2 	 (B) cation 3 
Figure 5.5 X-ray structures and atom numbering schemes for (A) [(71 6- 
C 14Hi4)Ru(en)Cl] in complex 2, and (B) [( 6-C 1 4H12)Ru(en)Clf in complex 3, at 
30% probability thermal ellipsoids. 
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vector by 45.1 ° (Table 5.5B). In the DHA (C141-112) complex 3, the tricyclic ring 
system deviates significantly from planarity. The outer ring (C) is bent down toward 
the Cl ligand about the C7A-C1OA hinge by 40.6 ° . The long axis of DHA is rotated 
away from the Ru-Cl vector by 64.1 ° (Table 5.5B). In both complexes, there are H-
bonding interactions between NH protons of en and F atoms of PF6 ions. No 
intermolecular arene ring stacking is observed for either complex. 
E(T,
6-C14H14)Ru(en)(9EtG-N7)][PF6]e(MeOH) 	(6) 	and 	[(6 
C14H12)Ru(en)(9EtG-N7)][PF 6]2.2(MeOH) (7). Both of these crystal structures 
show the presence of strong intramolecular it-it arene-nucleobase stacking. As can be 
seen in Figure 5.6, the outer ring (C) of THA/ DHA lies directly over the purine base 
(see also Figures 5.4C and 5.41)). The centroid-centroid separation between ring C 
and the purine ring is 3.45 A for 6 and 3.31 A for 7, with dihedral angles of 3.3° and 
3.1°, respectively (Table 5.513). Ring C is bent down towards the purine about the 
C7A-C 1 OA hinge by 27.8° in 6, and by 31.9° in 7. The long axes of THA (6) and 
DHA (7) are rotated away from the Ru-N7 vectors by 25.6° and 20.9°, respectively. 
There is intramolecular H-bonding between en NH and G 06 (NIB °"06 2.812 A and 
N1B-H1B1 ... 06 163.3° for 6, NIB ... O6 2.840 A and NIB-H1NR"06 163.1° for 7, 
Tables 5.4C and 5.41)). Additionally for 7, the second H atom (H1NA) on the same 
en NIB is H-bonded to 06 of a neighbouring G base (Figure 5.8) with NIB---06 
distance of 3.031 A. For both structures, dimers are formed via a pair of H-bonds 
between G N2H and G N3 (N2N3 3.105 A for 6, 3.085 A for 7). For 6, the second 
G N21-1 proton (1-12Y) together with G NiH proton (H1X) form two H-bonds to 0 of 
MeOH (N2 ... 01M 3.085 A, N1 ... 01M 2.829 A, Figure 5.7). No intermolecular 
arene-base ring stacking is observed for complexes 6 or 7. 
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(A) cation 6 (B) cation 7 
Figure 5.6 X-ray structures and atom numbering schemes for (A) [(,q 6_  
C 14H i4)Ru(en)(9EtG-N7)] 2 in complex 6, and (B) [(i 6-C i4 -I i 2)Ru(en)(9EtG-N7)] 2 
in complex 7, at 30% probability thermal ellipsoids. The space-filling models 
clearly show the intramolecular arene-guanine base stacking and H-bonding 
interactions between en NH and G 06. Color code: C of C 14H 14 and C 14H 12 yellow, 
C of 9EtG and en gray, Ru purple, 0 red, N blue, and H white. 
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Figure 5.7 The H-bond network for a dimer of ftt 6-C i4H i4)Ru(en)(9EtGN7)]-
[PF6 ] 2 (MeOH) (6) in the X-ray crystal structure. The atom labelling scheme is 
shown for one cation. PF 6 ions are omitted f6i clarity. 
Figure 5.8 The helical chain-type structure of [(i 6-C4Hi2)Ru(en)(9EtG-
N7)][PF6] 2 2(MeOH) (7) (along the c axis ), showing guanine-guanine base pairing 
via N2-H ... N3, intramolecular H-bonding between en NH and G 06, intermolecular 
H-bonding between en NH and G 06, and the intramolecular outer arene ring-
guanine base stacking. PF 6 ions and MeOH molecules are omitted for clarity. 
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5.3.4 NMR Structures of Biphenyl Complexes in Solution 
[(11 6-biphenyl)Ru(en)Cl][PF6] (1) in DMF-d 5. The 'H NMR spectrum of 
complex 1 at 298 K was assigned using 2D COSY (Figure 5.9) and NOESY 'H 
NMR spectroscopy (Figure 5.10). The aromatic resonances are divided into two 
groups: the high-field resonances (6 6.28, 6.08 and 5.98) corresponding to the 
protons 1-1(o), H(p) and 1-1(m) of the coordinated phenyl ring (A), and the low-field 
resonances (6 7.86 and 7.52) corresponding to the protons H(o), H(m') and H(p') of 
the pendent phenyl ring (B) (H(m') and H(p') overlap at 6 7.52). The strong NOE 
H(m') 











7.7 7.0 	6.5 	6.0 	4.4 	2.6 
Figure 5.9 2D COSY 'H NMR spectrum of [(1 6-biphenyl)Ru(en)Cl][PF 6] (1) in 
DMF-d6 at 298 K showing assignment of arene and en resonances. For structure, see 
Figure 5.10. 
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C H H 2 
NH(dl,d2) 
7.7 	7.0 	6.5 	6.0 	4.4 	2.6 
o 	m 
	






Figure 5.10 2D NOESY 'H NMR spectrum of [(ij 	(1) in 
DMF-d6 at 298 K. Bottom: structure with inter-iigand NOEs indicated by dotted 
lines. 
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between 11(o') and 11(o) is in accordance with the distance of 2.2 A determined for 
the X-ray crystal structure of 1. 7  Only one resonance is observed for the ortho 
protons and one for the meta protons. 
The four en NH protons give rise to two broad resonances at 6 6.72 and 4.26. 
These are assigned to the two types of protons on the same N: NH(ul, u2) (6 6.72 
which point up towards ring A, and NH(dl, d2) (6 4,26) which point down away 
from ring A. 44 NH(ul, u2) show NOEs to 11(o), H(m), and 11(p) of ring A with 
medium intensity compared with the NOE of NH(u)-NH(d), whilst the NOEs 
between NH(d 1, d2) and the ring A protons are very weak. These NOE intensities (cc 
1/r6) are in accordance with the crystal structure of i in which the biphenyl ligand is 
in the syn orientation with respect to the Cl ligand (a = 26.8°, see Table 5.5A and 
Figure 5.24). The average distances of NH(ul, u2) protons to H(o), H(m) and 1-1(p) 
are 3.65 A, 3.54 A and 2.71 A, respectively, whilst the average distances of NH(dl, 
d2) protons to 11(o), 11(m) and H(p) are longer, 3.84 A, 3.71 A and 4.41 A, 
respectively. 
[(i1 6-bi phenyt)Ru(en)(9EtG-N7)][PF6]2'(MeOH) (4) in Acetone-d 6 
Crystalline complex 4 is poorly soluble in water and therefore ['H, 'H] 2D NMR 
spectra were acquired for acetone-d 6 solutions. 'H NMR signal assignments were 
obtained from 2D DQFCOSY (Figure 5.11) and NOESY (Figure 5.12) 'H NMR 
data. Compared to the parent chioro-complex 1 in DMF-d 6, the signal for the NH(dl, 
d2) protons of 4 was surprisingly broad and low-field shifted to 6 5.34 whereas the 
signal for NH(ul, u2) protons at 6 6.49 was relatively sharp. These assignments for 
en-NH protons were confirmed by the 2D ['H, ' 5N] HSQC NMR spectrum of 15N4 
in acetone-d6 solution. Correlations between NH(ul, u2) and en CH 2CH2 were 
observed in the DQFCOSY NMR spectrum (Figure 5.11), but cross-peaks for 
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NH(dl, d2) correlations with en CH2CH 2 were too broad to detect. The NOE cross-
peak between NH(dl, d2) and NH(ul, u2) was broad, but observable. NOEs were 
observed between the ethyl protons of 9EtG and H(m'), H(o') and H(pt) of ring B 
(Figure 5. 12B). These, together with NOEs between H8 and H(o')/H(o), and between 
Et-C H 3 
H(p') 	H(o) 	Et-CH2 	
en- \H(m)
I










7.0 	5.0 	3.0 
6(1 H) 
Figure 5.11 2D DQFCOSY 'H NMR spectrum of [( 6-biphenyl)Ru(en)(9EtG-
N7)] 2 (4) in acetone-d6 at 298 K, showing assignment of arene and en resonances. 
The resonance for NI-1(d) is very broad but can be detected in the 2D ['H,' 5N] HSQC 











H(o) H(o 	1(m) 	
H(p) 	NH(dl,d2) 






CHI 	 2.5 
0 s 
0 








IN 	 N 
NNH 
H 2 N 
Figure 5.12 NOB data for [( 6-bipheny1)Ru(en)(9EtG-N7)] 2 (4). (A) and (B) 
Regions of the 2D NOESY 'H NMR spectrum in acetone-d6 at 298 K. (C) Structure 
with NOEs indicated by dotted lines. The en NH resonances were assigned via the 
['H,' 5N] HSQC spectrum of 15N-4 in acetone-d5 . 
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NH(u 1, u2) and 1-1(p) (Figure 5.12A), indicate that a syn conformation predominates 
for the pendent phenyl ring (B) with respect to the G base. Also the presence of 
NOEs between 118 and NH(dl, d2) (broad) and the absence of NOB cross-peaks 
between H8 and NH(ul, u2) suggests that H8 of 9EtG points towards N}1(dl, d2). 
The cross-peaks NH(dl, d2) in the 2D ['H, ' 5N] HSQC NMR spectrum of 15N-4 in 
DMSO-d6 solution sharpened as the temperature was raised from 295 to 310 K, 
Table 5.10. 
[( 6-biphenyI)Ru(en)(Guo-N7)] 2 (5) in Aqueous Solution. 2D 
NOESY and DQFCOSY 'H NMR spectra of complex 5 in 10% D20 / 90% H 20 at 
Table 5.8 Selected Proton Chemical Shifts (ppm) for Cations [(r 6- 
biphenyl)Ru(en)C1] +  (1), ft11 6  -biphenyl)Ru(en)(H 20)] 2+  (la) and [(116 - 
biphenyl)Ru(en)(9EtG-N7)] 2 (4) and [( 6-biphenyI)Ru(en)(Guo-N7)] 2 (5) and [(i-6 -
biphenyl)Ru (en)(5'-GMP-N7)] (8). 
Corn- - ('H) 
plex 1-1(o) H(m) H(p) H(o) H(m) H(p) NH (u) NH(d) H8 
la 7.86 7.52 7.52 6.28 5.98 6.09 6.72 4.26 - 
1b 779 7.59 7.59 6.17 5.98 5.90 6.02 3.98 - 
l ab 7.82 7.63 7.63 6.21 6.09 5.93 6.08 4.14 
4C 
7.70 7.39 7.48 6.45 6.54 6.06 5.34 
e 6.49 8.38 
(AS) (-0.12) (-0.24) (-0.15) (0.24) (0.45) (0.13) (broad) 
4b 7.46 7.30 7.46 6.30 6.40 5.72 
6.53 broad 1 8.10 (AS)c (-0.36) (-0.33) (-0.17) (0.09) (0.31) (-0.21) 
5b 
7.34 7.48 6.30 6.41 5.74 6.52 (u 1) 
broad 1 8.37 
(AS) (-0.33) (-0.29) (-0.15) (0.09) (0.32) (-0.19) 6.56 (u2) 
8d 7.48 7.31 7.45 6.36 6.46 5.68 6.32 (u 1) 5.26 (dl) 
8.71 (AS)c (-0.34) (-0.32) (-0.18) (0.15) (0.37) (-0.25) 6.36 (u2) 5.11 (d2) 
a DMF-d6 , 298 K; b  10% D2 0 / 90% H20, 298 K; C acetone-d6 , 298 K; d  10% D20 / 
90% 1120, 310 K, C  M = 	(G)-(1a), change in shift upon species la binding to G 
base. "too broad to observe. 
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Table 5.9 'H NMR Chemical Shifts of the Non-exchangeable Protons of Guanosine, 
[(116 -biphenyl)Ru(en)(Guo-N7)] [PF6] 2 (5), 5 GMP and [(ri 6-biphenyl)Ru(en)(5 




Complex 5 5IGMpb Complex 8 
H8 7.97 8.36 8.20 8.71 
5.88 5.77 5.92 5.84 
Hi' 
(6.05)c (449)C (6.10) (5.78)' 
 4.70 4.38 4.70 4.64 
 4.40 4.24 4.50 4.41 
 4.20 4.21 4.30 4.30 
H5'/H5" 3.89/3.82 3.96/3.84 4.0/3.96 4.1/4.0 
aB ased on the excess guanosine in reaction mixture for 5 at 298 K. bBased  on the 
excess 5'-GMP in reaction mixture for 8 at 310 K. C  3J(H1'/H2') in Hz. 
298 K were used to assign the proton resonances (Tables 5.8 and 5.9). In contrast to 
the parent chloro-complex 1 in DMF-d 6, the en NTI(dl, d2) signals for 5 were too 
broad to detect at ambient temperature, but the NH(u) signals were reasonably sharp 
(as for 4). The 2D ['H, ' 5N] HSQC NMR spectrum for 15N-5 at 298 K contained two 
cross-peaks for NH(ul, u2) at 8 6.5 1/-29.38 and 8 6.55/-28.87, but no cross-peaks for 
NH(dl, d2) (see Table 5.10). When the temperature was raised to 328 K, broad peaks 
for NH(d 1, d2) appeared. At this temperature, the four cross-peaks at ö 6.451-29.1, 
4.98/-29.1, 6.48/-28.62, and 4.65/-28.62, can be assigned to NH(ul), NH(dl), 
NI-I(u2) and NH(d2), respectively (Figure 5.13A and Table 5.10). In contrast to 
complexes 1 and 4, the two ' 5N atoms of en in 5 are magnetically non-equivalent, as 
expected in view of the chirality of the sugar. But as for 1 and 4, only one resonance 
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(A) 15 N-5 
	
(B)' 5N-8 
6.5 	5.5 	4.5 	 6.5 	5.5 
6(1 H) 8 ( 1 H) 
Figure 5.13 2D ['H, ' 5N] HSQC NMR spectra of (A) {( 6-bipheny1)Ru( 15N-
en)(Guo-N7)] (' 5N-5) and (B) [(r] 6 bipheny1)Ru( 15N en)(5!GMPN7)] (' 5N-8) in 
10% D20 I 90% H20 at various temperatures (T). For 15N-5, the en NH(dl, d2) 
resonances are too broad to observe at T < 328 K. For 15N-8, two sets of en NH 
cross-peaks are present at 274 K, attributable to two isomers. 
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Table 5.10 'H and ' 5N NMR data for 	 (' 5N-4), 
[(,q6 -Bip)Ru( 1 5N2-en)(Gua-N7)] 2 	('5N-5), 	[(116  -THA)Ru( 15N2-en)(9EtG-A17)] 2 
(' 5N-6) and [(in 6-THA)Ru(' 5N2-en)(5'-GMP-N7)J 2 (' 5N-9) at Various Temperatures. 
Complex 
T/K 
en 	('Hu), 	('Hd) (' 5N) 
________________  
ö('Hul), 6( 1 Hdl) (6(' 5N)) 6('Hu2), 	Hd2) (6(' 5N)) (NMR solvent) 
is N-4 
(DMSO-d6) 
328 6.87, 5.12a(26.9O) 6.87, 5.12a  (-26.90) 
310 6.90,5 .08a  (-26.85) 6.90, 5.08' (-26.85) 
295 6.94, broad   (-26.88) 6.94, broad   (-26.88) 
' 5N-5 
(DMSO-d6) 
328 6.84,5.15 a  (-26.75) 6.87,5.04 a  (-2650) 
310 6.89, 5.14 a  (-26.78) 6.92, 5.02a  (2650) 




336 6.42,4 .90a  (-28.95) 6.44, 4.69' (-28.69) 
328 6.45, 4.98' (-29.10) 6.48, 4.65' (-28.62) 
298 6.5 1, broad b(29.38) 6.55, broad b(28 . 87) 
273 6.65, broad   (-29.60) 6.68, broad   (-29.50) 




6.50, 3.85 a (-29.35) 
6.43, 6.0a  (-29.74) 
6.50, 3.85' (-29.35) 
6.43, 6.0a 	(-29.74) 
H20) 
274 
6.55, 3.89 (29.40) 6.55, 3.89 (29.40) 
6.45, 6.05 (-29.92) 6.45, 6.05 (-29.92) 





6.19, broad (-27.92) 
6.27, broadb  (-29.28) 
6.25, broadb  (-27.89) 
6.27, broad b  (-29.28) 
278 
6.19, 4.95 (-28.90) 
6.41, 5.90 (-30.32) 
6.25, 4.65 (-28.80) 
6.44, 5.84 (-30.10) 
1120) 
a signal is broad and weak b  too broad to observe; C  For 15N-6 and ' 5N-9 at low 
temperature there are two sets of NH cross-peaks attributable to the presence of two 
isomers, probably due to slow rotation of THA rings about arene-Ru t-bonds. 
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to fast rotation of the biphenyl ligand about the arene-Ru it-bond together with fast 
propeller twisting on the NMR time scale. A series of 2D ['H, ' 5N] HSQC NMR 
spectra of ' 5N-5 in DMSO-d6 were also acquired at various temperatures (Table 
5.10). The NH(dI, d2) resonances was also too broad to detect at 298 K in this 
solvent but appeared when the temperature was raised to 3 10 K. The similarity of the 
results for DMSO-d 6 and aqueous solutions suggests that overlap with the water 
resonance is not the reason why the NH(dl, d2) resonances of 5 are unobservable in 
aqueous solution at low temperature. 
In the 2D NOESY 'H NMR spectrum of 5 (Figure 5.14), NOEs were 
observed for H8-FI(o'), H8-11(o), NH(ul, u2)-H(m) and NH(ul, u2)-H(p), indicating 
that the syn conformation predominates for ring B with respect to the G base. A 
similar orientation for ring B occurs in the crystal structure, and the observed NOEs 
are in agreement with the average crystallographic distances of NH(ul, u2)-H(m) 
2.70 A, NH(ul, u2)-H(p) 3.37 A, NH(ul, u2)-H(o) 4.73 A, H8-H(o) 3.35 A, H8-
H(o') 3.82 A, H8-H(m) 4.68 A, H8-H(m') 4.81 A, H8-H(p) 5.85 A and H8-H(p') 5.40 
A. The NOE cross-peaks for H8-H1', H8-H2', H8-H3' and H8-H4' have intensity 
ratios of Ca. 5 1: 1: 1, respectively (Figure 5.15A). The strong NOE for H8-Hl' 
observed in this spectrum, suggests that a syn orientation predominates for the G 
base with respect to the ribose ring. This conformational feature is different from the 
solid state where an anti orientation was found for 5. The value of 3J(H1t/II2) = 4.49 
Hz is lower than that for free Guo (6.05 Hz), suggesting that the sugar conformation 
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H(o) 
jNH H 1 
RuuhIJ;...N/ 
\'u1 N 
N t Hd2/ 
9 O 
	
6 1 	/ 
NNH Hdl 
H2 N 
Figure 5.14 NOE data for {(1 6-bipheny1)Ru(en)(Guo-N7)] 2 (5). Top: 2D NOESY 'I-I 
NMR spectrum for 5 in 10% D 20 I 90% H20 at 298 K. Bottom: structure with 
NOEs indicated by dotted lines. 
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4.5 	 H2' ...9 
H 20 
5(1H) 	 - 
NHd1 	0 
NHd2c 	0 
5.5 	 -5.5 
I 
8.8 8.6 
o( 1 H) 
 
8.0 	8.5 	9.0 
(1H) 
Figure 5.15 2D 'H NOESY NMR spectra of (A) [(r1 6-biphenyl)Ru(en)(Guo -N7)] 2 
(5), and (B) [(i 6-biphenyl)Ru(en)( 5 '-GMP-N7)] (8), in 10% D 20 / 90% H 20, 
showing the guanine H8-sugar ring coimectivities. In (A) the intensity ratio of NOE 
cross-peaks for H8-HP : H8-H2' : H8-H3' : H8-H4' is Ca. 5 : 1: 1: 1. The stronger 
NOE for H8-Hl' suggests that a syn conformation predominates. 3J(H1YH2')= 4.49 
Hz (6.05 Hz for free Guo). In (B) the intensity ratio of NUE cross-peaks of H8-H1' 
H8-H2' : 118-H3' is ca. 1: 10: 1.5. There is no H8- H4' NOE cross-peak. The strong 
NOE between H8 and H2' indicates C2'-endo (S) and anti conformations for the 
sugar and base, which fits well with their conformations in canonical B-DNA. 
3J(H1'/I-12')= 5.78 Hz (6.10 Hz for free 5'-GMP). 
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[(i1 6-biphenyl)Ru(en)(5' -GMP-N7)] (8) in Aqueous Solution. 2D 
NOESY and DQFCOSY 1 H NMR spectra of 8 in 10% D 20 / 90% H20 at 310 K 
were used to assign the protons NMR resonances (Tables 5.8 and 5.9). The four en 
NH resonances at 6 6.36, 5.27, 6.39 and 5.09 can be assigned to NT-i(ul), NH(dl), 
NH(u2) and NH(d2), respectively. All are of reasonable intensity at this temperature. 
Their assignments were confirmed by reference to the 2D ['Fl, ' 5N] HSQC 'H NMR 
spectrum of ' 5N-8 (Figure 5.13B). The inequivalence of en NH 2 can be accounted for 
by the chirality of the sugar ring of 5'-GMP. Only one resonance is observed for the 
ortho protons and one for the meta protons of biphenyl, as for 5. In the 2D NOESY 
NMR spectrum (Figure 5.16), the NOE cross-peaks for H8-H(o'), H8-H(o) and 
NH(ul, u2)-H(p) indicate that the syn conformation predominates for the biphenyl 
ring with respect to the G base. There are NOEs between H8 and NH(dl, d2), but not 
between H8 and NH(ul, u2), suggesting that 118 of G points toward NH(dI, d2). The 
ratio of the intensities of the NOE cross-peaks H8-H1', H8-I-12' and H8-H3' is ca. I 
10 : 1.5, respectively (Figure 5.15B). There is no H8-H4' NOE cross-peak. The 
strong NOE for 148-142', and the absence of an NOE between H8 and H4', suggest a 
C2'-endo (S) anti conformation for the sugar ring. The value of 3J (H1'/H2') = 5.78 
Hz for 8 is similar to that for the free 5'-GMP (6.10 Hz). These data suggest that the 
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H(p) 	H(o) 
H8 	H(o')d 	NHO 
H(m)NHuI H(P) 
8.5 	7.5 	6.5 	5.5 
( 1 H) 
Figure 5.16 2D NOESY 'H NMR spectrum of [( 6-bipheny1)Ru(en)(5'-GMP-N7)] 
(8) in 10% D 20 I 90% 1-120 at 310 K, showing NOEs for 118-H(o'), H8-H(o), and 
H(p)-NH(ul,u2). The labelling scheme for 8 is similar to that for 5 in Figure 5.14. 
5.3.5 NMR Structures of THA and DHA Complexes in Solution 
[(1 6-Cj4H1 4)Ru(en)Cl] (2) and [( 6-C14Hi2)Ru(en)Cl] (3) in DMSO-
d6. The 2D NOESY 'H NMR spectrum of 2 in DMSO-d 6 provided a basis for the 
assignment of 'H NMR resonances of 2 (Figure 5.17). There are strong NOEs 
between NH(ul, u2) and NH(dl, d2), between NH(ul, u2) and 11(1, 4)1 11(2, 3), 
between 11(1, 4) and 11(8, 9), and between 1-1(8, 9) and 11(5, 8). No NOEs were 
observed between NH(dl, d2) and aromatic protons. For 3, the resonances were 
assignable directly from the 1D 'H NMR spectrum (Figure 5.20). In each case, one 
set of sharp signals was observed for the THAIDHA ring. 
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H(6, 7) 	 1 H(5, 8) 
H(2, 3) 	 H(9, 10) 
NH(ul,u2) I I H(1, 4) NH(dl,d2) 	CH 2CH 2 
3 
( 1 H) 
6.0 	5.0 	4.0 	3.0 	2.0 
I OCI aBI A) 





H' I Y 
Figure 5.17 2D NOESY 'H NMR spectrum of [( 6-C i4H 14)Ru(en)CI][PF 6} (2) in 
DMSO-d6 at 298 K, showing assignments of the arene and en resonances. NOEs of 
NH(ul, u2)-NH(d1, d2), NH(ul, u2)-H(1, 4), NH(ul, u2)-H(2, 3), H(1, 4)4-1(8, 9), 
and H(8, 9)-H(5, 6) are indicated by dotted lines. 
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[(116-C14H14) Ru(en)(9EtG-N7)]2 
	
(6 	and 	15N-6) 	and 	[(i 6 - 
C14H14)Ru(en)(5'-GMP-N7)] (9 and 15N-9) in Aqueous Solution. In contrast 
to the 1 H NMR resonances for the biphenyl complexes 4, 5 and 8, the resonances of 
the tetrahydroanthracene rings of complexes 6 and 9 in the aqueous solution were 
very broad, as were their G base and en ligand 'H NMR resonances (Figures 5.18 
and 5.19). When solutions of 6 and 9 were heated to 339 K and 318 K, respectively, 
the peaks became sharper, but the resolution was not sufficient for NOESY studies. 
On cooling to 278 K, more than two sets of signals were detected in both cases, but 
chemical exchange processes complicated the interpretation of the NOESY data. 2D 
['H, ' 5N] HSQC NMR spectra of complexes 15N-6 and ' 5N-9 in aqueous solutions 
were acquired to confirm the assignment of the en NH signals, and the low 
temperature spectra suggested the existence of two isomers (Table 5.10). 
[(1 6-C14Hi2)Ru(en)(9EtG-N7))] 2 (7) and [(r1 6-C14H12)Ru(en)(5'-GMP-
N7)] (10) in Aqueous Solution. The 'H NMR resonances of the 
dihydroanthracene complexes 7 and 10 were very broad at ambient temperature. For 
complex 10, two H8 signals were observed at 298 K (Figures 5.20 and 5.21). When 
the solutions of complexes 7 and 10 were heated to 339 K and 318 K, respectively, 
the signals became sharper but the resolution was not sufficient for 2D NOESY 
studies. At 278 K, more than two sets of signals were detected in both cases, but 
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8.3 	6.0 	5.0 	4.0 	3.0 	2.0 
Figure 5.18 'H NMR spectra of (A) [( 6-C 14H, 4)Ru(en)Cl][PF6] (2) in DMSO-d6 at 
298 K, (B) [(116-C14H,4)Ru(en)(9EtG-N7)]  (6) in 10% D20 / 90% H20 at various 
temperatures showing that the resonances of the tetrahydroanthracene rings are broad 
at 298 K but separate into two sets at low temperature (278 K). 
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Figure 5.19 'H NMR spectra of (A) ftri6-C14H,4)Ru(en)C1][PF6]  (2) in DMSO-d6 at 
298 K, and (B) [(ij  (9) in 10% D 20 I 90% T'20  at 
various temperatures showing that the resonances of the tetrahydroanthracene rings 
are broad at 298 K but separate into two sets at low temperature (278 K). 
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(A) Complex 3 	ring c 	ring A 	H9,10 
III NHd 	CH 2 CH2 298K 	 NHu 
A 	10/ 




8.0 	7.0 	6.0 	5.0 	4.0 	3.0 	2.0 
Figure 5.20 'H NMR spectra of (A) ft11 6-C 1 4H,2)Ru(en)Cl][PF6] (3) in DMSO-d6 at 
298 K, and (B) {( 6-C, 4H i2)Ru(en)(9EtG-N7)] (7) in 10% D201 90% H20 at various 
temperatures showing that the resonances of the dihydroanthracene rings are broad at 
298 K but separate into two sets at low temperature (278 K). 
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Complex 3 	ring C 	ring A 	H9,10 
298 K 
LI 
	NHu 	 NHd 	CH2CH2 
Figure 5.21 'H NMR spectra of (A) [(71 6-C 14H, 2)Ru(en)CI][PF 6] (3) in DMSO-d6 at 
298 K, and (B) [( 6-C, 4H,2)Ru(en)(5'-GMP-N7)] (10) in 10% D20 I 90% H20 at 
various temperatures showing that the resonances of the dihydroanthracene rings are 
broad at 298 K but separate into two sets at low temperature (278 K). 
5.3.6 pH Dependence of NH Resonances of [(71 6-biphenyl)Ru(en)(5'. 
GMP-N7)] (8). 
We used ' 5N-edited 'H{' 5N} NMR and pH titration methods to investigate H-
bonding interactions between en NH and the 5'-phosphate or 06 groups of 5'-GMP in 
' 5N-8. The 2D ['H, ' 5N] HSQC NMR spectrum of 15N-8 at 
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Figure 5.22 (A) 2D ['H, ' 5N] HSQC NMR spectrum of [( 6-biphenyI)Ru( 15N2-
en)(5'-GMP-N7)] (' 5N-8) at pH 7.1 (Ru 5 mM, 10% D20 / 90% 1120, 298 K). (B) 
Structure with proposed H-bonds indicated by dotted lines. (C) 15N-edited 1 H{ 15N} 
spectra at various pH values. (D) Plot of the chemical shifts of en ' 5N112 'H NMR 
resonances of 15N-8 versus pH. The large variation in shift of the NH(d 1, d2) 
protons can be accounted for by H-bonding interactions with the 5'-phosphate and G 
06 groups, promoted by deprotonation of -OP0 3H and NiH, respectively. The 
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Figure 5.23 pH dependences of the 5'-GMP H8 'H (A) and phosphate 31 P (B) NMR 
resonances for [(Tj  8 (V) and free 5'-GMP (I) at 
298 K, showing the lack of protonation of N7 for 8 at low pH and deprotonation of 
N  and phosphate at higher pH. The corresponding pK a (1) values were determined 
to be 5.96 ('H), 5.93 (31P) for 8 and 6.30 ('H), 6.24 (31 P) for free 5'-GMP 
(protonation of the phosphate group), and second pKa (2) 8.45 ('H) for 8 and 9.85 
( 1 1-1) for free 5'-GMP (deprotonation ofNl of G). 
298 K showed four cross-peaks at 6 6.361-29.04, 5.27/-29.04, 6.39/-29.01, and 5.09/-
29.01, assignable to NH(ul), NH(dl), NH(u2) and NI-I(d2) (Figure 5.22A). 2D ['H, 
15N] HSQC NMR spectra of ' 5N-8 were recorded over the pH range 2.8-10.9 and 
enabled the two NH(u) resonances to be distinguished on the basis of small 
differences in their 15N chemical shifts. A plot of chemical shift of each en NH signal 
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versus pH is shown in Figure 5.22D. The two NH(ul, u2) protons have the same pH 
dependence and shift slightly to high-field as the pH is increased; the two NH(dl, d2) 
protons also show similar pH behaviours and shift greatly to low-field over the range 
from pH 5.98 to 7.53. However, at pH < 5.98 or pH > 7.53 these two NH(d) peaks 
became too broad to observe. 
'H NMR and 31 P NMR pH titrations at 298 K were also carried out for a 
solution of unlabelled [(ij  (8), containing a 10% 
excess of 5-GMP. At pH 7. 1, 'H NMR peaks at 5 8.71 and 5 8.20 were observed for 
H8 protons of 8 and free 5-GMP, respectively; 31 P NMR peaks at 5 4.61 and 5 3.96 
were observed for the 5-phosphate of 8 and free 5-GMP, respectively. Plots of S 
('H) and S (3 'P) against pH are shown in Figure 5.23. The curves were fitted to the 
Henderson-Hasselbalch equation, giving pK a  values of 5.96 for 8 and 6.30 for free 5'-
GMP ('H curves). These values are attributed to deprotonation of the 5-phosphate 
groups. The pKa values determined from the 31 P curves (Figure 5.23B, 5.93 and 6.24) 
are in good agreement with the values from 'H curves. Also pKa values of 8.45 for 
complex 8 and 9.85 for free 5'-GMP were determined from the 'H curves. These 
values are attributed to deprotonation of G NiH. 
5.4 Discussion 
5.4.1 General 
There are many potential applications of organometallic chemistry in 
medicine. Examples include the anticancer activity of cyclopentadienyl complexes 
such as titanocence dichloride, 45  which has been on clinical trial, and receptor-
targetted anti-oestrogen organometallic complexes. 41,4'  The work in this chapter is 
concerned with organometallic Ru(II) complexes of the type [(TI 6_ 
arene)Ru(II)(en)Cl][PF6] which exhibit promising anticancer activity. Initial in vitro 
and in vivo data suggest that the most active complexes contain the most 
hydrophobic r 6- arene ligands, examples being complexes 2 and 3 which contain the 
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tricyclic 11 6-anthracene derivatives THA and DHA. 68 In general, ( 6—arene)Ru(II) 
bonds are relatively stable in water '48  and are more resistant to hydrolysis than the Cp 
ligands in titanocene dichloride, [Cp2TiC] 2].49 The target for Ru(II) arene complexes 
may be DNA and we found that f(TI  exhibits a high specificity 
for binding to guanine (G) . 7 The aim of the present work is to elucidate the nature of 
the interactions which give rise to such specificity. Therefore the structures and 
dynamics of adducts of ((rl  with G derivatives have been 
studied both in the solid state and in solution. 
Very few X-ray structures of Ru-nucleobase adducts have been reported 
previously. 50 The structure for [( 6-biphenyl)Ru(11)(en)(Guo-N7)J[PF 6 ] 2 .3.751120 
determined in the present work appears to be the first reported X-ray structure for a 
ruthenium nucleoside complex. Also no X-ray structures of rl 6-coordinated DNA 
complexes appear to have been reported previously. Hydrophobic interactions of the 
arene ligand and 11-bonds involving en NH protons appear to exert a strong influence 
on the conformations of these guanine adducts. 
5.4.2 Arene-guanine Base Stacking 
Strong arene-nucleobase stacking is present in the crystal structures of [(TI 6_ 
C 1 4H i 4)Ru(en)(9EtG-N7)] 2 (6) and [(TI  (7). Figures 
5.6A and 5.613 show that it-it stacking between the outer ring (C) of THA or DNA 
and the guanine base is almost ideal 51 : ring C is parallel to and filly overlaps the 
purine ring (see also Figures 5.4C and 5.4D). The THA ligand in complex 6 has a 
diene ring C, but it adopts a very similar conformation to the DHA ligand in complex 
7 which contains an aromatic ring C. The interplanar (centroid-centroid) distance is 
3.45 A for complex 6 and 3.31 A for 7, with dihedral angles of 3.3° and 3.1°, 
respectively. The it-stacking of aromatic rings and unsaturated groups, or even 
between unsaturated groups themselves, has been widely investigated in studies of 
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crystal engineering, and energy transfer. Diene stacking has been employed in the 
design and control of polymer-chain structures. 52  For the biphenyl adduct 4, [(-
biphenyl)Ru(en)(9EtG-N7)] [PF6]2MeOH, intramolecular arene-nucleobase stacking 
is precluded by the anti orientation of 9EtG with respect to biphenyl. Here, there is 
intermolecular stacking between the pendent phenyl ring and the purine six-
membered ring (Figures 5.IB and 5.2A) with a centroid-centroid distance of 4.0 A 
and dihedral angle of 4.5°. Such intermolecular arene-nucleobase stacking may 
stabilize the cyclic tetramer structure in the unit cell (Figure 5.1B). For the adduct 5, 
[( 6-biphenyl)Ru(en)(Guo-N7)][PF 2 3.75(H20), there are two types of stacking: 
intramolecular stacking of the pendent phenyl ring with the purine five-membered 
ring (3.8 A, 23.8°), and intermolecular stacking of the purine six-membered ring with 
an adjacent pendent phenyl ring (4.2 A, 23.0°). These occur alternately giving a 
columnar-type structure (Figure 5.213). For aromatic systems, it-it interactions are 
usually accompanied by interplanar separations of 3.3-3.8 A. 51 However, longer 
distances for it-it stacking have been also reported (up to 4.7 A).52a52c53 The arene-
nucleobase stacking in the biphenyl adducts 4 and 5 are accompanied by longer 
centroid-centroid distances (average 4.0 A), compared with that of THA and DHA 
adducts 6 and 7 (average 3.4 A). This can be accounted for by the higher degree of 
freedom53C for movement of the biphenyl ring (free propeller twisting of phenyl ring 
in Bip, but relatively rigid tricyclic frames of THA and DHA). 
The extensive arene-nucleobase stacking but not arene-arene or base-base 
stacking in [(i6-arene)Ru(en)(G-N7)] 2 adducts represents a new structural feature 
for adducts of metal anticancer complexes with nucleobases. Intra- or inter-molecular 
base-base stacking has been reported in the X-ray structures of some Pt complexes of 
nucleobases, nucleosides and nucleotides. For example, cis-[(th)Pt(Me-5'-GMP) 2 }, 
cis-[(tn)Pt(5'-IMP)2] (tn = trimethylenediamine) and cis-[(NH3)2Pt(5'-IMP) 2] all have 
intracomplex base-base stacking with dihedral angles of 39.6°, 38.2° and 40.7 0 , 
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respectively. 54 Such features are relevant to the intrastrand cross-linking by cis-
platinium complexes on DNA. 55 In the adducts of cis-
[Pt(NFI3 )(Guo)2]Cl i s(C10405.7F120 and cis-[Pt(en)(Guo)2]Cl,510 5 .2H20, one 
guanine base is in nearly parallel contact with a guanine base on a neighboring cation 
at distances of 3.34 A and 3.31 A, respectively. 56 Stacking of acridine orange (AO) 
rings at a distance of 3.5 A was found in the complex 
[Pt {AO(CH 2)6(en)}(ox)](NO 3)7F120 and the phi ligands of [Rh(NH3)4(phi)] 3 (phi = 
9, 10-phenanthrenequinone diimine) cations stack in dimer pairs at a distance of 3.4 
A. This kind of self-stacking of aromatic rings has been interpreted as an indication 
of an ability to intercalate. 12,57  The arene-base stacking in [( 6-arene)Ru(en)(G-
N7)] 2 adducts indicates potential for intercalation or hydrophobic interactions of the 
arene ring with duplex DNA. Hydrophobic interactions between the arene ligand and 
purine base could provide a driving force for DNA binding. A recent analysis of free 
energy contributions to DNA binding, suggests that intercalation of ethidium, 
propidium, daunorubicin and adriamycin is driven by hydrophobic effects and van 
der Waals contacts within the intercalation site, minimising the solvent-accessible 
surfaces of the drug.' ° Recognition of specific sequences by DNA minor groove 
binding proteins is often dominated by hydrophobic protein-DNA interactions. 58 The 
X-ray crystal structure of HMG1 domain A bound to a cisplatin-modified 16-base-
pair deoxyoligonucleotide shows that the cisplatin intrastand crosslink destacks the 
G8-G9 purine rings and leads to exposure of their hydrophobic surfaces in the minor 
groove. Phe37 intercalates at the site of the intrastand cross-link cis-[Pt(NH3)2-
{d(GpG)-N7(G8),-N7(G9)}], stacking onto the U9 base at a distance of 3.5 A. 59 
Favorable intercalation directs protein binding and orientation .21 
5.4.3 Arene Conformation 
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The conformations of the parent chioro-complexes [(71 6-arene)Ru(en)C1] and 
guanine adducts [(il  are compared in Figure 5.24. In each 
case, there is a significant re-orientation and conformational change of the arene ring 
with respect to the parent chioro-complex, as a result of arene-nucleobase interaction. 
For the biphenyl-guanine adducts 4 and 5, the biphenyl ligand is rotated away from 
the Ru-N7 vector (around the arene-Ru it bond) by 109.2° for 4, and rotated back by 
13.6° for 5, compared to the parent chloro-complex 1, and is involved in inter- or 
intra-molecular stacking with the purine ring. A decrease of ca. 100  in propeller twist 
of biphenyl for 4 and 5 (compared to 1) may also be driven by the phenyl-purine 
stacking force since there is no stacking interaction in 1. 
Arene-nucleobase stacking forces in 6 and 7 appear to cause large changes in 
the conformations of the TFIA and DHA ligands compared with their parent chloro-
complexes 2 and 3, respectively (Figures 5.24C and 5.24D). When the Cl ligand in 
complex 2 is substituted by N7-G (complex 6), the THA ligand rotates back around 
the arene-Ru it-bond by 19.5° (Table 5.5B) and re-locates to a position where ring C 
is completely overlapped with the G base. Moreover, the planarity of this tricyclic 
frame is lost and ring C bends down toward the purine about the C7A-C1OA hinge 
by 27.8° (Table 5.513). Similarly, the DNA ligand is rotated away from the Ru-Cl 
vector by 64.1° in 3, and rotated back around the arene-Ru it-bond by 43.2° in 7 
compared to 3, whilst ring C is bent down toward the Cl ligand about the C7A-CIOA 
hinge by 40.6° in 3 and toward the purine by 31.90  in 7. The increase of 35.3° in 
hinge bending angle for 6 and decrease of 8.7° for 7 compared with their parent 
complexes 2 and 3, respectively, allow ring C to make parallel contact with the 
purine in either case. Thus it-stacking interactions between the arene ring and 
nucleobase lead to arene ring re-orientation and conformational adjustment. 
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(A) 1 /4 
(D)3/7 (La) ii 0 
Figure 5.24 Comparison of the conformations of the parent chioro-complexes [(Tl 
arene)Ru(en)C1f (light line) and the guanine adducts [( 6-arene)Ru(en)(G-N7)] 2 
(heavy line). Arene = Bip in (A) and (B), THA in (C), and DHA in (D); Guanine 
derivative = 9EtG in (A), (C) and (D), Guo in (B). Alignments are based on a 
superposition of the labelled atoms (Ru!, NIB and N213 of en). In each case there is 
a significant re-orientation of the arene with respect to the parent chloro-complex, 
resulting in arene-nucleobase interaction. 
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The arene ligands process flexibility through rotation around the arene-Ru it-
bonds, propeller twisting for Bip, and hinge-bending for THA and DHA. These allow 
optimisation of the geometry for simultaneous arene-base stacking with N7-covalent 
binding. When the Ru(arene) complex approaches DNA, the arene ligand could 
therefore adjust its conformation to accommodate interactions with the guanine base. 
This property may reduce the steric demands of the Ru drug and enhance DNA 
affinity. The steric requirement of the metal complex itself directly influences the 
rate of DNA binding and hence affects anticancer activity. The coordination of 
octahedral ruthenium complexes to DNA is more sterically demanding than for 
square-planar four-coordinated platinum complexes. 60,57  The antitumor complex 
mer-[Ru(111)(terpy)C131 (terpy = 2, 2': 6', 2" - terpyridine) can bind two guanine 
bases and rate of binding to calf thymus DNA is faster than the inactive complex cis-
[Ru(II)(bpy)2C12] (bpy = 2, 2' - bipyridine) which has one more rigid heterocyclic 
ring and binds to only one guanine base.3c.50a61  The binding of DNA bases to a-
[Ru(II)(azpy)2C12] (azpy = 2-(phenylazo)pyridine) is sterically less-hindered than for 
cis-[Ru(11)(bpy)2C12]. The azpy ligand has flexibility since one ring is free from 
coordination to Ru, compared with the rigid coordinated bpy ligand. a-
[Ru(II)(azpy)2C12] has a very high cytotoxicity.3d62  The higher DNA reactivity of 
Na[trans-Ru(III)(Im)(DMSO)C14] compared to Na[trans -Ru(III)(Im)2C 141 (IM = 
imidazole) may also be related to the presence of two bulky heterocyclic axial 
ligands in the latter. 63 
Comparison between the crystal structures of complexes 4 and 5 suggests that 
the biphenyl ligand can adopt anti or syn conformations with respect to the G base 
(Figures 5.4A and 5.413). In the crystal structures of 6 and 7, the THA and DHA 
ligands both adopt a syn orientation (Figures 5.4C and 5.413). In general, the 
orientation of arene ligand in G adducts may be different in the solid state compared 
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to solution since both crystal packing and solvent effects can play a role. The 
solution structures of guanine adducts were studied using 2D NOESY NMR 
experiments in water or in acetone (dependent on solubility). The NOEs for its 
biphenyl adducts 4, 5 and 8 reveal that a syn orientation of the biphenyl ligand with 
respect to the G base predominates in solution in each case (Figures 5.12, 5.14 and 
5.16). Accordingly, downfield shifts for resonances of the pendent phenyl ring 
protons (FI(p'), H(o') and H(m')) in these three G adducts relative to those of the aqua 
biphenyl complex la are observed. This effect is most pronounced for H(o'): Aö = 
—0.36 (4), —0.33 (5), —0.34 (8) ppm (Table 5.8). Taken together, the syn orientation 
appears to be favoured for ftrj 6-biphenyl)Ru(en)(G-N7)] adducts both in solid state 
and in solution. This can be attributed to hydrophobic interactions between the 
phenyl ring and purine base. 
5.4.4 Fluxional Behavior of Arene Adducts 
Structural studies on THA and DHA adducts in solution were also attempted. 
Compared with the parent chloro complexes 2 and 3, the 'H NMR resonances of the 
TEA and DHA rings in the guanine adducts 6, 7, 9, 10 are broadened (Figures 5.18-
5.2 1). This may be due to the restricted rotation of the THA and DHA ligands. 2D 
['H, ' 5N] HSQC NMR spectra of ' 5N-6 (274 K) and ' 5N-9 (278 K) in water both 
show two sets of NH cross-peaks attributable to the presence of two isomers A and B 
(probably corresponding to anti and syn conformations) (Table 5.10). The 2D NMR 
EXSY-NOESY spectra (278 K) of ' 5N-9 (not shown) indicated exchange among two 
possible conformations at low temperature. The fluxionality of organometallic 
complexes has been previously investigated .64  Very small rotational barriers have 
been calculated for ( 6-benzene)Ru(II) complexes and restricted rotation about the 
Ru-arene it bond has been observed only on the presence of particular electronic and 
steric factors. 65  For biphenyl adducts, there is no obvious broadening of the biphenyl 
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ring resonances for complexes 4, 5 and 8 at various temperaures (273 - 318 K), 
indicating free rotation of the biphenyl ligand. However, the resonances for Guo and 
5'-GMP in 5 and 8 do broaden at low temperature. In the case of ' 5N-8, two sets of en 
NH ['H, ' 5N] cross-peaks were present at 274 K (Figure 5.13B) and the H8 1 H signal 
separated into two. This can be attributed to slow rotation of G at low temperature. 
Thus it appears that G rotation is more restricted than biphenyl rotation. This is not 
surprising since the G base forms one leg of the "piano-stool" and its movement is 
restricted by both the arene and the en ligands. Synchronous movements of the 
pendent phenyl ring and the G base may be possible with propeller twisting of the 
pendent phenyl ring. Such movement would not be possible for THA and DHA 
adducts which have relatively rigid tricyclic rings and explains why free rotation of 
the biphenyl rings is little affected by the steric factors from the G base in the 
biphenyl adducts in contrast to the THA and DHA adducts. 
5.4.5 H-bonding Interactions 
The crystal structures of the guanine adducts 4, 5, 6 and 7 show that en NH 
protons are involved in stereospecific H-bonding. The average N 0 distance of 2.8 
A and N-H0 angle of 163° are indicative of the strong N-H ... 0 hydrogen-bonding 
between one en NH(d) proton and the 0 06 oxygen (Table 5.4). H-bonding 
interactions between the other en NH(d) proton and ribose 0(5') in the Guo adduct 5 
are not present since the N 0 distances, 3.7 A in cation I and 5.3 A in cation H, are 
long as in the reported Pt-Guo adducts. 66  The two NH(u) protons of en are not 
involved in the intramolecular H-bonding with G 06 but in relatively weak H-
bonding with the counterion PF6 or with 0 06 of a neighbouring molecule. Such 
stereo-specific H-bonding suggests that the en ligand may locate in a specific 
position to H-bond to the neighboring exocylic oxygen atoms of the bases (or a 
phosphate group) and thus influence the site recognition of {( 6-arene)Ru(II)(en)} 2 
[It] 
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when covalently bound to DNA. The site-recognition ability of octahedral 
metallointercalators has been improved by the introduction of aliphatic ancillary 
hgands. For example, [Rh(NH3)4phi] 3+  , [Rh(en)2phi]3+  and [Rh[12]aneN 4phi]3+ (phi = 
9, 10-phenanthrenequinone diimine) bind to 5'-GC-3' sites. This sequence specificity 
is related to H-bonding between the axial amines of these metal complexes and the 
06 of G •23  The crystal structure of A-a-[Rh[(R,R)Me 2trien]phi] 3 bound to 5'-
GTTGCAAC-3' clearly shows sequence-specific interactions between the thymine 
methyl group and DNA, including H-bonding between axial amines and G 06 with 
an average N••0 distance of 2.9 A and H-N0 angle of 1650.24  Platinum am(m)ine 
complexes also show H-bonding involving am(m)ine ligands in their nucleobase 
adducts in the solid state. For example, there is intermolecular H-bonding between 
the 0 06 and the en NH of a neighboring molecule in 
[Pt(en)(Guo)2]Cl,510121120,56b weak intramolecular H-bonding between an ammine 
NH and a 0 06 in cis-[Pt(NH 3 )2 {d(CpGpG)-N7(2),N7(3)}] 2 ,67 and weak 
intermolecular ammine-06 H-bonding but stronger intramolecular H-bonding with 
the terminal 5'-phosphate in cis-[Pt(NH 3)2 {d(pGpG)-N7(1),N7(2)}] 2t 61 Such H-
bonding interactions of NH ligands are thought to play a major role in determining 
the nature of platinated DNA adducts '26a  and this may be an important factor for the 
antitumour activity. 68  Similarly, en NH H-bonding may be important for the activity 
of Ru(II) arene complexes. Moreover, Ru-N bonds form the legs of the piano stool 
and impose much tighter steric constraints in comparision with planar Pt am(m)ine 
complexes. The NH(d) but not NH(u) protons are correctly oriented for 
intramolecular H-bonding with G 06. This strong intramolecular NH ... 06 H-bonding 
may partly account for the high selectivity of f(il  binding to 
guanine with little binding to adenine, cytosine, or thymine. Although many reported 
Pt and Ru complexes also bind covalently to adenine derivatives, 26 this does not 
appear to be the case for [(TI  
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Guanine is involved in intermolecular N2H•••N3 base pairing in the three 
9EtG adducts 4 (Figure 5. 1A), 6 (Figure 5.7) and 7 (Figure 5.8). Such dimerisation 
has been observed in a number of Pt(TI) crystal structures containing purine 
derivatives. 69  In the case of complex 5, base pairing is not observed; instead, the 
N}12 of G participates in H-bonding with 0(32) of the sugar from a neighbouring 
cation, and with 0(19)W of water (Table 5.4B). The overall structure of 5 contains a 
complicated H-bonding network involving the en group, purine, PF 6 ion and water 
molecules (9 per unit cell). Water is an important participant in intercalation 
complexes, and the specific binding of water to DNA complexes can make a 
significant contribution to the free energy of drug binding. 70 The presence of 
numerous water molecules together with PF6 ions contribute to the stabilisation of 
the columnar-type stacking in [(q 6-biphenyl)Ru(en)(Guo-N7)][PF6]23.75H20 (5). 
The 9EtG adducts 4, 6 and 7 also form interesting polymeric structures in the solid 
state. Figure 5.8 shows the right-handed helical chain-type structure of 7, which 
displays G-G base pairing, intramolecular N-H .. 06 H-bonds, intermolecular N-
H 06 H-bonds and intramolecular stacking of ring C with the purine of 9EtG. 
Attempts to prepare X-ray-quality single crystals of [(il 
 (8) were not successful, but NMR studies allowed investigation of NH H-
bonding interactions in aqueous solution. 31 P and ' 5N-edited 'H NMR and 2D ['H, 
15N] NMR methods have been used previously to detect NH H-bonding to 5'- 
phosphate and G 06 groups in Pt-am(m)ine adducts of G derivatives .26d,71,72,73.  
Similarly, ' 5N-edited 'H{ 15N} NMR and 31 P NMR spectroscopy together with pH 
titration methods were used to investigate the role of en NH protons in ' 5N-8. 
With increase in pH from 2.8 to 10.9, the two NH(ul, u2) protons of 15N-8 
exhibit a similar pattern of chemical shift changes, becoming slightly deshielded, 
whilst the two NH(dl, d2) protons also exhibit the same behaviour but become 
greatly shielded (Figure 5.22). Similar data have been reported for [Pt( 15N-en)(5'- 
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AMP)2] 2 , for which one en NH is capable of H-bonding with 5'-phosphate and 
becomes greatly shielded, but the other proton on the same en N is incapable of H-
bonding and becomes slightly deshielded as the pH increases. 26d  The NH(dl, d2) 
protons of 8 point towards 5-liMP as shown in the solution structure of 8 (Figure 
5.16), and are capable of H-bonding with the 5-phosphate 74 and G 06. This H-
bonding is promoted by deprotonation of the 5-phosphate and NiH groups. 71 " The 
pKa of the 5-phosphate group of 8 is 5.93, 0.31 units lower than that of free 5-liMP 
(6.24, Figure 5.23B), attributable to the increased stabilization of deprotonated 
phosphate via H-bonding. This can be compared to a lowering of the 5'-phosphate 
pKa value for [Pt(en)(5'-GMP) 2] 2 by 0.38 units,26d  and for [Pt(en)(5-AMP)2] by 0.4 
units. 75 The pKa of ci NiH of 8 is 8.45, 1.28 units lower than that of free 5-liMP 
(9.73 76)For comparison, the pKa of ci NiH is lowered by ca 0.9-1.3 when guanine 
derivatives are coordinated to Pt(II) via N7, 77 e.g 1.1 units for [Pt(dien)(5'-GMP)]. 7 " 
Lowerings of 0.8 for [Ru(II)(NH3)5(HGuo)] 2 and of 2.2 for 
[Ru(III)(NH3) 5 (HGuo)] 3 have been reported. The acidifying efffect of Ru(II) is 
therefore lower than that of Ru(III), attributable not only to the lower charge of 
Ru(II), but also to a smaller degree of back donation of electron density. 2,78  The 
larger lowering of PICa (1.28) in complex 8 may be associated partly with N7 
coordination to Ru(ll) and partly with strong (NI -)-C=O (N1=C-0) H-bonding with 
en NH. 2 
At pH > 7.53, NH(dl) and NH(d2) resonances of ' 5N-8 both became too 
broad to observe. This may be due to more restricted rotation of G about Ru-N7 due 
to the formation of stronger H-bonding at high p11 or due to base-catalysed proton 
exchange .79  The effect of restricted rotation of G on the broadening of en NH(dl, 
d2) resonances was also observed for [(TI  (' 5N-
5). The two NH(d) resonances disappeared when temperature was below 328 K, but 
sharpened above 328 K due to faster G rotation (see Figure 5.13A and Table 5.10). 
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The NH(dl, d2) signals of ' 5N-8 also disappeared at pH < 5.96 (Figure 5.22), 
perhaps due to overlap with the water resonance. The en NH resonances of [Pt( 5N-
en)(5-GMP)2] and [Pt( 5N2-dien)(5'-GMP)J have been reported to disappear, but 
outside a much wider pH range (39 •5)261711 The pH dependence of the chemical 
shift of NH(ul, u2) of 15N-8 show little evidence of strong fl-bonding with the 5'-
phosphate or G 06 groups. This result is in accordance with the X-ray crystal 
structures of [( 6-biphenyl)Ru(en)(9EtG-N7)] 2 (4) and [( 6-biphenyl)Ru(en)(Guo-
N7)] 2 (5): NH(ul, u2) are on the opposite side to NH(dl, d2) and point away from 
5'-GMP. The high stereo-specificity leads to the formation of strong H-bonds. 
5.5 Conclusions 
Organometallic Ru(II) complexes have been designed which incorporate 
several DNA recognition features. The Ru(II) center has a reactive coordination site 
and can form monofunctional adducts with DNA. The t-bonded arene ligand has 
potential to form hydrophobic and van der Waals contacts with nucleobases, and the 
diamine ligand has NH groups available for H-bonding. 
The structures of monofunctional adducts of [(rj  
(arene = Bip, 1; THA, 2; DHA, 3) with guanine derivatives have been determined in 
the solid state by X-ray crystallography, and in solution using 2D ['H, 1 H] NOESY 
and ['H, ' 5N] HSQC NMR methods. These guanine adducts show interesting 
features, including Ru(II) binding to guanine N7, stereospecific hydrogen-bonding of 
en NH with 0 06 (with average N"0 distance 2.8 A), and strong arene-nucleobase 
stacking (at distances of 3.3 - 4.2 A). The presence of arene-nucleobase interactions 
suggests that the ri 6-arene ligand could intercalate into DNA. The arene ligands 
especially process conformational flexibility through rotation around the arene-RU 7t-
bonds, propeller twisting for biphenyl, and hinge bending for the anthracene 
derivatives THA and DHA. These make simultaneous arene-nucleobase stacking and 
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N7-covalent binding compatible. The conformational flexibility can also reduce the 
steric requirements of the Ru drug and enhance DNA affinity. Stereospecific H-
bonding to G 06 involves only en NH(d) protons (oriented away from the arene) and 
not NH(u) protons (oriented toward the arene) and partly accounts for the high 
preference of ((il  for binding to G versus A. 
These model compounds suggest a new potential DNA-binding mode for 
ruthenium anticancer drugs, involving simultaneous intercalation and covalent 
coordination with DNA. Such features may lead to highly specific recognition of 
bases in DNA duplexes, and may be useful for optimising the anticancer activity of 
organometallic Ru(II) arene anticancer complexes. Initial studies using CD, LD, and 
melting experiments 80  suggest that monoflinctional binding of Ru(II) arene can cause 
significant perturbation to the structure of calf thymus DNA, accompanied by 
intercalation in some cases. 
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Highly Selective Binding of Organometallic 
Ruthenium Ethylenediamine Complexes to 
Nucleic Acids: Novel Recognition Mechanisms 
176 
Chapter 6 Selective Recognition of Nucleic Acids 
6.1 Introduction 
Studies of the molecular recognition of DNA and RNA are of fundamental 
importance in post-genomic chemistry. The rational design of new DNA-binding 
agents that recognise specific sequences or structures, and can modify specific DNA 
functions such as replication and transcription, provides an effective approach for 
development of novel chemotherapeutic anticancer drugs.' Noncovalent interactions 
play key roles in biological molecular recognition. 2 Metal coordination, combined 
with, for example, hydrogen bonding, hydrophobic and electrostatic interactions, can 
effectively enhance site- and base-selective recognition of nucleic acids. Selective 
coordination to nucleobases is influenced by structural and electronic factors arising 
from the nucleobase and the complex itself Both hydrogen-bonding and non-
bonding repulsive interactions between the exocyclic groups on the bases and the 
chelate ligands in metal complexes can lead to selective reactions. Hydrophobic 
interactions can increase DNA affinity and give rise to highly specific recognition of 
DNA base sequences .4  Zn(ll) macrocyclic tetraamine (1, 4, 7, 10-
tetraazacyclododecane, cyclen) complexes with quinolyl or naphthyl pendants 
selectively bind to AT-rich regions of DNA mainly via Zn(II)-N(3)(thymine) 
coordination, 5 whereas incorporation of anthraquinone pendants into the cyclen ring 
allows recognition of G bases via a dominant n—n stacking interaction. 6 There is 
precedent for incorporating potential DNA intercalators into metal anticancer 
complexes. Examples include [Pt(AO)(CH2)6(en)C121 +, cis-[Pt(NH3 )2(N9-AA)] (AO 
= acridine orange; N9-AA = 9-aminoacridine), 7 ' 8 and trans-[PtC12 (NH3)L] (L = 
planar aromatic N donor such as pyridine, thiazole, or quinoline), 9 where the 
additional intercalation or hydrophobic interaction after covalent binding of the Pt to 
nucleobases can lead to enhanced activity. 
Organometallic ruthenium(II) complexes of the type [( -q 6_arene)RuCI(X)(Y)] 
(X, Y are monodentate or chelating ligands) are cytotoxic to cancer cells, including 
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cisplatin-resistant cell lines. Preliminary structure-activity data have shown that 
compounds are active when X, Y belong to a chelating diamine such as 
ethylenediamine (en) or its derivatives containing NH groups in the amine. The 
complex [( 6-Bip)Ru(en)Cl]PF 6 is active in vivo against the A2780 xenograft model 
of human ovarian cancer, and is also active against A2780cis, the cisplatin-resistant 
xenograft.' ° The cytotoxicity increases with increase in size of the 11 6-arene. For 
example, complexes which contain 11 6-tetra- or di-hydroanthracene rings (TFIA, 
DHA) or biphenyl (Bip) have much higher activities than compounds containing a 
single ring such as rl 6-benzene (Ben) or 6—cymene (Cym).' °" A potential target for 
these organometallic Ru(II) complexes is DNA, and the preferred binding site 
appears to be guanine." The structures of guanine adducts of THA, DHA and Bip 
complexes and show stereospecific hydrogen-binding of en NH with G 06, and 
strong arene-nucleobase stacking, both in the solid state by X-ray crystallography, 
and in solution by NMR methods. 12,13  These studies have revealed several DNA 
recognition features and suggested a potential DNA-binding mode, involving 
simultaneous intercalation and covalent coordination. The diamine NH group and 
hydrophobic arene group as well as the Cl leaving group may therefore all play 
important roles in anticancer activity. 
It is now important to understand how stereospecific hydrogen-bonding can 
lead to specific DNA site-recognition and whether arene-purine hydrophobic 
interactions influence the kinetics of DNA binding. Therefore, both the 
thermodynamics and kinetics of the binding of [(Tj  complexes 
(arene = tetra-, di-hydroanthracene (THA, DHA), biphenyl (Bip), p-cymene (Cym) 
and benzene (Ben); X = Cl or H 20, Chart 6.2) to mononucleotides and 
mononucleosides (G, I, A, C, and T, Chart 6.1) have been studied by 'H, 31 P, 15N 
(' 5N-en) NMR spectroscopy, together with pH titrations. These studies show that 
these novel organometallic ruthenium ethylenediamine anticancer complexes are 
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highly selective in their recognition of nucleic acid bases and that the nature of the 
coordinated arene has a dramatic effect on the kinetics of binding. Such insights can 
direct new synthetic work for optimization of drug activity. 
Chart 6.1 Structures and atom numbering for nucleobases and their derivatives. 
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Chart 6.2 Arene complexes studied in this work 
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6.2 Experimental Section 
6.2.1 Materials 
Chioro complexes [(il 	(arene = Bip, THA, DHA, 
Cym, and Ben, Chart 6.2) were synthesized as described previously. 11,12  The mono-
nucleotides 5-OMP, 3'-GMP, 3', 5'-cyclic GMP, 5-IMP, 5-AMP, 3', 5'-cyclic AMP, 
5'CMP and 5'-TMP (all as sodium salts), and the nucleosides guanosine, inosine, 
adenosine, cytidine and thymidine were purchased from Sigma or Aldrich. The 
purity was checked by 'H and 3 'P NMR spectroscopy. D 20 (99.98%) was obtained 
from Aldrich. All NIMR experiments were performed in 10% D20190% H20. 
6.2.2 Preparation of Aqua Ru(arene) Complexes 
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An aliquot of a 100 mM aqueous solution of AgNO3 (0.98 mol equiv) was 
added to a solution of [(rj 6-arene)Ru(en)Cl][PF, giving a yellow-orange solution 
and an immediate precipitate of AgCI. This mixture was kept at ambient temperature 
overnight (protected from light) and was then filtered to remove AgCI. The resulting 
yellow solutions 14  were used freshly and directly for reactions with 5'-GMP and 
cGMP. 
6.2.3 pH Titrations 
For the reaction of [(TI 	(12 mM) with 5'-GMP (12 mM), 'H 
and 31 P NMR pH titrations were performed at 298 K within the first six hours, in 
order to record 1 1-1 and 31 P NMR resonances for the intermediates Ru-O(P03)GMP 
and Ru-O(P03)GMPN7-Ru (Scheme 6.1). 
For the reaction of [( 6-Bip)Ru(en)Clj' (8 mM) with cGMP (9 mM), the 
mixture was incubated at 298 K for 24 h. This sample was then used directly for 
recording 1 11 and 3P  NMR spectra at various pH values. 
For the reaction of [(TI 	(12 mlvi) with 5-IMP (14 mM), the 
mixture was incubated at 298 K for 24 h, followed by addition of a 14% molar 
excess of Ru. This mixture was used for a pH titration, which was completed within 
a further four hours. The resultant 'H and 31 P NMR spectra were recorded. The H8 
and 1-12 chemical shifts of all six IMP species were subsequently plotted as a function 
of pH. 
For the reaction of [(TI 6  -Bip)Ru(en)Cl] +  (5 mM) with mosine (6 mM), the 
mixture was incubated at 298 K for 12 h. 'H NMR spectra were then recorded at 
various pH values. 
For reactions of [(ii 6-Bip)Ru(en)C11 (10 mM) with 5'-CMP, 5'-TMP or 
thymidine (10 mM), the mixtures were incubated at 310 K for 48 h, and i  and 31 p 
NMR spectra were then recorded at various pH values. 
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For reactions of [(i 6-Bip)Ru(en)Clf with 5'-AMP, ten parallel experiments 
were performed in ten NMR tubes under the similar conditions with various pH 
values over the range of 3-10. For each sample, the mixture of [(q 6-Bip)Ru(en)Cl] 
and 5'-AMP (1:1, 5 mM) with an adjusted p11 was incubated at 310 K for 24 h, after 
which the pH value was determined again and used as the equilibrium pH value. 
Subsequently, 'H and 31 P NMR spectra were recorded. The amount of phosphate-
bound adduct at each of the ten equilibrium pH values was determined by integration 
of either 'H or 31 P NMR peaks. 
6.2.4 Competitive Reactions of 5'-GMP, 5'-AMP, 5'-CMP, and 5'-TMP with 
((11 6-Bip)Ru(en)C1J 4 
5'-GMP was mixed with one of three other nucleotides in a 1:1 mol ratio (5 
mM, GMP + AMP, GMP + CMP, or GMP + TMP). Each of the combinations was 
then added to an aqueous solution of [(T1 6-Bip)Ru(en)ClI( (final concentration 5 
mM). The reaction mixtures were monitored immediately by 'H and 31P NMR 
spectroscopy at 298 K or 310 K. The amounts of free and Ru-bound nucleotides were 
determined by peak integration. 
6.2.5 Kinetic Studies 
The reactions between chloro or aqua Ru(arene) complexes and nucleotides 
(5'-GMP, cGMP, 5'-IMP, 5-AMP, cAMP, 5'-CMP, or 5'-TMP), or nucleosides 
(guanosine, inosine, adenine, cytosine or thymidine), were carried out at a 
concentration of 5 mM Ru and 5 mM nucleobase in 10% D20190% H20 in NMR 
tubes. Most solutions were unbuffered to avoid intereaction of buffer components 
with Ru(II). The solution pH was determined at the commencement of the reaction 
and after the establishment of equilibrium. The kinetic studies of various chloro or 
aqua Ru(arene) complexes with cGMP were carried out in 100 mM NaCI0 4 at 298 
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K, pH 7.0. Due to the poor aqueous solubility of chioro Ru(THA) and Ru(DHA), the 
kinetics of reactions of various chioro Ru(arene) complexes with cOMP were 
performed at a concentration of 2 mM for both reactants. 'H, 3 'P NMR or ' 5N NMR 
data were recorded at appropriate time intervals. The first spectrum was acquired 10-
15 min after mixing of the reactants, to allow time for temperature equilibration of 
the sample in the probe. Quantitation of the reactions was achieved by integration of 
the peaks for the base protons H8 (G), H8 and H2 (I and A), H6/H5 (C) and C(5)H3 
(T), or by integration of 31P NMR peaks, or ['H, ' 5N] cross-peaks. 
6.2.6 Methods and Instruments 
NMR Spectroscopy. 'H NMR spectra were acquired on a Bruker DMX 
500 ('H = 500 MHz) NMR spectrometer using TBI ['H, ' 3C, X] or triple resonance 
['H, ' 3 C, ' 5N] probe-heads, respectively, and equipped with z-field gradients. 
1D 'H NMR spectra were typically acquired with 64 transients into 32 K data 
points over a spectral width of 6.0 kHz. Water suppression was achieved by 
presaturation. 3 !P NMR spectra were obtained on a Bruker DMX 500 ( 31P = 202 
MHz) NMR spectrometer at 298 K, using inverse-gated 'H decoupling. Typically 1D 
31 P-{'H} NMR spectra were acquired with 512 transients into 42 K data points over 
a spectral width of 40.7 kHz (200.8 ppm) using a relaxation delay of 1.3 s. Both I  
' 5N-edited 'H NMR spectra and 2D ['H, 15N] HSQC NMR spectra (optimised for 
'4H) = 73 Hz) were acquired using the sequence of Stonehouse et. al.'5 A GARP 
decoupling sequence was used for ' 5N decoupling during acquisition. Typically 1D 
'H-{' 5N} NMR data were acquired with 16 transients into 1024 data points over a 
spectral width of 2.5 kHz (5.0 ppm) with a relaxation delay of 2.0 s. 2D ['H, ' 5N] 
HSQC NMR data were acquired with 4 transients into 1024 data points over a 'H 
(F2) spectral width of 2.5 kHz (5 ppm, centered at the water resonance) for each of 
256 t, increments (TPPI), and over a 15N (Fl) spectral width of 0.76 kHz (15 ppm, 
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centered at —28 ppm) using a relaxation delay of 1.4 s between transients. Typically, 
1D 'H-{' 5N} NMR spectra were acquired over a 10 min period and 2D ['H, ' 5N] 
HSQC NMR spectra were acquired over a 30 min period. 
All data processing was carried out using XWIN-NMR version 2.0 (Bruker 
U.K. Ltd.). 'H NMR chemical shifts were internally referenced to 1, 4-dioxane (3.77 
ppm) or to the methyl singlet of TSP (0 ppm) in aqueous solutions. 3 'P resonances 
were referenced to 85% H3PO4 (external) at 0 ppm, and ' 5N resonances to I M 
' 5NH4C1 in 1.5 M FICI (external) at 0 ppm. 
pH Measurements. The pH values of NMR samples in 10% D20/90% 
H20 were measured at 298 K directly in the NMR tube, before and after recording 
NMR spectra, using a Corning 240 pH meter equipped with an Aldrich micro 
combination electrode calibrated with Aldrich buffer solutions at pH 4, 7, and 10. 
The pH values were adjusted with dilute H004  and NaOH. No correction has been 
applied for the effect of deuterium on the glass electrode. 
Calculation of pKa Values. The pH titration curves were fitted to the 
Henderson-Hasselbalch equation using the program KALEIDAGRAGH,' 6 with the 
assumption that the observed chemical shifts are weighted averages according to the 
populations of the protonated and deprotonated species. 
Determination of Rate Constants. The reactions of aqua Ru(arene) 
complexes with cUMP (1:1, 5 mM) (Ru-H20 + cGMP -+ Ru-N7cGMP) were 
analysed as second-order processes (see Figure 6.12). The second-order rate 
constants (k) were determined by fitting kinetic curves of concentration versus 
reaction time for formation Ru-N7cGMP using the appropriate equation and the 
program Scientist (see Figure 6.13). 
6.3 Results 
6.3.1 General 
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In order to investigate the specificity of the binding of J(Tl  
to nucleobases, reactions of the anticancer complex [(il  with various 
nucleosides and nucleotides (see Chart 6.1) in aqueous solution were studied by 'H, 
' 5N and 3 'P NMR spectroscopy. The binding sites for {( 6-Bip)Ru(en)} 2 on 
nucleobase derivatives were identified by 'H NMR and 3 'P NMR pH titrations, and 
each adduct was characterized by pIta  values derived from the pH titration curves. 
Some competition experiments were also performed to study the relative binding 
preferences of f(Tj  towards mononucleotides. The influence of pH, 
chloride and phosphate on the rate of binding of ((71 6_arene)Ru(en)Xl" (arene = Bip, 
THA, DHA, Cym, or Ben, and X = Cl or H20) complexes to 5-GMP and cGMP was 
also investigated by 'H and 31 P NMR. The detailed kinetics for the reactions with 
cGMP were analyzed. 
6.3.2 Reactions of [( 6-Bip)Ru(en)ClJ with Nucleotides and Nucleosides 
Guanine Forms only N7 Adducts. Phosphate-bound 
Intermediates Detected for 5'-GMP but not for cGMP. The H8 region of the 
NMR spectra of 5-GMP after reaction with [( 6-Bip)Ru(en)Cl] (1:1, 5 mM, pH 
7.15, 298 K) for 0.25-22 h are shown in Figure 6.1A. Three new H8 signals were 
observed: peak b (6 8.027) appeared rapidly (during the reaction mixing time) and 
was shifted to low frequency relative to free 5'-GMP (peak a, 8 8.175), but 
disappeared at later times; peak d at higher frequency (8 8.453) was evident after 2 h 
and finally disappeared as well; peak c appeared at higher frequency (8 8.733), 
increased in intensity with time, and was the only final product observed for this 
reaction. An identical reaction, which was followed by 31 P NMR (Figure 6.1B), 
revealed corresponding changes in intensities of 31P NMR peaks (a-d) which were 
consistent with the 'H NMR results. However, for 31 P, there were large shifts in 
peaks b (8 9.017) and d (8 9.237) to high frequency relative to the resonance for free 
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Scheme 6.1 Scheme for reaction of [( 6-Bip)Ru(en)Clf with 5'-GMP (5 mM, 1:1) in 
aqueous solution at pH = 7.15, 298 K. Species distribution (%) is shown after 55 mm 
reaction, and is based on 15NH2-en Ill  NMR intensities (except for the dinuclear 
species which was based on H8 intensities). The intermediate Ru-O(P0 3 )GMP (peak 
b) formed during the reaction mixing time, slowly rearranged into Ru-N7GMP (peak 
c), and then eventually disappeared after 22 h (see Figure 6.1A). The intermediate 
Ru-O(P0 3 )GMPN7-Ru (peak d) was evident after 2 h, and eventually disappeared 
after 22 h; it persisted if Ru was present in excess. When more Ru-Cl (50%) was 
added to the final mixture, more of species d (30%) formed after 24 hat 310 K. 
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Figure 6.1 (A) 'H, and (B) 31 P NMR spectra for the reaction of [(TI  
with 5'-GMP (1:1, 5mM, pH 7.15,298K) at various reaction times. Plots of (C) H8 
'H NMR chemical shift, and (D) 3 'P NMR chemical shift vs. pH for 5-GMP species 
a-d . The curves are computer-fitted with the pKa values listed in Table 6.1. The pH 
titration was performed for a similar reaction of [(q 6-Bip)Ru(en)Cl] (12 mM) with 
5'-GMP (12 mM). Peak assignments: a, free 5'-GMP; b, Ru-O(P03)GMP; c, Ru-





























'0 (' 5N) 
—25 - 
IKIZ 
Chapter 6 Selective Recognition of Nucleic Acids 
I 	 P 	 I 	 I 	I 	 I 
6.5 5.5 40 
Figure 6.2 2D ['H, 15  N] HSQC NMR spectrum of (A) ft11 6-Bip)Ru( 5N-en)C1] (5 
mlvi, pH 6.20) at 298 K, and (B) 20 mm, (C) 2.9 h, and (D) 20 h after addition of 5'- 
(iMP (1:1, pH 7.15). The cross-peaks for Ru-O(P03)GMPN7-Ru are very weak and 
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not shown. For the chloro and aqua adducts, the two protons on each 15N are non-
equivalent, but the two 15N atoms have the same shift, whereas in the GMP adducts, 
the four NH protons are all non-equivalent. Small changes in the shifts of the cross-
peaks for Ru-1120 in (B, pH 7.15) compared with those in (A, pH 6.20) are due to 
deprotonation (weighted average of aqua and hydroxo shifts; piC a of Ru-17120 : 7.7). 
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Figure 6.3 Species distribution versus time for the reaction of 5-GMP with [(T] 6_ 
Bip)Ru( 5N-en)Cl] (1:1, 5 mM, pH 7.15) at 298 K, as determined from integration of 
15NH2-en 'H NMR peaks (shown in Figure 6.4). Labels: •, Ru-Cl, a, Ru-H20, 0, 
RU-O(P03)GMP, 0, Ru-N7GMP. For structures of species, see Scheme 6.1. 
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4.482). The reactions were complete within Ca. 22 h. 
In order to identify the intermediates and products, a pH titration on a similar 
solution containing 12 mM Ru and 12 mlvi 5-GMP was carried out during the first 6 
h of reaction. Peaks b and d disappeared at pH values < 4, but the other peaks could 
be followed over the pH range 2-12. The 'H and 31 P NMR titration curves are shown 
in Figures 6.1 C and 6.1 D, and associated pICa  values were determined by computer 
fits to the Henderson-Hasselbalch equation. The characteristic piCa  values associated 
with peaks a, b, c and d, allow the intermediates to be assigned as Ru-O(P03)GMP 
(b), Ru-O(P03)GMPN7-Ru (d), and final product as Ru-N7GMP (c) (for structures 
see Scheme 6.1). Their piCa  values are listed in Table 6.1. Three piCa  values were 
determined for free 5'-GMP: 9.81, 6.49 and 2.57, attributable to the deprotonation of 
NIH, P03H, and N7, respectively. Ru-O(P03)GMP (peak b) undergoes 
deprotonation of NiH (pKa of 9.51), but no deprotonation of P03H. Ru-N7GMP 
(peak c) undergoes deprotonation of P03H (piCa of 5.77) and NiH (piCa of 8.39), but 
no deprotonation of N7. Ru-O(P03)GMPN7-Ru (peak d) undergoes deprotonation of 
NiH, but no deprotonation of P03H and N7. Notable is the lowering of the pKa(Nl) 
value by 1.42 units for Ru-N7GMP (peak c) and by 1.74 units for Ru-
O(P03)GMPN7-Ru (peak d) compared to free GMP (peak a). 
A similar reaction with 5'-GMP was also monitored by 2D [ 1 H, ' 5N] HSQC 
NMR by use of ' 5N-labeled [(r1 6-Bip)Ru(en)Clf (Figure 6.2). Four species labelled 
Ru-Cl, Ru-H20, RU-O(P03)GMP and Ru-N7GMP were detected during the time 
course of the reaction (Figures 6.2 and 6.3). This result, together with the 'H and 3 'P 
NMR time courses, allowed reaction pathways to be drawn up, as shown in Scheme 
6.1. First, the chloro complex Ru-Cl undergoes hydrolysis in water to give the 
reactive aqua complex Ru-1-120, followed by rapid reaction with the 5'-phosphate of 
5'-GMP, and then a slow displacement of bound phosphate by N7. The species 
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distribution determined after 55 min of reaction is shown in Scheme 6.1. 
The reaction of 3', 5'-cyclic GMP (cGMP) with [(TI  (1:1, 5 
mM, pH 7.28, 298 K) was monitored by 'H and 31P NMR for a period of ca. 12 h. 
After 11 mm, a new H8 'H NMR peak (b, 8 8.22 1) was observed, shifted to high 
frequency by 0.337 ppm compared to free cGMP (peak a, 6 7.884), Figure 6.4A. 
This was the only new H8 signal observed, and after 12 h was the only H8 peak in 
the spectrum. In the 31 P spectrum (Figure 6.413), only one new peak appeared (b, 6-
1.022). This peak was shifted to low frequency by only 0.043 ppm relative to that for 
cGMP (peak a, 6 —0.979). A pH titration of a similar reaction solution gave pKa 
values of 9.69 and 2.08 for peak a (free cGMP), and a single pICa  value of 8.13 for 
the product peak b, as derived from the H8 1 11 curves (Figure 6.4C and Table 6.1). 
Peak b can be assigned as Ru- N7cGMP (see Scheme 6.2). pK a values of 9.67 (peak 
a) and 8.13 (peak b) are attributable to deprotonation of NI H. The pKa value of 2.08 
(peak a) is attributable to protonation of N7. Notable is the lowering of the pa  for 
NI by 1.54 units relative to free cGMP (peak b). During the reaction, no phosphate-
bound adducts were detected. The reaction course is shown in Scheme 6.2. After 10 
h, > 95% of the cGMP was present as Ru-N7cGMP. 
The reaction of guanosine (Guo) with [(q 6-Bip)Ru(en)Cl] (1:1, 5 mM, 310 
K, pH 7.20) was followed by 'H NMR for 1 d. Only one new peak assignable 12 to 
Ru-N7Guo appeared at high frequency (6 8.22) relative to free Guo (6 7.9), and after 
14 h,> 97% of Goo was present as Ru-N7Guo. A similar reaction was performed at 
pH 9.29, and only the Ru-N7Guo adduct was present after 14 h (Table 6.3.). 
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Scheme 6.2 Scheme for reaction of [(Tl  with cGMP in aqueous 
solution at pH = 7.28, 298 K. 
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Figure 6.4 (A) 1 1-1, and (B) 31 P NMR spectra for the reaction of [(TI  
with cGMP (1:1, 5 mM, pH 7.28, 298 K) at various reaction times. Peak 
assignments: a, free cGMP; b, Ru-N7cGMP. See Scheme 6.2 for structures. (C) Plots 
of H8 'H NMR chemical shifts of cGMP species a and b vs. pH for a similar reaction 
with 8 mM Ru and 9 mM cGMP. The curves are computer best fits giving the pKa 
values listed in Table 6.1. 
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Table 6.1 Selected Chemical Shifts and pKa Values for 5'-GMP and cGMP and Their 
{(ii6-Bip)Ru(en)12 Adducts at 298 K. 
Species' (peak)" 	 pKa (group) 	6 (H8)c 	8 (31p)C 
5'-GMP (a) 	 9.81 ± 0.10 (NiH) 	8.175 	3.899 
6.49 ± 0.18 (-P0311) 
2.57 ± 0.01 (N7) 
RU-O(P03)GMP (b) 	9.51 ± 0.05 (NiH) 	8.027 	9.017 
Ru-N7GMP (c) 	 8.39 ± 0.06 (NiH) 	8.733 	4.582 
5.77 ± 0.04 (-P031-1) 
RU-O(P03)GMPN7-Ru (d) 8.07 ± 0.04 (NiH) 	8.453 	9.237 
cGMP (a) 	 9.67 ± 0.24 (NiH) 	7.884 	-0.979 
2.08 ± 0.02 (N7) 
Ru-N7cGMP (b) 	 8.13 ± 0.03 (NiH) 	8.221 	-1.022 
'For structures see Schemes 6.1 and 6.2. For peak labels see Figures 6.1 and 6.4. 
For 5'-GMP, pH 7.20 and for cGMP, pH 7.28. 
Ru(II) Binds to N7 and NI of Inosine, and Phosphate-Bound 
Intermediates are Formed with 5'-IMP. The reaction between 5'-IMP and [(71 6 
Bip)Ru(en)Clf' (1:1, 5 mM, pH 7.26) was monitored by 'H and 31P NMR 
spectroscopy. During the reaction, the pH value dropped from 7.26 (when mixed) to 
6.55 (after 3 dat 310K). The H8 and H2 regions of the 'H NMR spectra of 5'-IMP at 
different reaction times are shown in Figures 6.5A-C. 3 'P NMR peak assignments are 
given in Table 6.2. During the course of the reaction, 5 new sets of 118 and H2 peaks 
(peaks b, c, d, e and f) were seen. Of these, 3 sets (peaks c, d and e) are due to 
intermediates: their intensities decreased at later reaction times and almost 
disappeared after 3 days at 310 K. The intermediates and products were identified by 
a 'H NMR pH titration on a similar solution (Figure 6.51)). It can be seen that peaks 
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Scheme 6.3 Scheme for reaction of [(Tl 	with 5-IMP (1:1, 5 mM) in 
aqueous solution at pH = 7.28, 298 K. Species distribution (%) is shown after 24 h 
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Figure 6.5 The H8 and 112 region of 'H NMR spectra for the reaction of 5'-IMP with 
[(Ti 6-Bip)Ru(en)ClI (1:1, 5 mM, initial pH 7.26) at 298 K after (A) 13 mm (pH 
7.15), (B) 3.7 h (pH 6.74), and (C) after a further 3 days at 310 K (pH 6.55). (D) 






Chapter 6 Selective Recognition of Nucleic Acids 
'H NMR chemical shifts for species a-f. pK, values were determined from 118 shifts. 
Assignments: a, H8 (U) and H2 (0), free 5'-IMP; b, 118 (•) and H2 (0), Ru-N7IMP; 
c, 118 (V) and 112 (V), Ru-O(P03)IMP; d, 118 (•) and 112 (0), Ru-NJIMP; e, 118 (*) 
and H2 (s), Ru-O(P03)]MPNI-Ru; and f, H8 (A) and 112 (s), Ru-N7IMPNJ--Ru. For 
structures see Scheme 6.3. Note that d, e and fare NI -boundspecies. 
Scheme 6.4 Scheme for reaction of [(TI 6_Bip)Ru(en)Cl] +  (5 mM) with inosine (5.5 
mM) in aqueous solution at pH = 7.22. Species distribution (%) is shown after 24 h 
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Figure 6.6 (A) The 118 and H2 region of the 'H NMR spectrum of inosine (5.5 mM) 
after reaction with [( 6-Bip)Ru(en)Clf (5 mM) for 24 h at 310 K with initial pH 
7.22. (B) Plots of 118 and H2 chemical shifts vs. pH for the five species a-d detected 
during the above reaction. Peaks labels: H8, solid symbols; H2, open symbols, i.e. a, 
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Table 6.2 Selected Chemical Shifts and pKa Values for 5t-IMP and Inosine (mo) and 
Their {(i 6-Bip)Ru(en)} 2 Adducts at 298 K. 
Specie? (peak)" 	pKa (group)' 	8 (H8)"5 (fl)d 
5-IMP (a) 9.22 ± 0.05 (NiH) 8.497 8.169 
6.36 ± 0.05 (P03H) 
1.35 ± 0.01 (N7) 
Ru-N7IMP (b) 7.74 ± 0.03 (NIH) 9.053 8.131 
5.71 ± 0.03 (P03H) 
Ru-O(P03)IMP (c) 9.04 ± 0.03 (NiH) 8.404 7.909 
Ru-NJIMP (d) 6.35 ± 0.05 (P0311) 8.339 8.016 
Ru-O(P03)IIVIPNJ-Ru (e) 8.330 7.99 
Ru-N7IIMPNJ-Ru (f) 	5.73 ± 0.03 (P03H) 	8.856 	8.155 
mo (a) 	 8.79 ± 0.02 (NIH) - 8.344 	8.225 
0.909 ± 0.003 (N7) 
Ru-N7Ino(b) 	 7.11 ±0.04 (NiH) 	8.745 	8.201 
Ru-NJIno (c) 	 8.135 	7.977 
Ru-N7InoNl-Ru(e) 	- 	 8.624 	8.165 
'For structures see Schemes 6.3 and 6.4. b  For peak labels see Figures 6.5 and 6.6. 
Based on 118 chemical shifts. d11  6.31 for 5'-IMP and pH 6.19 for Inc. For 5'-IMP, 
the corresponding 31 P NMR resonances appeared at 8 3.278 for peak a, 8 8.983 for c, 
and 8 8.272 for e, 8 3.410, 4.393 and 1.612 for peaks b, d and f, but specific 
assignments were not made. 
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Table 6.3 Species Distribution and N(7)/N(1) Ratios for Into and Guo Binding by 
{(1 6-Bip)Ru(en)} 2t 
H change B 	  
over 24 h Free B 
Species distribution (%)a 
Ru-N713 	Ru-NIB 	Ru-N7BNJ-Ru 
 N(7)/N(1)' 
5.18-5.53 15.4 74.7 8.6 1.3 7.72 
mo 	7.22-6.19 13.9 59.4 23.0 3.7 2.36 




a Based on integration of 'H NMR resonances. Conditions: Ru: B 5 mM : 5 MM for 
Guo and 5mM: 5.5 mM for ho, after 24 h incubation at 310K. No added salt. 
b N(7)JN(1) = {[Ru-N7B] +[Ru-N7BN1-Ru]}/{[Ru-N1B]+[ Ru-N7BN1-Ru}}, where 
B = ho or Guo. 
c, d and e disappeared at lower pH (C 5.8). From 'H H8 shifts, the pKa values 
associated with all 6 sets of IMP peaks were determined and are listed in Table 6.2. 
Free 5'-IMP (a), PKa values of 9.22, 6.36 and 1.35 were determined for NiH, P03H 
and N7, respectively, whereas peak b has two associated pK a values of 7.74 and 5.71 
assignable to NiH and P031-1, but no pKa assignable to N7. Peak b can therefore be 
assigned as Ru-N7IMP. Peak c has an NiH PICa value of 9.04 and no associated 
phosphate pKa, and is assigned to Ru-O(POOIMP. Peak d has a P03H pKa of 6.35 
but no NiH pKa, and is assigned to Ru-N]IMP. Peak e has no measurable pKa values 
at all and is assignable to Ru-O(P03)IMPNJ-Ru. Peak f has a P03H piCa of 5.73, but 
no N7 and Ni pJa  values and is assigned to Ru-N7IMPNI-Ru. The distribution of 5'-
IMP species at pH 6.46 after 24 h at 310 K was determined by H8 and H2 peak 
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integration and is shown in Scheme 6.3. 
The reaction of inosine (ho, 5.5 mM) with [(11 6-Bip)Ru(en)Clf (5 mM) was 
followed by 'H NMR for 2 d at 310 K with an initial pH of 7.22. After 1 d, the pH 
value of the solution had decreased to 6.19. A representative 1 H NMR spectrum for 
the 118 and 112 region is shown in Figure 6.6A. Three products are formed 
corresponding to 3 new sets of 118 and 112 peaks: b, d and c. The products were 
identified by 1 11 NMR pH titration (Figure 6.613, note that product c disappeared at 
pH C 4.0). The pKa values are derived from H8 chemical shifts 17  and are listed in 
Table 6.2. Peak a has two associated pIta values of 8.79 and 0.91, attributable to 
protonation Of N  H and N7 of free inosine. Peak b has one piCa value of 7.11, 
attributable to the protonation of NiH of Ru-N7Ino. After 24 h at 310 K, the species 
distribution was determined to be: Ru-N71no: 59.4%, Ru-NJTno: 23.0%, Ru-
N71noNJ-Ru: 3.7% (Scheme 6.4). Species distributions and N(7)/N(1) binding ratios 
for reactions of Trio with [(il  at various pH values (5.5-10.3) are 
listed in Table 6.3. With increase in pH, the N(7)/N(1) binding ratio decreased 
significantly from 7.72 (pH 5.5) to 0.22 (pH 10.3). 
Little Reaction with cAMP or Adenosine, and Only 5'-Phosphate 
Binding for 5 1 -AMP. The reactions of 5'-AMP with [(ii 6-Bip)Ru(en)Cl] (1:1, 5 
mM, 310 K) at various pH values were monitored for 24 h by 'H and 3 'P NMR 
spectroscopy (Figures 6.7A and 6.713). A rapid reaction was observed (within the 
time of mixing) which gave rise to one new set of H2 and H8 'H NMR signals (peak 
b, H2 6 8.006 and 118 6 8.402, pH 6.8), shifted to low frequency relative to free 5'-
AMP (peak a, H2 6 8.240 and 118 8 8.555) and in slow exchange on the NMR time 
scale. Similarly, one new signal (peak b, 8 9.125) was observed in the 31P NIMR 
spectrum (Figure 6.713) shifted to high frequency by 5.568 ppm (pH 6.8). The 
variation in intensity of 31P NMR peak b with pH is shown in Figure 63C. It can 
been seen that it reached its maximum intensity at pH ca. 7.2 and decreased in 
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intensity at either lower or higher pH; at pH 3.0, only free 5'-AMP peaks were seen, 
and at pH 9.6, > 90% of 5'-AMP was free. The variations of 'H (1-18 and H2) and 31 P 
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Figure 6.7 (A) 'H, and (B) 31 P NMR spectra for the reaction of 5'-AMP with [(Il 
Bip)Ru(en)Clf (1:1, 5 mM) after 24 h at 310 K at various pH values. Peak 
assignments: a, free 5'-AMP; b, Ru-O(P0 3)AMP. (C) Plot showing the variation 
with pH of species b as a percentage of the total 5'-AMP present, based on 3 'P NIMR 
peak intensities. There is negligible binding of Ru to the purine base of 5'-AMP over 
the pH range of 3.0-10.0. 
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Figure 6.9 Top: (A) 'H, and (B) 31 P NMR spectra for reaction of 5-CMP with [(TI 6 
Bip)Ru(en)Cl] (1:1, 5 mM, pH 7.2, after 24 h at 298 K). Bottom: The T-CH3 region 
of 'H NMR spectrum for reactions of (C) 5-TMP with Ru(Bip) (1:1, 10 mM, pH 5.9, 
after 2.5 dat 310 K), and (D) thymidine with Ru(Bip) (1:1, 5 mM, pH 6.55, after 3 d 
at 3 10 K). 
NMR chemical shifts with pH are shown in Figures 6.8A and 6.8B, and pJa  values 
determined from H8 'H NMR shifts are listed in Table 6.4. Free 5'-AMP (peak a) has 
two associated pKa values of 6.41 and 4.05, attributable to the deprotonation of P03H 
and NiH, respectively. Peak b can be assigned to the phosphate-bound adduct Ru- 
O(P03)AMP and has no measurable pK, value within the pH range 4-10. 
Reactions of cAMP and adenosine (Ado) with [(q 6 -Bip)Ru(en)Cl] +  (1:1, 5 
mM, 310 K) were monitored by 'H NMR at different pH values (4.0, 7.0, and 9.0). 
Only small amounts (<5%) of products were formed for both cAMP and Ado, even 
after 3 d at 310 K (Table 6.7). These are possibly N7/NI adducts (based on H8 and 
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H2 chemical shifts). pH titrations were not attempted due to the low concentrations 
of products. 
Table 6.4 Selected Chemical Shifts and pKa Values for 5'-AMP and 5-CMP and 5'-
TMP and Thymidine and Their f(Tl 	Adducts at 298 K. 
Species (Peak)' pKa b (group) 3 (H )C 3 (31p)c 
5'-AMP (a) 6.41 ± 0.07 (-P03H) 8.555 3.557 
4.05 ± 0.08 (NiH) 
Ru-O(P03)AMP (b) 8.402 9.125 
5'-CMP (a) 6.43 ± 0.04 (-P03H) 8.091 3.696 
4.36 ± 0.03 	(N3FI) 
Ru-O(P03)CMP (b) 7.875 8.960 
Ru-N3CMP (c) 	6.12 ± 0.08 (-P03H) 	d 	3.917 
5'-TMP (a) 	 9.99 ± 0.03 (N3H) 	1.914 	1.95 
6.65 ± 0.07 (P0311) 
Ru-N3TMP (d) 	6.32 ± 0.02 (P03H) 	1.694 	2.05 
Ru-O(P03)TMPN3-Ru 	- 	 1.781, 1.754, 
(b, c and e) 	 1.667 
Thymidine (a) 	9.76 ± 0.12 (N3H) 




' For peak labels see Figures 6.7 and 6.9. b  Based on H8 or H6 or T-CH3 chemical 
shift. CH8  and pH 6.8 for 5-AMP, H6 and pH 7.10 for 5'-CMP, CU3 and pH 5.81 for 
5-TMP, and CH3 and pH 5.37 for thymidine. d  Peak c of H6 is overlapped with 
phenyl resonances in the 'H NMR spectra. 31 P NMR resonances at ca. 3 9.0 for Ru-
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51-CMP Forms 5 1 -Phosphate Adduct and a Minor N3 Adduct. 
Reactions of 5'-CMP with [( 6-Bip)Ru(en)Cl] (1:1, 5 mM, pH 7.23, 310 K) were 
followed for up to 3 d, and 'H and 31 P NMR spectra are shown in Figures 6.9A and 
6.9B. A rapid reaction was observed and gave rise to a new H6 'H NMR peak shifted 
to low frequency (b, 6 7.875), which accounted for ca. 56% of the total 5'-CMP after 
1 d. There was a corresponding new 31 P NMR peak (b, 8 8.960) shifted to high 
frequency by 5.264 ppm. In the 31 P NMR spectrum, an additional minor peak c 
appeared at 3.917 ppm. The corresponding H6 signal for peak c was not detected, 
perhaps due to peak overlap with the phenyl resonances. The 'H and 31 P NMR pH 
titration curves are shown in Figures 6.8C and 6.81) (note that peak b disappears at 
pH <4.2). pKa values were determined from H6 'H NMR shifts and are listed in 
Table 6.4. Free 5'-CMP (peak a) has pKa values of 6.43 and 4.36, attributable to the 
deprotonation of P03H and N3H, respectively. Peak b can be assigned to Ru-
O(P03)CMP, and has no measurable pJa  value within the pH range 4-11. Peak c has 
an associated pKa value of 6.12 (based on 31P NMR titration), attributable to the 
deprotonation of P03H and can be assigned to the Ru-N3CMP product. 
The reaction of cytidine with [(Tl 	(1:1, 5 mM, pH 7.2) was 
monitored by 'H NMR. Based on new biphenyl 'Fl resonances, only 13% of cytidine 
reacted even after 3 d at 310 K (Table 6.7), possibly via N3 binding. A pH titration 
was not attempted due to the low concentration of the product. 
Ru(II) binds to Phosphate and N3 of 5'-TMP. Reactions of 5'-TMP 
with [(Il  (1:1, 5 mM, pH 7.2, 298 K) were followed by 'H and 31 P 
NMR spectroscopy for up to 3 d. Due to the overlap of H5 and H6 and Hi' signals 
of TMP with those for biphenyl protons, the analysis for this reaction was based on 
the T-CH3 signal. A rapid reaction was observed within 10 min and gave rise to one 
new T CH3 peak c at 8 1.754 shifted to low frequency relative to that for free TMP 
(beak a, 8 1.914). After 2 h, peaks b (8 1.781), d (8 1.694) and e (8 1.667) appeared 
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and increased in intensity with time, with a decrease in intensity of peak c. The pH 
value of the solution decreased steadily during the reaction from 7.3 (initial) to 6.20 
(1 d). The reaction reached equilibrium after 1.5 d, at which time the relative 
intensities of 5'-TMP CH3 peaks were a: 39%, b: 24%, e: 15%, d: 12% and e: 10%. 
A representative 'FT NMR spectrum of the T CE3 region is shown in Figure 6.9C, 
and 'H NMR pH titration curves are shown in Figure 6.8E. pJa  values were 
determined for peaks a and d (Table 6.4). Free 5'-TMP has pKa values of 9.99 and 
6.65 for N3H and P0311, respectively. Peak d shows one pKa value of 6.32 for 
P03H, and the absence of deprotonation of N31-1, and is assigned to Ru-N3TMP. 
Peaks b, c and d all have no associated deprotonation for P03H and N31-1, and can be 
assigned to adducts of the.type Ru-O(P03)TMPN3-Ru, possibly isomers. 18 
The reaction of [(TI  with thymidine (1:1, 5 mM, pH 7.20) 
was monitored by 'H NMR at 310 K. The pH of the solution decreased from 7.20 
(initial) to 5.37 after 3 d, compatible with N3 coordination to Ru with concomitant 
N3H deprotonation. Two new thymidine CE3 'H NMR peaks (b 6 1.755 and c 6 
1.677) appeared at lower frequency compared to that for free thymidine (peak a, 6 
1.90; Figure 6.91)). The pH titration curves for peaks a, b and c are shown in Figure 
6.8F, and PKa values for free thymidine and its adducts are listed in Table 6.4. For 
free thymidine (peak a), the pKa value of 9.76 is attributed to deprotonation of N31-1. 
Peaks b and c both have no associated deprotonation of N3H and disappeared at pH 
< 3, and can therefore be assigned to two isomeric forms of Ru-N3Tymidine 
adducts. 19 After 3 d, N3-bound adducts accounted for 34.7% of the total thymidine. 
In contrast to the sharp doublet signal for the T CR3 protons of free thymidine (peak 
a), signals b and c were broad, perhaps due to an exchange process. 
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Figure 6.10 (A) 'H, and (B) 31 P NMR spectra for reaction of [(TI  
with 5'-GMP (1:1, 5 mM, pH 7.24) in 5 mM phosphate buffer at 298 K . Peak 
assignments: a, free 5'-GMP; b, Ru-O(P03)GMP; c, Ru-N7GMP; d, HP04 2 ; e, Ru-
O(P03). Note that the species Ru-O(P03)GMP (b), and Ru-O(P03) (e), rapidly 
formed during the mixing time, and both decreased in concentration because of 
displacement by 0 N7, which was almost complete after 4 d. (C) Distribution of 
species versus reaction time. Labels for species as above. Phosphate-bound species b 
and e are intermediates. Distribution plots for species d and e are not shown. 
(a) PO4 
Chapter 6 Selective Recognition of Nucleic Acids 
(b) Ru-O(P0 3) 
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Figure 6.11 (A) 31 P NMR spectra for reaction of [(nóBip)Ru(en)Clf*  with Na2HPO4 
(5 mM, 1:1, 298 k, initial pH 7.26) after 15 min and 2 h (pH 6.95). Note peak a 
(HP042 ) at 5 2.20 and peak b (Ru-O(P0 3)) at 8.307. (B) Plot showing the percentage 
of phosphate present as Ru-O(P03), based on 31 P NMR peak intensities. The reaction 
reached equilibrium after 2 h when 64% of the phosphate was present as Ru-O(P0 3). 
The equilibrium constant (K) for formation of Ru-O(P0 3) was determined to be 3.2. 
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Only 5'-GMP Forms Adducts with [(i 6-Bip)Ru(en)CI] in 
Competition with 5'-AMP, 5'-CMP, or 5'-TMP. Reactions of [(Tl 
Bip)Ru(en)C1f with 5'-GMP in competition with either 5'-AMP, 5'-CMP or 5'-TMP 
in a 1:1 molar ratio (5mM) at pH 7.2 were monitored by 1 H and 31 P NMR at 310 K. 
In each case, after 2 d, the only new peaks observed corresponded to those for Ru-
N7GMP (data not shown). 
6.3.3 Kinetic Studies 
Phosphate, Chloride and Hydroxide Decrease the Rate of GMP 
N7-Binding. The kinetics of reactions of chloro and aqua Ru(Bip) with 5'-GMP and 
cGMP in various solutions (different NaCl and phosphate concentrations) and at 
various pH values were monitored by ill  and 31 P NMR spectroscopy. The observed 
half-lives (ti/2) for N7-binding are listed in Table 6.5. The kinetics of reaction of 
chioro Ru(Bip) with Na2HPO4 (5 mM, 1:1, 298 K, initial pH 7.26) were also 
monitored by 1 1-1 and 31 P NMR spectroscopy (Figure 6.11). The reaction reached 
equilibrium after 2 h with the equilibrium constant (K) for formation of Ru-O(P03) 
was determined to be 3.2. 
For the reactions of 5'-GMP with chloro Ru(Bip) in 100 mM NaCl, the t112 
value for formation of Ru-N7GMP was 7 h with 89% of the 5'-GMP bound as Ru-
N7GMP after two weeks. In 5 mM phosphate buffer, the t1,2 was 5 h, with 95% of 
OMP bound as Ru-N7GMP after 4 days (Figure 6.10). In 50 mM phosphate buffer, 
the tj/2 was more than 15 h, with only 50 % Ru-N7GMP formed even after one week. 
Under similar conditions at pH ca.7.3 in 1120, the reaction of 5GMP  with aqua 
Ru(Bip) was 1.7 times faster than that with chloro Ru(Bip), and the reaction of 
Ru(Bip) with cGMP was 3 times faster than with S-GMP. No phosphate binding was 
detected for cGMP reactions, see Figure 6.4 and Scheme 6.2. Therefore chloride, 
dianionic phosphate ions and 5-phosphate groups compete with N7 for binding to 
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Ru(II). 
The reaction rate was also dependent on pH (Table 6.5). For the reactions 
with 5'-GMP, t112 for formation of Ru-N7GMP increased from 1.1 h to 5.0 h when the 
PH was raised from 5.37 to 9.40. Similarly for cGMP, the reactions were much faster 
at low pH. The t112 for formation of Ru-N7cGMP increased from 0.5 h to 4.3 h when 
the pH was increased from 5.60 to 9.22. Since the pK a of H20 in [(TI 6 
Bip)Ru(en)(H2O)] 2 is 7.7, the hydroxo complex Ru-OH is the predominant species 
in solution at high PH, 20  and thus slows down Ru-N7 binding. 
Table 6.5 Half-lives (ti/2) for formation of Ru-N7 bound adducts of 5'-GMP and 
cGMP with [( 6-Bip)Ru(II)(en)Clf (Ru-Cl) and [( 6-Bip)Ru(II)(en)(H20)] 2 (Ru-
H20). 
RU-Cl/H20 	G 	ConditionSa 	pH" 	t1 (h)c 
Ru-Cl 5'-GMP 100 mM NaCl 7.25, 7.25 7.0 
5 mM phosphate 7.24, 7.30 5.0 
50 mlvi phosphate 7.22, 7.18 15.0 
H2O 5.37, 5.41 1.1 
7.22, 7.26 3.1 
9.40, 9.13 5.0 
Ru-H20 5'-GMP 1120 7.34, 7.59 1.8 
9.11, 9.40 4.0 
Ru-CI cGMP H20 7.30, 7.60 1.0 
Ru-H20 cGMP H20 5.60, 5.88 0.5 
7.16, 7.69 0.8 
9.22, 9.64 4.3 
a Ru G = 1: 1, 5 mM, 298 K. b  pH (start), pH (equilibrium). 't1,2  from concentration 
versus time plots; rate constants were not determined. 
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Arene-purine Hydrophobic Interactions Greatly Enhance N7-
binding to GMP. Reactions of five Ru(arene) (arene = Bip, TFJA, DHA, Ben and 
Cym) complexes with cGMP were investigated by 'H and 31P NMR under 
physiologically-relevant conditions. Fitted plots of concentration vs time for the 
reaction of aqua Ru(arene) with cGMP (1:1, 5 mM, pH 7.0) are shown in Figure 
6.14A, and the second order rate constants (k) 2 ' were determined by Scientist kinetic 
model (Figures 6.12 and 6.13) and are listed in Table 6.6. Reactions of cGMP with 
aqua Ru(TFIA), Ru(Bip) and Ru(D1-Lk) complexes were more than 3 times faster (k = 
14.7, 8.0 and 7.1 x 102 M -1 -s-1 , respectively) than those for aqua Ru(Cym) and 
Ru(Ben) complexes (Ic = 2.5 and 1.1 x 10.2 M -1 -s-1 , respectively). For the reactions of 
chloro Ru(arene) complexes with cUMP (1:1, 2 mM), there were two steps: Ru-Cl 
hydrolysis followed by Ru-N7 binding (see Scheme 6.2). The observed ty2 values for 
formation of Ru-N7 adducts are listed in Table 6.6. No attempt was made to 
determine the rate constants. Plots of concentration against time are shown in Figure 
6.14B. The sequence of t,12 values for the reactions of chloro Ru(arene) is consistent 
with that for analogous reactions of the aqua Ru(arene) complexes: Ru(THA) c 
Ru(Bip) C Ru(DHA) << Ru(Cym) C Ru(Ben) (Table 6.6). For the THA, Bip and 
DHA complexes, 100% of the N7-bound product was observed after 2 d, whereas 
only ca 80% of the N7-bound product formed for Cym and Ben complexes after 4 d. 
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(A) 	
II Kinetic model A+B=P (A=B) 
IndVars T 
DepVars : A, P 
Params A0, P0, K2 
A AO/ (1+K2*A0*T) 
P:= P0+K2*SQR(AO)*T/(l+K2*A0*T) 
[Ru-F120] + [cGMP] -* [Ru-N7cGMP] (1:1, 5 mM) 
[cOMP] = 0.005/(1 + k2 x 0.005 T) 
[Ru-N7cGMP] = k2 x (0.005)2 T 1(1+ k2 x 0.005T) 
(B) 
Ru-N7cGMP 
t112 =41.4±0.7 m 
Conc 
/MM 
k2 (x 10.2  M 1 s 1 ): 
8.06 ± 0.15 
Free cGMP 
0 	6 	12 	18 	24 
Time (h) 
Figure 6.12 (A) Scientist kinetic model for second-order reactions studied in this 
work. (B) Variation in the concentration of free cGMP and the product of Ru-
N7cGMP with time during reaction of cGMP with [(tl  (1:1, 5 
mM, pH 7.0, 100 mM NaCI04, 298 K). The curves are best fits to second-order 
kinetics. 
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(A) (1 6-THA)Ru(H20) + cGMP 
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(C) (i 6-Cym)Ru(H20) + cGMP 
	
(D) ( 6-Ben)Ru(H2 0) + cGMP 
J 
I. 
Conc 	 Conc 
/MM /MM 
0.0 	6.6 	13.2 	19.8 26.4 33.0 	0 	12 	23 	35 	46 	58 
Time (h) 	 Time (h) 
Figure 6.13 Variation of the concentration of free cGMP and Ru-NZcGMP with time 
during reactions with (A) [(11 6-THA)Ru(en)(H20)] 2 , (B) [( 6-DHA)Ru(en)(F120)] 2 , 
(C) [(rj 6-Cym)Ru(en)(H20)] 2 (D) [( 6-Ben)Ru(en)(H20)] 2 (1:1, 5 mM, pH 7.0, 
100 m NaCI04, 298 K). The curves are best fits to second order kinetics. 
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Table 6.6 Rate Constants (k) and Half-lives (t112) for Reactions of Ru(arene) 
complexes with cGMP . a 
Aqua Ru(arene)b Rate constant  
( x 10 M's') 	
2 (h)c 	Chloro Ru(arene)b t112 (h)' 
Ru(THA)(H20) 	14.72 ± 0.69 	0.38 *0.02 	Ru(THA)Cl 
Ru(Bip)(H20) 	8.06 * 0.15 
	
0.69 ± 0.01 	Ru(Bip)Cl 
Ru(DHA)(1120) 7.08 * 0.20 
	
0.78 ±0.02 	Ru(DTA)C1 
Ru(Cym)(H20) 	2.49 ± 0.03 
	
2.23* 0.03 	Ru(Cym)Cl 
Ru(Ben)(H20) 	1.13 ± 0.02 
	






a Conditions: Ru : G = 1:1, 100 mM NaC104, 298 K, 5 mM for aqua Ru(arene) and 2 
mM for chloro Ru(arene); pH was adjusted to 7.0 at reaction commencement and found 
to be ca. 7.2 at equilibrium for each reaction. b  For the THA, Bip and DHA complexes, 
100% of the N7-bound products observed after 2 d, whereas only ca 80% of the N7-
bound products formed for Cym and Ben complexes after 4 d. C  Calculated from t112 = 
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Figure 6.14 Plots showing the variation of the concentration of (Tl 
 products with time during the reaction of (A) [( 11 6-arene)Ru(en)(H20)} 2 (5 
mM), (B) [(fl 6-arene)Ru(en)C1f (2 mM) with cGMP (1:1, pH 7.0), 100 mM NaCI0 4 , 
298 K, based on the integration of G H8 1 H NMR peaks. The curves in (A) are 
computer-fits to second order kinetics giving the rate constants listed in Table 6.6. 
These reactions were all followed for periods of between 24 h and 4 days (see 
Figures 6.12 and 6.13). The reactions of the chloro complexes in (B) were followed 
for up to 1 week, and the half-lives for the formation of Ru-N7 adducts are shown in 
Table 6.6. No attempt was made to fit these data and determine the rate constants. 
(C) Posssible it-it stacking between arene and purine in cGMP adducts with 
Ru(T1-IA), Ru(Bip) and Ru(DHA). 
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6.4 Discussion 
6.4.1 Identification of Binding Sites 
Purines exhibit a dichotomy between binding at Ni and N7. The proton 
favors Ni. In neutral solution, N7 is usually the predominant binding site for 
transition metal ions on N9-substituted purines such as adenosine and guanosine. 
However, in adenine derivatives, Ni is only slightly less favorable than N7. 22 Ni-
substituted pyrimidines (cytidine, thymidine, uridine) offer only one favorable ring 
binding site, N3. 23 Reactions of purine and pyrimidine nucleosides and nucleotides 
with Pt(II) and Pd(II) complexes, for example, have been investigated previously, 
usually by 'H and 3 'P NIMR spectroscopy. 24 '25 '26 Resolution of the N7-N1 dichotomy 
is unequivocal in the cases of Pt(II) and Pd(II) because the metal ion is both 
diamagnetic and, on the NMR time scale, in slow exchange between the two sites. 
Similarly, in this study, the diamagnetic nature of Ru(II), together with slow ligand 
exchange, allow the acid-base properties of the products to be individually assessed 
by pH titrations, and the populations of all species in solution can be determined 
through measurement of NMR peak areas. 3 'P NMR was also used to reveal directly 
the interaction between Ru(II) and the phosphate group. 21c,2'  Thus, it has been able to 
assess the selectivity of {(ii 6-arene)Ru(en)} 2 complexes towards binding sites on 
purine and pyrimidine nucleic acid derivatives. 
Adducts of J(Tl 	with nucleosides and nucleotides exhibited 
characteristic 'H and 3 'P NMR signals, and'àcid-base properties which allow their 
structures to be assigned (Figures 6.1-6.9, and Tables 6.1-6.4). In the cases of 5'-
GMP, cGMP, Guo, 5'-IMP and Eno, metallation at N7 gave Ru-N7 products with 
high frequency shifts of 0.3-0.6 ppm for H8 resonances, but slight low frequency 
shifts of 0.02-0.04 ppm for £12 resonances, compared with free ligands. Metallation 
at Ni (only found in the reactions with 5'-IMP and mo) gave Ru-NI products with 
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low frequency shifts of 0.16-0.21 ppm for H8 and 0.22-0.26 ppm for H2 resonances. 
A similar chemical shift behavior for H8 and H2 protons upon metallation at N7 or 
Ni sites of purities has been reported for other metal ions. 25a  For all nucleotides, the 
"P NMR resonances exhibit large downfield shifts of ca. 5 ppm when the phosphate 
group coordinates to the Ru center (Tables 6.1-6.4). 
The pH dependences of 'Fl and 31 P NMR chemical shifts of nucleobase 
derivatives were studied in detail. Protonation of N7, Ni, N3 or 5'-phosphate 
produced significant low- or high-frequency shifts of 'H or 31 P NMR resonances 
(Figures 6.1, 6.4, 6.5, 6.6, 6.7 and 6.9). Ru(TI) binding to N7, Ni, N3 or the 5'-
phosphate group prevents the protonation of that site and therefore no change in 
chemical shift due to protonation is expected. Therefore the Ru(II) binding sites can 
be identified, as shown in Tables 6.1, 6.2 and 6.4. It is notable that small amounts of 
dinuclear adducts 28  of the type Ru-N7BNJ-Ru and Ru-0(P03)BNi(N7-Ru (B = 
nucleosides and nucleotides) were detected in solution. Binding site identification 
was supported by the following. (i) The significant pH decrease (from 7.2 to ca. 6) 
during reactions with I and T derivatives, is indicative of NI -coordination to Ru for 
5'-IMP or inosine, and N3-coordination for 5'-TMP and thymidine, with concomitant 
deprotonation. This was not observed for reactions with G and A and C derivatives 
for which almost no N  or N3-binding occurred (Table 6.7). (2) Ru-N7 adducts have 
lowered pKa values of 1.4-1.7 units for Ni, and of 0.6-0.7 units for 5'-phosphate 
groups, but Ru-0(P0 3) binding causes only a small lowering of pKa values of 0. 18- 
0.30  for Ni, and Ru-N] binding has little effect on the pKa values of S'-phosphate 
groups, relative to the free ligands (Tables 6.1, 6.2 and 6.4). These data are consistent 
with metallation at N7 which usually acidifies the proton at Ni, 29 ' 30 ' 31 and consistent 
with the presence of an outer-sphere interaction involving H-bonding of the 5'-
phosphate group to an en NH proton in Ru-N7 adducts (but not in Ru-N] adducts) 
which can contribute to the larger lowering of the pa  value of 5'-P0 3H for Ru-N? 
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3 d 0 
pH 
1 d 3 d 
Guanosine (Guo) Ru-N7Guo 100 100 7.20 7.25 7.37 
Ru-N/Guo 0 0 
Inosine (mo) Ru-N7Ino 59.4 54.3 7.22 6.19 5.9 
Ru-NIlno 23.0 22.8 
Ru-N7InoNl-Ru 3.7 7.7 
Thymidine Ru-N3Thymidine 30.6 34.7 7.20 5.19 5.37 
Cytidine Ru-N3Cytidine 11.6 13.5 7.24 7.19 7.33 
Adenosine (Ado) Ru-N7 INI Ado <3 <5 7.24 7.28 7.30 
5-OMP Ru-N7GMP >95 moob 7.10 7.22 7.26 
Ru-O(P03)GMP <5 0 
cGMP Ru-N7cGMP 100 7.28 7.26 
5-IMP Ru-N7IMP 82.0 79.7 7.28 6.46 6.55 
Ru-N/IMP 4.4 3.1 
Ru-N7IMPNJ-Ru 8.7 12.5 
Ru-O(P03)IMPNI-Ru 1.6 0.7 
RU-0(P0 3)IMP 1.4 0.5 
5-IMP Ru-N3 adducts (b, c, d, e) 58.0 56.8 (2 d) 7.23 6.03 6.23 (2 d) 
Ru-O(P03) adducts (b, c and e) 46.8 47.2 (2 d) 
5-CMP Ru-N3CMP 8.6 7.4 7.23 7.10 7.10 
Ru-O(P0 3 )CMP 56.1 40.7 
5-AMP Ru-N7INJ products 3.1 3.5(2 d) 7.04 6.78 690(2 d) 
Ru-0(P03)AMP 68.6 63.5 (2 d) 
cAMP 	 Ru-N7/N1 products 	 <5 	<5 	7.30 	7.27 	7.10 
a Based on total nucleoside/nucleotide and determined by integration of 'H or 31 P 
NMR resonances. Reaction conditions: Ru : nucleobase 5 mM : 5 mM (except for 
inosine : 5 mM : 55 mM), and at 310 K (298 K for cUMP). b  To this sample NaCl 
(100 mM) was added and the solution was incubated at 310 K; reversal of 5'-GMP 
binding was very slow and amounted to only ca. 10% after 1 week. 
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Figure 6.15 Regio- and stereo- specificities: H-bonds and nonbonding repulsions for 
the interaction of I(TI  with nucleobases, as detected in nucleoside 
and nucleotide reactions. For clarity, the arene and the CH2CH2 of the en ring have 
been omitted, except for the G adduct. For the purine adducts, the diagrams indicate 
in a general way the reactions with N7 and Ni and are not intended to apply 
specifically to the dinuclear adducts. 
220 
Chapter 6 Selective Recognition of Nucleic Acids 
adducts compared to Ru-NJ adducts .25b,32,33 (3) Ru-O(P0 3), Ru-NI and Ru-N3 
adducts disappeared at pH < 5.0 (Figures 6.1, 6.5, 6.6 and 6.7), due to protonation of 
N  and the 5'-phosphate group. 34 
6.4.2 Selective Recognition of Nucleobases 
A summary of the extent of reaction of various nucleosides and nucleotides 
with [(TI  is given in Table 6.7. Nucleotides and their corresponding 
nucleosides have similar affinities for Ru, except for a significant amount of 5'-
phosphate binding in the former case. A schematic representation of the possible 
interactions between the nucleobases and the en NH2 groups is given in Figure 6.15. 
H-bonding and non-bonding repulsive interactions, in addition to the electronic 
properties of the various nucleobase coordination sites, 35  appear to play key roles in 
these site-selective reactions. 3b  For G, N7 is the favoured site for Ru(arene) binding. 
Our previous studies of Ru-N7 guanine adducts have revealed a strong H-bonding 
interaction between one en NH(pointing towards the 0 base) and 0 C60 with N•••O 
distance 2.8 A and N-H"•O angle 163°, which is present in the X-ray crystal 
structures of [(il  and [( 6-Bip)Ru(en)(Guo)] 2 . Such high 
stereospecific H-bonding has also been detected in aqueous solution by NMR. 12 
Thus, coordination at N7 is stabilized by H-bonding of en NH 2 with 0 C60 and 
coordination at Ni is unfavourable due to the repulsive interaction of en NH2 with 
02 NH2. This is consistent with the data for reactions of Ru(Bip) with Guo, 5'-GMP 
and cGMP: only Ru-N7 adducts were detected (and no Ru-NI adducts) over the pH 
range 2-12 (Tables 6.1 and 6.3). inosine (I), in contrast to G, has no NH 2 group. 
Coordination at either N7 or Ni can be stabilized by H-bonding of en NH with C60, 
and significant amounts of Ru-N7 and Ru-NJ adducts were detected for reactions of 
inosine and 5'-IMP with Ru(Bip) (Table 6.7). Binding at N  is promoted at high pH 
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with the concomitant deprotonation of NiH (Table 6.3). Adenine (A) has a C6 NIH2 
group and coordination at either N7 or N  of A is weakened by repulsive interactions 
with the exocylic amino group: no base-binding was observed for reactions of 
Ru(Bip) with Ado, cAMP or 5'-AMP over the range pH 3.1-9.6 (Table 6.7, Figure 
6.7). For thymine (T), significant amounts of Ru-N3 adducts were formed in 
reactions of Ru(Bip) with both thymidine and 5'-TMP at pH ca. 6.0 (Table 6.7). 
Coordination at N3 may be favoured by H-bonds between en NH and the exocyclic 
oxygens at C2 and C4, 36 For C, only small amounts of Ru-N3 adducts (ca. 10%) 
were found for reactions of cytidine and 5'-CMP (Table 6.7). Coordination at N3 is 
weak due to the repulsive interaction of en NH with the C4 NH2 group. 
Based on the above nucleoside and nucleotide studies, the reactivity of the 
various binding sites of nucleobases 37 towards Ru(Bip) at neutral pH decreases in the 
order G(N7) > 1(N7) > I(Ni), T(N3) > C(N3) > A(N7), A(Ni). In competitive 
binding experiments with 5'-GMP versus either 5'-AMP or 5'-CMP or 5'-TMP, the 
only final adduct was [( 6-Bip)Ru(IT)(en)(N7-GMP)]. Also in enzymatic digestion 
experiments, it was found that the binding of ftrj 6-p-cymene)Ru(en)Clf to a 14-mer 
oligonucleotide occurred specifically at guanine Experiments on the 
inhibition of RNA synthesis show that the termination sites produced by (Tl 
arene)Ru(en)} 2 adducts of DNA are at guanine residues .38  Such a high specificity 
for guanine-N7 does not appear to have been reported for other metal-based 
anticancer agents. Many other Pt and Ru anticancer complexes also bind covalently 
to adenine. The complex [Ru(ll)(NH3)5Cl] reacts with many nitrogen bases,3b 
preferentially with the N7 of guanine, 31a Ni of adenine 39  and N4 of cytosine. 31b  For 
cis-[Ru(II)(DMSO)4Cl2], the reaction sites in double-stranded polynucleotides are 
thought to be N7 of both guanine and adenine . 40 The trifunctional organometallic 
complex [( 6-Ben)Ru(H20)3] 2 binds to both N7 and Ni of adenine .41  Cis-
{(NH3)2Pt(ll)} 2 ' binds to adenosine at both N7 (55%) and Ni (45%),42  and the 
ii 
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monofunctional complex {(dien)Pt(II)} also binds to adenosine at both N7 (50%) 
and Ni (50%).23a Cis_ {(NH3)2Pt(JJ)} 2  forms both GG and AG intrastrand cross-links 
that account for about 65% and 25%, respectively, of DNA platinations. 43 
Organometallic metallocene dichloride antitumor agents of the type [Cp2MC12] (M = 
Mo, Ti) exhibit little, if any, coordinative selectivity in nucleotide competition 
experiments. 44 '45 The anti-HIV agent Zn(II)-[12]aneN 4 shows a high selectivity for 
N3 of thymine and uridine derivatives amongst all of the nucleobases, with formation 
of cyclen NH H-bonds to the C2 and C4 carbonyl oxygens of T or U. 46 
The ability of the NH proton of ethylenediamine to act as an H-bond donor 
towards an exocyclic oxo group but not towards an amino group appears to play an 
important role in controlling site recognition of the nucleobases by these Ru(arene) 
anticancer agents. When the en ligand is replaced by H-bond acceptor ligands (such 
as acetylacetonate derivatives), Ru(arene) can also recognise adenine bases. 47 Initial 
data suggest that there is a correlation between the anticancer activity of Ru(arene) 
complexes and the presence of an en NH H-bond donor group. Activity is lost when 
the en NH2 hydrogens are substituted, e.g. with methyl groups . 48 The choice of the 
specific chelating ligand appears to be an effective way of controlling selectivity for 
nucleobase recognition by octahedral Ru complexes. The steric constraints for 
nucleobase binding to an octahedral site are much more demanding compared to 
those for binding at a square-planar site, e.g. Pt(II). 
6.4.3 Phosphate Binding 
The first stage in reactions of [(il 	with nucleotides (5'-GMP, 
5'-IMP, 5'-AMP, 5'-CMP and 5'-TMP) involved rapid 5'-phosphate binding (Figures 
6.1 and 6.5, Table The phosphate adducts of 5'-GMP and 5'-IMP rearranged 
into N7 and Ni adducts, but for adenine, cytidine, and thymidine nucleotides, 
significant amounts of phosphate complexes were still present at equilibrium (Table 
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6.7). For 5'-AMP reactions, it can been seen that Ru-O(phosphate) binding is 
sensitive to pH, reaching a maximium at pH 7.2 (Figure 6.7). Lower pH values 
promoted protonation of the 5'-phosphate group, and higher pH values promoted the 
competitive binding of OFF and thus reduced the formation of the 5'-phosphate 
adducts. Similarly, inorganic dianonic phosphate ions were also found to bind rapidly 
to {( 6-Bip)Ru(en)} 2 to form a Ru-O(P0 3) product (Figure 6.11). Thus binding of 
{( 6-Bip)Ru(en)} 2 to N7 of 5'-GMP was significantly retarded by phosphate buffers 
at neutral p11 (Figure 6.10 and Table 6.5). In contrast, no binding of Ru(II) towards 
the phosphodiester group of cGMP or CAMP was detected (Figure 6.4). 
At neutral pH, cis-[Pt(NFI3)2Cl2] forms monodentate adducts with the 
inorganic ortho-, pyro- and tn-phosphate ions, 50  and an N7, P0 macrochelate cis-
[Pt(NH3)2(5'-GMP-N7, P0)] with the nucleotide 5'-GMP, but does not bind to the 
phosphate group of the methyl phosphate diester of 5'-GMP (Me-5'-GMP). 5 ' 
{Cp2Mo} 2 coordinates to nucleotides (5'-dAMP, 5'-dCMP and 5'-dTMP) through 
Mo-N71N3 and Mo-0(phosphate) chelation, but does not show direct phosphate 
coordination to the methyl-phosphate diester of 5'-dGMP (Me-5'-dGMP)), diphenyl 
phosphate ((C5H50)2P(0)OH), or diethyl phosphate ((CH3CH 20)2P(0)OH). 52 Zn(JI) 
cyclen also acts as a good monotopic receptor for dianionic phosphate monoesters. 53 
'H NMR studies of reactions of Zn(II)-bis(cyclen) with 5'-dTMP and 5'-dTDP 
indicate that the terminal phosphate dianion interacts with one of the Zn(II)-cyclens 
and the imido anion of dT bound to the other Zn(II)-cyclen. 54 Zinc-containing 
carboxylate-bridged heterodimetallic complexes can react with the phosphodiester 
ligand diphenyl phosphate to form bis(phosphate) complexes. 51  {(NH3)5 Ru(III)} 3 
does not appear to coordinate directly to 5'-phosphate groups of nucleotides, 16  but 
the chelation of N7 and phosphate group of 5'-(d)GMP with cis/trans-
[Ru(II)C12(DMSO)], 57 and N7,0(P)-macrochelation of adenosine and guanosine 5'-
mono-, -di-, and -tn-phosphates 41 with [(TI  have both been 
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detected by 111  and 31 P NMR pH titrations. The latter organometallic complex is also 
capable of coordinating to the phospho- diester group of 5'-ADP .41 
The {(rj 6-arene)Ru(II)(en)} 2  complexes studied here bind to dianionic 
phosphate and phosphomonoesters, but very weakly to phosphodiesters. This has 
potential biological implications. The reversible binding to phosphate 58 as well as 
transient binding to membrane phospholipids may facilitate cellular uptake 59 of 
Ru(arene) species. Direct Ru(II) coordination with the backbone phosphodiester 
groups of DNA will be weak, but electrostatic interactions and H-bonding may be 
involved in the initial recognition of [(nóarene)Ru(II)(en)(H2O)J2+ prior to binding 
to guanine N7, as proposed for some Pt complexes. 60 
6.4.4 Kinetic Studies 
The rate of reaction of [(11 	with N7 of OMP depends upon 
whether Cl, H20, Off, or phosphate occupies the available coordination position 
(X). Chloro Ru(arene) complexes rapidly hydrolyze in water to give more reactive 
aqua Ru(arene) species (Scheme 6.1, and Figures 6.2 and 6.3). Hydrolysis is 
suppressed in the presence of 100 mM chloride ions. The intracellular chloride 
concentration (ca. 4-23 mM) is significantly lower than the extracellular 
concentration (ca. 103 mM). 6 ' Thus reactive Ru-F120 species are likely to 
predominate inside cells under physiological conditions. The reactions of [(11 6_  
Bip)Ru(en)(H 20)] 2  with both 5'-GMP and cGMP are more than 3 times slower at 
pH 9 compared to pH 5 to 7 (Table 6.5). This is attributable to the lower reactivity of 
Ru-OH compared to Ru-OH2 (as is also the case for am(m)ino Pt(II) complexes), 
since the pKa, values for [(ii 6-arene)Ru(en)(H2O)J 2 complexes studied here are all 
within the range 7.7_8.25.2062 
6.4.5 Arene-purine Hydrophobic Interactions 
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There appear to be few previous studies of the mechanisms of ligand 
substitution reactions of (il  complexes. Reactions of aqua Ru(arene) 
complexes with N7 of cOMP obey second-order kinetics and therefore appear to 
proceed via an associative pathway involving a seven-coordinate transition state. 63 
The rates of reaction of [(rl  complexes (and chloro 
complexes) with cGMP depends markedly on the nature of the arene, decreasing by 
over an order of magnitude in the series: THA > Bip > DHA>> Cym> Ben (Figure 
6.14 and Table 6.6). There is no correlation between the rates of cGMP N7-binding 
and pKa values of aqua Ru(arene) complexes. 64  The faster rates of reaction for [(6 
arene)Ru(II)(en)(H 20)] 2 complexes containing the large arene ligands THA, Bip 
and DHA65 imply lower activation free energies (AG) for formation of seven-
coordinate transition states. A significant contribution to AGt  may arise from it-it 
stacking of the arene and purine ring 12  in the transition state (negative AH). Such an 
interaction is not possible for the p-cymene and benzene complexes. Arene-purine it-
it stacking may also result in a positive contribution to ASI through desolvation of 
cGMP in the reaction transition state. 
Hydrophobic interactions could produce a driving force for DNA binding; A 
recent analysis of free energy contributions to DNA binding suggests that 
intercalation of ethidium, propidium, daunorubicin, and adriamycin is driven by 
hydrophobic effects and van der Waals contacts within the intercalation site. 66 
Studies of the interaction of thymine derivatives with zinc cyclen containing a 
pendant acridine show that acridine-thymine ring-stacking increases the affinity of 
Zn(II) for dT N3. 67 For many other reported metal agents, however, the presence of 
a rigid aromatic rings, e.g. quinoline in trans-[Pt(quino1ine)(NF1 3 )(9EtG)Cl] 2 ,65 has 
been found to significantly retard the rate of N7-binding of 5'-GMP. In contrast, for 
the Ru(arene) complexes studied here, the flexibility of large arene ligands reduces 
the steric requirements and makes simultaneous arene-nucleobase stacking and N7- 
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covalent binding compatible. Our initial investigations of reactions of calf-thymus 
DNA show that chloro Ru THA, DHA and Bip complexes bind to DNA faster than 
the Cym complex, and CD, LD experiments suggest that the larger arene rings 
(THA, DHA and Bip) are oriented on DNA in a manner compatible with 
intercalation. 38 The rate of DNA binding appears to be specifically enhanced by 
hydrophobic interactions between the arene and the purine base. 
6.5 Conclusions 
It is shown here that anticancer complexes of the type [(q 6-arene)Ru(en)Cl] 
are highly selective in their recognition of binding sites on nucleosides and 
nucleotides. This arises not only from the differences in basicity between the binding 
sites, but also from the demanding constraints imposed on the reactive 
monofunctional site in these pseudo-octahedral "piano-stool" Ru(II) arene 
complexes. 
{( 6-arene)Ru(en)} 2  complexes exhibit a remarkably high preference for 
binding to guanine N7. Such binding is stabilized by H-bonding between the C60 of 
G and NH of the en ligand. 12 The lack of binding to adenine can be attributed to 
unfavorable interactions between the C6 NH2 group and Ru en NH 2. Such a repulsive 
interaction also occurs for G when Ru binds to Ni, but, if this NH 2 group is absent, 
as in inosine derivatives, then a significant amount of binding to Ni is observed. 
Similarly, binding of Ru to N3 of C derivatives is weak due to the repulsive 
interaction with the C4 NH 2 group. Binding to N3 of T is significant, but was not 
competitive with binding to G N7 at neutral pH. It is clear that nucleobase site-
selectivity is strongly related to interactions with the en NH 2 group which is 
attractive toward exocyclic carbonyl oxygens but repulsive towards exocyclic amino 
groups of nucleobases. 
Reactions of the chloro Ru(ll) arene complexes with nucleotides proceed via 
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hydrolysis followed by rapid binding to the phosphate monoester group. In contrast, 
binding to the monoanionic phosphodiester group of nucleotides is weak and was not 
detected. Bound phosphate groups are then readily displaced by base nitrogens. 
Studies of the kinetics of binding of [(11 6-arene)Ru(en)XI (X = H20, Cl) to cGMP 
suggested that arene-purine base-stacking plays a significant role in stabilizing the 
transition state in the associative substitution reactions. Reactions of complexes 
containing arenes (THA, Bip and DHA) which can take part in it-it stacking are up to 
an order of magnitude faster than those containing arenes which cannot (Cym, Ben). 
Such kinetic effects could play a role in the biological activity of this class of 
complexes. 
These studies provide a basis for investigating the recognition of duplex DNA 
by octahedral arene Ru(II) complexes. It is anticipated that it should be possible to 
enhance the discrimination of DNA base recognition by appropriate modification of 
the chelating ligand. By appropriate choice of arene it may also possible to achieve a 
high degree of selectivity via kinetic effects due to it-it arene-base stacking 
interactions (intercalation). Dual mode G N7/intercalative binding may also induce 
novel structural distortions in duplex DNA and hence the recognition by DNA 
binding proteins and repair enzymes. Consideration of all these factors allow 
optimization of the design of this series of anticancer complexes. 
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cisplatin 0.5 12 8 
1(T1 6-C1411 14)Ru(en)C 1]EPF6j 0.4 1 >100 
[0j 6-C 14H 12)Ru(en)Cl][PF6] 2 0.5 92 
[ 6-Bip)Ru(Et-en)C1][PF6 ] 7 0.6 27 
III 6-C4H14)RuC12(dmso)] >100 
[Tj 6-C14F114)Ru(CNCH 3)2C1][PF6] >100 
[ 6-C14H 12)RuC12(dmso)] >100 
111 6-C14H12)Ru(CNCH3) 2C11[PF61 >100 
a  Aird, R. E.; Cummings, J.; Ritchie, A. A.; Muir, M.; Morris, R. E.; Chen, H.; Sadler, 
P. J.; Jodrell, D. I. Brit. J. Cancer 2002, 86, 1652-1657. 
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